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The burden of non-ST elevation acute coronary syndrome (NSTEACS) in older (≥75 
years) patients is rising. However, there are few studies to date on the pattern of 
coronary disease in this cohort. Using intracoronary imaging, I aimed to evaluate the 
vulnerable plaque burden among older patients presenting with NSTEACS, establish 




Prior to percutaneous coronary intervention (PCI), 3-vessel intracoronary imaging was 
performed with virtual histology intravascular ultrasound (VH IVUS) and optical 
coherence tomography (OCT). Angiographic, VH IVUS and OCT images were 
analysed offline and blinded to patient data. Major adverse cardiovascular events 
(MACE) at one year were defined as death, ACS, stroke, repeat unplanned 
revascularisation, and bleeding. 
 
Results 
Recruitment of older patients was successful, with 69.8% of approached patients 
recruited (91 patients, mean age 80.8 years, 63.7% male), and successful imaging 
performed in >70% of anatomically suitable vessels. There was a high success rate of 
PCI overall (90.4%). 
 
With increasing age, %atheroma volume (<79 years: 42.7% vs. 79-82 years: 43.4% 
vs. >82 years: 50.0%, p<0.001) and burden of thin-cap fibroatheroma (TCFA) (5.7% 
vs. 9.3% vs. 14.1%, p<0.001) increased. Men had a higher burden of atheroma on all 
modalities but plaque composition did not differ between the sexes. Calcification on 
VH IVUS increased with frailty (robust: 13.7% vs. pre-frail: 13.0% vs. frail: 17.7%, 
p=0.018). Vulnerable plaque features on OCT such as rupture, microchannels and 





Calcification was initially associated with a reduction in the %stenosis of a lesion, 
mediated by a high rate of positive remodeling that slowed with severe calcification 
(R=0.363, p<0.001). Moderately calcified lesions had a higher residual %stenosis post-
PCI (23.1% vs. none: 14.2% vs. severe: 19.0%, p=0.014) and were associated with 
higher MACE at 1 year (low: 9.5% vs. moderate: 31.6% vs. high 12.0%, p=0.044), 
driven by ACS. Previously identified vulnerable TCFA did not predict MACE at 1 year 
in this cohort (p=0.291).  
 
Conclusions 
Even in high-risk older patients, PCI after NSTEACS is successful and associated with 
a low rate of MACE at 1 year. At no age does the accumulation of coronary plaque 
plateau but frailty, not age, was associated with increased calcification. Calcium is not 
an inert plaque component, but actively shapes vessel remodeling. Moderate 
calcification had the highest risk for adverse outcomes at 1 year due to recurrent ACS, 







This thesis developed as part of a much larger study into determinants of adverse 
outcomes in older patients presenting with acute coronary syndrome. As such, it would 
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1.1 Acute Coronary Syndrome In Older Patients 
 
Ischaemic heart disease (IHD) is a disease of ageing. In 2013-2014, almost half of all 
myocardial infarctions (MI) occurred among patients aged over 70 years in the UK1. 
Moreover, older patients presenting with acute coronary syndrome (ACS) are at higher 
risk of poor outcomes even after adjustment for confounding factors such as co-
morbidities2. However, the rate of invasive angiography in patients with non-ST 
elevation ACS (NSTEACS) declines with age3. This has led to a treatment paradox, 
whereby high-risk older patients who are more likely to benefit from invasive treatment 
following ACS are less likely to receive it. 
 
1.1.1 The Epidemiology of ACS In Older Patients 
Table 1.1 illustrates the under-representation of older patients in international ACS 
registries for which data on older patients has been published. In the Global Registry 
of Acute Coronary Events (GRACE), the median age of patients was 65 years, and 
24% were over the age of 75 years4. However, almost half of those with NSTEACS in 
GRACE were over the age of 70 years, reflecting the later age of presentation of 
NSTEACS versus ST elevation MI (STEMI). In a large Canadian registry, the 
proportion of women presenting with NSTEACS increased with age (23.1% of those 
≤64 years vs. 46.0% of those ≥75 years, p<0.001)5. The proportion of patients with 
ACS with previous angina (41.8% of those ≤64 years vs. 65.6% of those ≥75 years, 
p<0.001), MI (25.2% vs. 41.7%, p<0.001), heart failure (5.0% vs. 17.9%, p<0.001), and 
cerebrovascular disease (4.1% vs. 12.1%, p<0.001) also increased with age5. The 
presence of such co-morbidities can influence the diagnosis, treatment and prognosis 



















% in Oldest 
cohort 
% angiography 
in oldest cohort 
In-hospital mortality 
in oldest cohort 
Canadian ACS Registry5 1999-2001 Canada 4,627 >75  25.3% OR 0.79* 5.5% 
EuroHeart Survey ACS6 2000-2001 International 10,253 ≥75  25% 38.5% 9.7% 
CRUSADE7 2001-2003 USA 56,963 >65  58.4% 63.3% 7.1% 
GRACE3, 4 2001-2007 International 31,982 >75  24% 41% 4.5% 
SPACE8 2005-2007 Saudi Arabia 5,055 >70  16% 54% 7% 
PL-ACS9 2003-2009 Poland 78,422 >80  17.5% 24% 5% (I), 14% (C) 
MINAP10 2006-2010 England and Wales 155,818 ≥85 12.9% 14% 40.8% (I), 66.2% (C)† 
Table 1.1 Under-representation of older patients in registries of NSTEACS  
Older patients are under-represented in the largest international registries of NSTEACS and several 
group patients >75 years in the “oldest” cohort within the registry. In addition, there is a low uptake of 
invasive management for older patients in these registries despite the fact that this has been 
demonstrated to be a superior treatment option vs. conservative management. 
*every decade increase in age resulted in a decrease in coronary angiography 
(I) invasive treatment, (C) conservative management 
†all-cause mortality during mean follow up of 2.29 years 
 
Schoenenberger et al enrolled a large, prospective cohort of 13,662 patients with ACS 
aged ≥70 years and stratified them by year of presentation (2001-4, 2005-8, 2009-
12)11. Over the observed 12 year period, mean age increased (78.6 vs. 79.3 vs. 79.6 
years, p<0.001), incidence of STEMI decreased (53.6% vs. 49.7% vs. 48.1%, p<0.001) 
and the prevalence of dementia increased (3.9% vs. 4.1% vs. 5.2%, p<0.001)11. In-
hospital adverse outcomes decreased over time (14.4% vs. 11.5% vs. 11.3%, 
p<0.001), but not in the oldest (nonagenarian) sub-group11. 
 
1.1.2 Age Predicts Adverse Outcomes Following ACS 
Older patients presenting with ACS are at high risk of poor short and long term 
outcomes. Each 10-year increase in age confers a 70-75% increase in in-hospital 
mortality in patients presenting with ACS (Table 1.1, Figure 1.1)2, 12. In the GRACE 
registry, when comparing the youngest (<45 years) with the oldest (≥85 years) age 
groups, cardiogenic shock was nearly 6 times more common and the rate of major 
bleeding was nearly tripled12. Predictors of peri-procedural mortality following 
percutaneous coronary intervention (PCI) in ACS in patients ≥75 years include 
presentation with haemodynamic instability, chronic renal failure, prior stroke and left 
main stem (LMS) disease and patients  ≥75 years are more likely to suffer a non-fatal 










































Figure 1.1 In-hospital mortality by age in ACS registries 
In-hospital mortality increased with age in all 4 large international ACS registries (the Canadian ACS 
and GRACE registries have not published data for patients >85 years). 
 
The increased risk persists after hospital discharge. In a prospective cohort study that 
enrolled 7,217 patients undergoing PCI in Rotterdam, after adjusting for confounding 
factors, all-cause mortality was significantly higher in octogenarians at 30 days, 1 year 
and four years14. However, the proportion of cardiac deaths declined over time and this 
reduction was more pronounced in octogenarians (although the difference in the 
proportion of non-cardiac deaths at 4 years between younger patients and 
octogenarians did not reach statistical significance: 57.5 vs. 72.2%, p=0.090)14. There 
was no difference in the incidence of MI following PCI in younger patients and 
octogenarians (9.7 vs. 14.0 per 1,000 person-years at four years), but a lower rate of 
target vessel revascularisation in the octogenarian cohort (25.0 vs. 37.7 per 1,000 
person-years at four years)14. 
 
1.1.3 Frailty And The Vulnerable Patient 
Frailty, a vulnerability to physiological stressors due to a decline in reserve and 
resilience with age, is emerging as an important concept in identifying older people at 
risk of adverse outcomes such as functional decline, institutionalisation and death. It 
has been defined by a consensus group as “a medical syndrome with multiple causes 
and contributors that is characterised by diminished strength, endurance, and reduced 
physiologic function that increases an individual's vulnerability for developing 
increased dependency and/or death”15. Although it is related to the ageing process, 
the concept of frailty may help to explain the variance in functional decline with 
CRUSADE7 
EuroHeart survey ACS6 




chronological ageing, and could predict an individual’s vulnerability to adverse events 
in older age. A better understanding of the mechanisms underlying frailty may pave 
the way to identifying potential targets for its prevention and/or treatment. 
 
There is currently no universally accepted definition or measurement tool for frailty, 
leading to difficulty in comparing studies of frailty. De Vries et al proposed that, as frailty 
is a multi-dimensional concept, a measurement tool should incorporate physical (e.g. 
nutrition, physical activity, mobility and strength), psychological (e.g. cognition and 
mood) and social (e.g. availability of support) components16. 
 
Fried et al were the first to develop an objective frailty scoring system, using data 
obtained from the Cardiovascular Health Study, a prospective observational cohort 
study of 5,317 participants aged ≥65 years from 4 communities in the USA17. Table 
1.2 outlines the Fried Frailty Criteria. Overall, 6.9% of the original study population 
were categorised as frail at baseline, and the prevalence of frailty increased with age 
and female gender17. Over a 7 year follow-up period, 43% of those originally 
categorised as frail had died, compared to 23% of those in the pre-frail group and 12% 
of the robust group (p<0.0001)17. Frailty, as measured by the Fried criteria, was also 
associated with hospitalisation, falls, and worsening mobility17. In addition, those who 
were pre-frail at baseline were more than twice as likely to become frail over 3 years, 
compared to those who were robust at baseline17. 
 
Frailty Characteristic Cardiovascular Health Study Measure 
Nutritional status Weight loss >10 lbs unintentionally in the preceding year 
Strength Grip strength, the lowest 20% scoring positive (by gender and body mass index) 
Endurance/Energy Self-reported exhaustion 
Mobility Walking time over 15 feet, the lowest 20% scoring positive 
Physical activity Kcals/week, lowest 20% scoring positive 
Table 1.2 Fried frailty criteria 
Frail: ≥3 criteria present, pre-frail: 1-2 criteria present, robust: 0 criteria present 
 
Gharacholou et al enrolled 545 patients aged ≥65 years undergoing PCI, of which 
65.3% was an urgent or emergency procedure18. The mean age of participants was 
74.8 ± 6.4 years and 18.6% were frail, 47.4% pre-frail, and 20.6% were robust 
according to the Fried frailty criteria18. Frailty was associated with increasing age, 
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female sex and increasing co-morbidity but there were no differences between frailty 
groups in the short-term (30-day) outcome rate18. Singh et al showed, in the same 
population, that the addition of frailty, quality of life and a co-morbidity index to a 
conventional cardiovascular risk score (the Mayo Clinic Risk Score: presence of 
cardiogenic shock, LMS disease, severe renal disease, urgent or emergency 
procedure, congestive heart failure, angiographic evidence of thrombus, multi-vessel 
disease or older age19) improved the risk prediction for older patients undergoing PCI 
(C-statistic improved from 0.628 with the risk score alone to 0.724, p=0.007)20. 
 
White et al measured self-reported Fried Frailty Score in 4,996 patients with NSTEACS 
aged ≥65 years21. The majority of the cohort were robust (72.3%), with 23.0% pre-frail 
and 4.7% frail. Increasing frailty was associated with older age, previous 
cardiovascular co-morbidities and GRACE risk score (all p<0.001) but the percentage 
of patients undergoing angiography did not differ (robust: 39.5% vs. pre-frail: 36.8% 
vs. frail: 41.8%, p=0.177)21. Frail patients experienced a higher likelihood of the 
composite endpoint of cardiovascular death, MI, or stroke compared with robust 
patients (39.7% vs. 23.1%; hazard ratio [HR]: 1.76; 95% confidence interval [CI]: 1.36–
2.28; p<0.001). In addition, after adjustment for baseline characteristics and GRACE 
score, frailty remained independently associated with the composite endpoint21. 
 
1.1.4 The Treatment Paradox 
Despite being a high-risk group, data from multiple global registries have consistently 
shown that older patients are much less likely to undergo invasive revascularisation 
following ACS (Table 1.1). In an analysis of three international registries (GRACE, and 
2 Canadian registries: ACS I and ACS II), the rate of angiography following ACS 
decreased with age: 86.3% in patients ≤65 years, 80.3% in those 65-74 years, and 
56.9% in patients ≥75 years (p<0.001)3. In addition, older patients waited longer for 
angiography following ACS (≤65 years: 3 days, interquartile range (IQR) 2-5; 65-74 
years: 4 days, IQR 2-6; ≥75 years: 4 days, IQR 4-7; p<0.001)3. Physician-reported 
reasons given in the Canadian ACS II registry for not following an early invasive 
strategy included presence of significant co-morbidities (15.7% of those ≥75 years vs. 
2.4% of those ≤65 years, p<0.001), patient or family refusal (10.2% vs. 5.2%, p=0.01), 
and bleeding or safety concerns (8.5% vs. 0%, p<0.001)3. Although rates of PCI in 
older patients have increased over time (Figure 1.2), they are still well below the rates 
















Figure 1.2 Temporal trends in the use of PCI in older patients with ACS 
The use of PCI decreases as the age of patients increases although, overall, the use of PCI has 
increased for all ages, p<0.001 across time points in each age group11 
 
Although the use of an invasive strategy offers the greatest relative benefit to younger 
patients, it offers the greatest absolute benefit to those over 75 years; within each age 
group, the 1-year mortality rate was significantly lower in those who underwent PCI 
compared to those who didn’t (≤65 years: 1.6% vs. 4.9%; 65-74 years: 4.9% vs. 10.5%; 
≥75 years: 11.6% vs. 21.8%; p<0.001)3. In an analysis of the Polish Registry of Acute 
Coronary Syndromes of 13,707 patients aged ≥80 years enrolled from 2003-2009, 
invasively managed patients had a higher rate of major bleeding but lower rates of MI, 
and in-hospital, 30-day, 6-month, 1-year and 2-year mortality compared to propensity 
score-matched patients that were managed conservatively. The rate of stroke was not 
significantly different between the two groups. Over the course of the study, the rate of 
PCI for NSTEACS in older patients did increase from 7.3% in 2003 to 37.3% in 20099.  
 
Savonitto et al randomised 313 patients (mean age 82 years) with NSTEACS to either 
early (<72 hours) angiography or an initial conservative strategy, where angiography 
was only allowed in the case of ischaemia refractory to medical therapy, reinfarction, 
ischaemic heart failure or ventricular arrhythmia22. There was a significant reduction in 
in-hospital recurrent ischaemia (0.6% in the early angiography group vs. 9.4% in the 
initial conservative management group, p=0.0004). However, at 1 year, only patients 

























end-point (all-cause mortality, MI, disabling stroke, and repeat hospital stay for 
cardiovascular causes or severe bleeding) when managed with early angiography 
(22.1% vs. 40%, p=0.03)22. Likewise, the recent “After 80” study conducted in Norway, 
(n=457), showed a benefit with an invasive strategy compared with conservative 
treatment in patients presenting with NSTEACS in terms of reduction in the composite 
end point of death, MI, need for urgent revascularisation and stroke (41% vs. 61%, 
p=0.0001). However, this study excluded high-risk frail patients and had a high non-
recruitment rate of eligible patients (89%) due to short life expectancy, ongoing or 
recent bleeding, unable to comply with protocol, clinically unstable including ongoing 
ischaemia, refusal to participate, ‘logistical and other reasons’23. 
 
Finally, a meta-analysis of 6 randomised controlled trials (RCT) compared a routine 
invasive strategy to selective invasive strategy for 1887 patients ≥75 years of age with 
NSTEACS. A routine invasive strategy was superior for the composite end-point of 
death or MI (odds ratio [OR] 0.65; 95% CI 0.51-0.83), but this was primarily driven by 
the reduced risk of MI (OR 0.51; 95% CI 0.40-0.66) with no difference between the 
groups in all-cause mortality (OR 0.85; 95% CI 0.63-1.20) or cardiovascular death (OR 
0.84; 95% CI 0.61-1.15)24. 
 
1.1.5 Coronary Intervention In The Older Patient With ACS 
1.1.5.1 Vascular Access 
Age is a powerful predictor of peri-procedural bleeding complications following PCI and 
it is known that radial artery access reduces the risk of bleeding complications 
compared to femoral artery access25. In addition, transfemoral access in older patients 
can be complicated by calcified and atherosclerotic peripheral arteries, thus increasing 
the risk of vascular injury. Moreover, older patients are less likely to be able to tolerate 
prolonged bed rest after a femoral approach procedure due to issues such as prostate 
problems or arthritis. However, older patients are less likely to undergo PCI via 
transradial access. In the UK, analysis of the British Cardiovascular Intervention 
Society Database demonstrated a lower rate of radial access with increasing age 
(p<0.0001)26. In this cohort, utilisation of transradial access was also associated with 




1.1.5.2 Coronary Anatomy 
Older patients with acute coronary syndrome have been shown to have more complex 
disease than younger patients, with one study demonstrating a higher rate of multi-
vessel disease in octogenarians compared to patients <65 years (79% vs. 40%, 
p<0.05)27. In a study of older patients (≥65 years), multi-vessel or LMS disease was 
more common in frail patients compared to pre-frail or robust patients (74% vs. 68% 
vs. 60%, p=0.019), even after adjusting for age and sex (p=0.005)18. Because of this 
increased complexity of coronary disease, procedural success is lower in older patients 
(9.4% vs. 4.0%, p<0.001)14.  
 
In addition, the coronary vessels of older patients are frequently calcified (85% of 
lesions in one series of nonagenarians undergoing PCI). Figure 1.3 shows a typical 
appearance of the coronary arteries of an older patient presenting with ACS. In an 
angiographic sub-study of patient-level pooled analysis of 2 large-scale, prospective, 
randomised trials consisting of 6,855 patients with ACS (Acute Catheterization and 
Urgent Intervention Triage Strategy [ACUITY] and Harmonizing Outcomes with 
Revascularisation and Stents in Acute Myocardial Infarction) demonstrated an 
increase in target lesion calcium with increasing age28. In turn, moderate or severe 
target lesion calcification was a significant predictor of non-coronary artery bypass graft 
(CABG) related major bleeding (HR 1.24, 95% CI 1.02-1.52, p=0.03)28. There is little 
data available on the use of calcium debulking techniques such as rotational 
atherectomy in older patients but, in one registry of 218 patients, age >70 years was 






















Figure 1.3 Examples of the pattern of coronary artery disease in older patients 
with ACS 
Panel A: 77 year old male who presented with a non-ST elevation MI (NSTEMI). Angiography of his left 
coronary system showed multi-vessel disease and he received one stent to his left anterior descending 
(LAD) artery. 
Panel B: 85 year old female who presented with an NSTEMI. She had diffuse disease of her LAD and 
circumflex (Cx) arteries, both of which were stented. 
Panel C: 82 year old male with heavy calcification of his right coronary artery (RCA). PCI was attempted 
but unsuccessful. 
 
A single-centre retrospective study of 158 patients with ACS categorised participants 
as elderly (≥75 years, n=65) or non-elderly (<75 years, n=93) and performed pre-
intervention grayscale intravascular ultrasound (IVUS) in culprit arteries30. There were 
no differences between groups in the Synergy between PCI with Taxus and cardiac 
surgery (SYNTAX) score (10.8 ± 7.6 vs. 9.4 ± 5.4, p=0.500) or quantitative coronary 
angiography (QCA) measurements such as % diameter stenosis (73.1 ± 12.2 vs. 76.5 
± 10.0, p=0.15)30. On IVUS, elderly patients had a higher remodeling index (RI, 1.15 ± 
0.14 vs. 1.12 ± 0.14, p=0.05) and a trend towards a higher incidence of calcification 
(85% vs. 72%, p=0.06) and attenuated plaque (63% vs. 47%, p=0.07) on qualitative 
assessment30. These findings correlate with a previous IVUS study that demonstrated 
that octogenarians had a greater calcium arc (199 ± 91o vs. 115 ± 71o, p<0.0001) and 
calcium length (5.5 ± 2.9 vs. 3.5 ± 2.8mm, p=0.006) than patients <65 years at the 
ACS culprit lesion site27. However, plaque burden and maximum stenosis were not 
significantly different between the two age groups. 
 
1.1.5.3 Percutaneous Coronary Intervention Strategy 
In an effort to reduce peri-procedural complications in older patients with ACS, it has 
been suggested that an incomplete revascularisation strategy may be preferable in this 
high-risk cohort with multi-vessel disease and complex co-morbidities. A prospective, 
single centre study followed 502 patients ≥75 years of age who presented with ACS 
A C B 
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and multi-vessel disease and who underwent either complete or incomplete 
revascularisation31. There was no difference in major adverse cardiovascular events 
(MACE: cardiac death, non-fatal acute MI, target lesion/target vessel revascularisation 
and cerebral artery events) between the two groups after a median follow-up of 36 
months (20.4% in the incomplete revascularisation group vs. 14.9% in the complete 
revascularisation group, p=0.141)31. However, there was a higher mortality rate in the 
incomplete revascularisation group both in-hospital (2.9% vs. 1.3%, p<0.0001) and at 
follow-up (13.6% vs. 7.7%, p=0.05)31. This may be due to the fact the incomplete 
revascularisation group had a higher incidence of multi-vessel disease and a higher 
SYNTAX score, and patients in the complete revascularisation group that had failed 
PCI (n=21) were transferred into the incomplete revascularisation cohort. 
 
In a multi-centre RCT, 800 patients ≥80 years with NSTEACS and stable angina were 
randomised to receive either second-generation everolimus-eluting drug eluting stents 
(DES) or bare metal stents32. The incidence of MI (8.7% vs. 4.3%, p=0.014) and target 
vessel revascularisation (7.0% vs. 2.0%, p=0.0009) in the first year of follow-up were 
higher in the bare metal stent group, but there was no difference in mortality (7.2% vs. 
8.5%, p=0.51) or major haemorrhage (1.7% vs. 2.3%, p=0.61) between the groups32. 
 
1.1.5.4 Coronary Artery Bypass Grafting 
There are few studies examining the role of CABG in older patients with ACS. In a non-
randomised prospective study of 249 patients aged ≥80 years with LMS disease 
(65.1% presented with ACS), patients who underwent CABG were more likely to have 
MACE (defined as cardiac death, MI, repeat revascularisation, and stroke/transient 
ischaemic attack) at 30 days than those who underwent PCI (27.6% vs. 18.3%)33. 
However, after a mean follow up of 23±16 months, the MACE-free survival rates 
between the groups were similar (56.7% in the PCI group and 64.8% in the CABG 
group, p=0.33). In a retrospective study of 10,141 older ACS patients with multi-vessel 
disease (mean age 87.2 years), higher mortality was noted in the early months after 
CABG compared to PCI (OR 1.48, 95% CI 1.34-1.64, p<0.01), but CABG provided 
significantly lower mortality (OR 0.60, 95% CI 0.53-0.69, p<0.05) and freedom from the 
composite outcome of death, repeat revascularisation, stroke and MI at 3 years (OR 
0.83, 95% CI 0.76-0.91, p<0.01)34. However, both of these studies were conducted in 
the early 2000s in North America, before widespread use of DES and contemporary 
pharmacotherapy, so their results may not be applicable in the modern era of PCI. 
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1.1.6 Representation Of Older Patients In Cardiovascular Research 
Despite this well documented increase in risk, older patients are significantly under-
represented in cardiovascular clinical trials. In the Canadian ACS II registry, 9.6% of 
patients ≥75 years did not undergo angiography following ACS because their physician 
felt it was not supported by trial evidence3. A systematic review of RCTs in ACS 
showed that 55.2% of studies between 1996 and 2000 did not enrol any patients over 
the age of 75 years, and 31.9% actively excluded patients in this age group35. Although 
enrolment of older patients (≥75 years) has increased through the decades, only 10.3% 
of patients fell into this age category in the RCTs published between 1996 and 200035. 
However, previous cohort studies of older patients have shown good recruitment rates 
(72% of eligible participants were recruited to the Newcastle 85+ study) and a 
willingness among this age group to actively participate in medical research36.  
 
Of the 44 previously published RCTs in ACS in 2014, 10 studies (22.7%) had upper 
age limits (4 RCTs excluded patients >75 years, 4 excluded >80 years, 1 excluded >85 
years and 1 excluded >90 years) and the average age of participants across all RCTs 
was 62.0±6.8 years. Two RCTs (4.5%) specifically recruited older patients32, 37. Of the 
70 published prospective observational studies, 11 (15.7%) had upper age limits (1 
study excluded >55 years, 3 excluded >75 years, 5 excluded >80 years and 2 
excluded >85 years) and the average age of participants was 61.3±5.9 years. Six 
prospective observational studies did not define whether there were any exclusion 
criteria related to age. Two observational studies (2.9%) specifically recruited older 
patients38, 39. However, at least in RCTs, the percentage of trials actively excluding 
older patients does seem to be falling, from 31.9% in 1996-200135 to 22.7% in 2014. 
 
In addition, older participants in clinical trials may not be representative of the elderly 
population presenting with ACS. Kandzari et al analysed data from a multicentre 
registry of 55,172 patients with ACS, comparing those who were simultaneously 
enrolled in a clinical trial to those who were not, and showed that 24.1% of patients 
enrolled in trials were ≥75 years compared to 35.7% of those who were not 
(p<0.0001)40. Comparison of the patients in this community registry with those in the 
Virtual Coordinating Center for Global Collaborative Cardiovascular Research clinical 
trials group revealed that those patients in clinical trials are younger, more likely to be 
male, are less likely to have cardiac risk factors (including hypertension, 
hyperlipidaemia, diabetes and smoking), and less likely to have co-morbidities such as 
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heart failure, stroke and previous MI41. These differences are more pronounced with 
increasing age41. These factors make it more difficult to extrapolate evidence from 
clinical trials to the treatment of older patients in daily clinical practice. 
 
Recently, the PREDICT (Increasing the PaRticipation of the ElDerly In Clinical Trials) 
Consortium, a group funded by the European Union to study and help boost the 
number of elderly people taking part in research, has compiled a charter for the rights 
of older patients in clinical trials (Table 1.3)42. The Consortium aims to narrow the gap 
between populations recruited to clinical trials and real clinical practice. Guidelines 
published by the European Forum for Good Clinical Practice Geriatric Working Party 
suggest that research in older people should actively recruit patients over 75 years 
with no upper age limit, should recruit a majority of women, and should justify exclusion 
of co-morbidities in order to accurately reflect the population studied43. 
 
Older people have the right to access evidence-based treatments 
Promote the inclusion of older people in clinical trials and prevent discrimination 
Clinical trials should be made as practicable as possible for older people 
Clinical trials in older people should be safe 
Outcome measures should be relevant for older people 
The values of older people participating in clinical trials should be respected 
Table 1.3 The PREDICT charter 
 
1.1.7 Conclusion 
As our population ages, the burden of ACS in complex older patients (and especially 
NSTEACS) is on the rise. Currently, older patients with ACS are at higher risk of 
adverse outcomes but are far less likely to receive contemporary invasive 
management. There is a dearth of good quality RCTs comparing contemporary 
treatments in older patients, and the benefits of incomplete versus complete 
revascularisation, use of pharmacotherapy, and CABG are unclear. Accurate risk 
stratification in the older age groups, taking into account frailty status, may aid 
individualised decision making with respect to identifying which patients will benefit 
most from invasive revascularisation, but more research is needed in this field.  
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1.2 The Role Of Virtual Histology Intravascular Ultrasound In ACS 
 
In recent years, novel intravascular imaging modalities have been developed to aid 
identification of high risk atherosclerotic plaques that are prone to causing adverse 
cardiovascular events. Radiofrequency data analysis of IVUS images is one such 
technique that has been validated both in vivo and ex vivo; the most widely used 
version is the virtual histology (VH) IVUS (Volcano Corporation, San Diego, CA)44. VH 
IVUS utilizes spectral pattern analysis techniques to differentiate plaque components 
and potentially identify high-risk vulnerable lesions. 
 
1.2.1 Plaque Characterisation on Grayscale and VH IVUS 
Grayscale IVUS uses high frequency (20-45MHz) ultrasound to visualize the 
components of the vessel wall by measuring the amplitude of the reflected ultrasound 
wave. This allows both quantitative measurements of lumen and vessel dimensions, 
as well as qualitative characterization of intra-arterial pathology. However, the 
sensitivity of echolucent plaque on IVUS to identify lipid pools present on histology was 
only 67% in one study45. Atherosclerotic plaques are also seldom made up of just one 
tissue type. They are a heterogenous mix of calcium, necrotic tissue, and fibrous 
tissue, and grayscale IVUS is unable to accurately distinguish between small areas of 
adjacent tissue components46. 
 
Whereas only the amplitude of the reflected ultrasound wave is used to construct the 
grayscale IVUS picture, VH IVUS utilizes spectral pattern analysis of the frequency 
and amplitude of the reflected wave to generate a more accurate representation of the 
tissue subtypes present (Figure 1.4)47. The VH IVUS algorithm was generated in vitro 
by analysing multiple spectral parameters to discriminate between fibrous tissue 
(green), fibro-fatty tissue (FF, light green), dense calcium (DC, white) and necrotic core 
(NC, red) (Figure 1.5)47. While the original VH IVUS development and validation 
utilised a 30MHz rotating transducer, VH IVUS is now performed with either a 20MHz 














Figure 1.4 Schematic diagram of VH IVUS radiofrequency spectral pattern 
analysis 
VH IVUS uses both the amplitude (A) and the frequency (f) of the reflected ultrasound wave to generate 
a tissue map (1). The data derived from the analysis of the power spectrum (2) is then fed into a statistical 
classifier (3) to generate plaque component classifications for the regions being analysed and, 
ultimately, the full IVUS image (4) (fibrous tissue: dark green, fibro-fatty: light green, necrotic core: red, 










Panel A: grayscale IVUS 
Panel B: VH IVUS 
Figure 1.5 The appearance of plaque components on VH IVUS 
Panel A: grayscale IVUS image of an eccentric and mildly calcified plaque 
Panel B: the same plaque with VH IVUS plaque components overlaid 
 
1.2.1.1 Accuracy Of VH IVUS In Identifying Plaque Components 
An ex vivo validation study conducted by the patent holder, Volcano Corp., reported 
excellent accuracy between VH IVUS and histology in 184 plaques from 51 coronary 
arteries (fibrous: accuracy 93.5%, sensitivity 95.7%, specificity 90.9%; FF: accuracy 
94.1%, sensitivity 72.3%, specificity 97.9%; NC: accuracy 95.8%, sensitivity 91.7%, 
specificity 96.6%; DC: accuracy 96.7%, sensitivity 86.5%, specificity 98.9%)44. In 
contrast, in vivo validation of VH IVUS against directional coronary atherectomy in 307 
image pairs from 30 patients yielded slightly lower predictive accuracies (fibrous: 
87.1%, FF: 87.1%, DC: 96.5%, NC: 88.3%), as directional coronary atherectomy can 
only sample the superficial part of the plaque and extracted tissue may reverse in the 










VH IVUS and histology in the measurement of absolute or relative NC area, and the 
authors questioned the ability of VH IVUS to accurately identify this important plaque 
component50. However, this study was limited by the iatrogenic nature of the induced 
atherosclerosis, the small sample size, and the use of an animal model rather than 
human. More recently a study in human coronary arteries showed that VH IVUS had a 
high sensitivity (94%) for detecting NC when compared to histology, but low specificity 
(53%) and low positive predictive value (PPV, 48%)51. However, this study was limited 
by the small sample size (9 vessels from explanted hearts, with an average segment 
length of 35mm) and the very low plaque burden in those vessels51. The significant 
limitations of these validation studies mean that care must be taken when directly 
comparing plaque components seen on VH IVUS to histology or other intravascular 
imaging modalities. 
 
1.2.1.2 Validation Of Lesion Classification 
Virmani et al9 have suggested a modification to the American Heart Association 
classification of atherosclerotic plaques10, taking into account stable and vulnerable 
lesion sub-types. Histological studies have shown that the plaque type most commonly 
associated with ACS and sudden death is the inflamed thin-cap fibroatheroma (TCFA, 
Figure 1.6), which consists of a large lipid core with a thin, inflamed fibrous cap 
infiltrated with macrophages52.  
 
 
Figure 1.6 A representative image of VH-TCFA 






Garcia-Garcia et al proposed standards for VH IVUS lesion classification based on 
histological classification (Figure 1.7)53. The definition of VH IVUS-derived TCFA (VH-
TCFA) was first validated in a rabbit model of atherosclerosis and was shown to have 
a high sensitivity, specificity and positive predictive value (88%, 96%, and 87% 
respectively for non-calcified TCFA)54. Although this was an animal model, a previous 
study of 15 patients undergoing carotid endarterectomy showed that the accuracy of 
VH IVUS in identifying lesion type compared favourably to histology, with 99.4% 
accuracy for TCFA, 96.1% for calcified TCFA, 85.9% for fibroatheroma (FA), 72.4% for 
calcified FA, 85.5% for fibrocalcific plaque, and 83.4% in pathological intimal thickening 
(PIT)55. These findings were corroborated in a study of 8 ex vivo human coronary 
arteries which demonstrated VH IVUS to have a diagnostic accuracy of 82% in 
identifying TCFA56. However, these validation studies of the identification of TCFA by 







Figure 1.7 Decision tree for lesion classification on VH IVUS 
A plaque becomes a lesion when the plaque burden is >40% for 3 consecutive images, and lesions separated longitudinally by >5mm of artery with a plaque 
burden <40% should be considered separate lesions. Where different plaque subtypes co-exist within a lesion, the lesion should be classified according to the 
highest risk subtype i.e. thin capped fibroatheroma> fibroatheroma> pathological intimal thickening> fibrotic plaque> intimal medial thickening.
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1.2.2 VH IVUS Characterisation Of Patients With ACS 
A study of 40 patients (32.5% with stable angina, 67.5% with ACS) demonstrated that 
patients with plaque rupture had a higher average cross sectional area of NC (0.30 vs. 
0.22mm2, p=0.02), DC (0.09 vs. 0.04mm2, p=0.01) and FF tissue (0.58 vs. 0.34mm2, 
p=0.03), and a lower cross sectional area of fibrous tissue (1.94 vs. 1.00mm2, 
p<0.01)57. The site of plaque rupture was also shown to have a higher proportion of 
NC than the site of minimum lumen area (MLA, 16.7 vs. 11.8%, p=0.03)57. Hong et al 
demonstrated that patients with ACS had a higher proportion of NC (21.3 vs. 15.5%) 
and a lower proportion of fibrous tissue (55.5 vs. 62.3%) compared to those with stable 
angina58. The pattern of calcification may also be implicated in plaque vulnerability, 
with spotty calcification potentially increasing the likelihood of plaque rupture due to 
biomechanical stress. In a series of 225 patients with ACS, an NC/DC ratio ≥2 had a 
sensitivity of 50%, specificity of 76%, and a PPV of 91% for high-risk NSTEACS 
(p=0.010).  
 
The CULPLAC trial enrolled 189 patients (70% with ACS, mean age 62.5 years) and 
demonstrated that VH-TCFA were more frequent in the culprit lesions of patients who 
presented with ACS (55.1% vs. 36.6% in non-culprit lesions in ACS patients vs. 14.4% 
in stable lesions, p=0.007)59. However, there were no differences in proportions of the 
four tissue components between culprit and non-culprit plaques, suggesting that it may 
be the lesion phenotype rather than the proportion of “adverse” tissue present that is 
responsible for plaque instability.  
 
In a study of 172 patients with STEMI, VH-TCFA were identified in 37.8% of culprit 
lesions after thrombus aspiration, and plaque rupture was more commonly seen in VH-
TCFA than non VH-TCFA (53.8% vs. 34.5%, p=0.009)60. However, this study was 
limited because residual thrombus is mis-classified as fibrous or FF tissue in the VH 
IVUS algorithm61, and this may have led to an underestimation of the incidence of VH-
TCFA. VH-TCFA were more commonly located proximal to the MLA and the site of 
maximum NC59, 62, raising the prospect that they may not be covered by culprit lesion 
stenting. In one study of patients with STEMI, 50% of culprit VH-TCFA were not fully 
covered by the stent despite optimal angiographic placement, and this was more 




In a study of 105 patients (70 ACS and 35 stable angina), four IVUS and VH IVUS 
factors were found to be associated with an ACS culprit lesion phenotype: NC/DC ratio, 
MLA <4mm2, remodelling index >1.05, and the presence of VH-TCFA64. These factors 
were subsequently utilised to construct the Liverpool Active Plaque Score (LAPS), 
where a score of >6 predicted an active plaque phenotype with a sensitivity of 75% 
and specificity of 91% in an independent validation cohort64.  
 
1.2.2.1 Serial VH IVUS Studies 
It is recognized that atherosclerotic lesions are dynamic and can evolve from one sub-
type to another. In a study of stable angina patients, Kubo et al utilised VH IVUS to 
assess the progression of plaques over 12 months in 99 patients65. Fifteen out of 20 
VH-TCFA found at baseline had healed into different plaque types at 12 months (13 
FA and 2 fibrotic plaques) and 12 new VH-TCFA had formed (6 from PIT and 6 from 
FA). VH-TCFA that had not healed were more likely to be located in the proximal 
segment of the vessel (distance from ostium to lesion was 16mm vs. 31mm for healed 
VH-TCFA, p=0.013). Calcified FA were the only lesion type to remain unchanged over 
12 months. In a study combining VH IVUS with optical coherence tomography (OCT), 
evaluating plaque at bifurcation lesions at baseline and 6 months in 24 patients (80% 
with stable coronary disease), most high-risk plaques (81%) remained unchanged66. 
 
In a study of 63 patients with STEMI, 99 non-culprit lesions were evaluated by VH IVUS 
at baseline and 13 months. An increase in the proportion of NC (14% to 18%, 
p<0.0001) and DC (6% to 10%, p<0.0001) at follow-up was demonstrated67. 
Furthermore, 9/41 VH-TCFA had healed into either FA or fibrotic plaques at 13 month 
follow-up, but 18/41 FA and 3/16 PIT had transformed into VH-TCFA67. In a 
comparison of 26 patients with STEMI and 11 patients with chronic total occlusions 
(CTO, imaged proximal to the obstruction), the non-culprit lesions were more likely to 
be dynamic in the STEMI patients, with plaque composition changing significantly at 6 
month follow-up compared to no significant change in the patients with CTO68. In 
addition, there was a trend in STEMI patients for lesions to progress to a more 
advanced plaque type (67% vs. 11%, p=0.089)68.  
 
Although these studies are limited by the small sample sizes, the results suggest that 
the development of vulnerable non-culprit plaques is, in part, determined by the 
underlying environment and presence of ACS-causing plaque elsewhere in the 
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coronary vasculature. Further research is required into the factors leading to this 
increase in plaque vulnerability after ACS. 
 
1.2.2.2 The Role Of VH IVUS In Predicting Adverse Outcomes After ACS 
To date, three studies have prospectively evaluated the association between VH IVUS-
defined plaque classification and adverse outcomes in patients with ACS: the Providing 
Regional Observations to Study Predictors of Events in the Coronary Tree study 
(PROSPECT)69, the VH IVUS in Vulnerable Atherosclerosis study (VIVA)70, and the 
European Collaborative Project on Inflammation and Vascular Wall Remodeling in 
Atherosclerosis – Intravascular Ultrasound study (ATHEROREMO-IVUS)71. 
 
PROSPECT Study 
In this multi-centre study, 697 patients (median age 58.1 years) with ACS (30.3% 
STEMI, 65.6% non-STEMI, 4.2% unstable angina [UA]) underwent three vessel VH 
IVUS (623 patients had successful VH IVUS image acquisition) and were followed up 
for a median of 3.4 years69. Of 2811 lesions identified, 596 were VH-TCFA in 313 
patients. On multivariate analysis, predictors of non-culprit lesion-related MACE (death 
from cardiac causes, cardiac arrest, MI, or rehospitalisation due to unstable or 
progressive angina) were plaque burden ≥70% (HR 5.03, 95% CI 2.51-10.11, 
p<0.001), MLA ≤4.0 mm2 (HR 3.21, 95% CI 1.61-6.42, p=0.001) or presence of VH-
TCFA (HR 3.35, 95% CI 1.77-6.36, p<0.001). In addition, other predictors of MACE 
included median DC area ≥0.2mm2 (HR 2.01, p=0.02) and median NC area ≥0.4mm2 
(HR 2.06, p=0.02)69. 
 
VIVA Study 
In the VIVA single centre study, patients with stable angina (n=100) and ACS (n=70) 
underwent three-vessel VH IVUS pre-intervention, and post-intervention in the culprit 
artery70. Baseline demographics were not reported. After a 3-year follow-up, 18 MACE 
(death, MI, and unplanned revascularisation) occurred in 16 patients. On univariate 
analysis, non-culprit lesion factors associated with non-restenotic MACE (MACE 
excluding events related to in-stent restenosis) were VH-TCFA (HR 7.53, 95% CI 1.12-
50.55, p=0.038), plaque burden >70% (HR 8.13, 95% CI 1.63-40.56, p=0.011) and RI 





Limitations of PROSPECT and VIVA 
These studies confirmed that non-culprit lesions responsible for future MACE are 
characterized by the presence of VH-TCFA.  However, the application of VH IVUS to 
interrogate non-culprit lesions for potential intervention is subject to a number of major 
limitations. First, while TCFA were commonly identified in non-culprit lesions (22.0% in 
PROSPECT, 60.2% in VIVA), the absolute event rates per individual VH-TCFA were 
low (4.9% in PROSPECT, 2.9% in VIVA). The differences in MACE were strongly 
driven by rehospitalisation and revascularisation, which may have been driven by 
physician bias rather than death or MI. In addition, in PROSPECT, a significant number 
of non-culprit lesions associated with recurrent events were not imaged on VH IVUS 
(51.9%). This was likely due to the fact that only the proximal 6-8 cm of the major three 
epicardial arteries were evaluated as the type of VH IVUS catheters used precluded 
navigation to the distal parts of the coronary arteries. Finally, non-culprit lesion-related 
adverse events were also associated with non-TCFA lesions at baseline (49.0% in 
PROSPECT, 38.5% in VIVA) and these were not imaged with VH IVUS when the 
patient re-presented with an adverse cardiovascular event. It is possible that many 
initially ‘benign’ plaques had progressed to TCFA, resulting in subsequent events. 
 
ATHEROREMO-IVUS Study 
ATHEROREMO-IVUS was a single centre cohort study that enrolled 581 patients 
(mean age 61.6 ± 11.3 years, 75.6% male) with either stable angina (43.7%) or ACS 
(54.7%)71. It aimed to answer some of the limitations of VH IVUS raised after 
publication of PROSPECT and VIVA. Following diagnostic coronary angiography, VH 
IVUS imaging was performed in one non-culprit vessel only (as 3 vessel VH IVUS is 
time consuming and impractical in the clinical setting) and the primary endpoints were 
death, ACS, or unplanned coronary revascularisation at 1-year follow-up72. The 
secondary endpoint was defined as a composite of death or ACS at one year, as the 
events in VIVA and PROSPECT were primarily driven by revascularisation and 
rehospitalisation respectively.  
 
Of the 724 lesions identified, 271 (37.4%) were classified as VH-TCFA and these were 
independently associated with MACE (HR 1.96, 95% CI 1.08-3.53, p=0.026). There 
was no association between the presence of VH-TCFA and either C-reactive protein 
or circulating cytokines in patients with ACS73, 74. As in PROSPECT, a combination of 
the presence of TCFA, plaque burden ≥70% and MLA ≤4mm2 increased the risk of 
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MACE significantly (HR 3.70, 95% CI 1.72-7.95, p<0.001)71. In addition, 
ATHEROREMO-IVUS was the first study to show that VH-TCFA in non-culprit vessels 
are associated with the secondary endpoint of death or ACS at 1 year (HR 2.56, 95% 
CI 1.18-5.54, p=0.017)71. VH-TCFA with a plaque burden ≥70% were also associated 
with a higher MACE rate both at early (<6 months) and late (>6 months) follow-up, 
whereas smaller VH-TCFA were only associated with late adverse events71. 
 
1.2.3 Comparison of VH IVUS With Other Imaging Modalities 
Several other intracoronary imaging modalities are currently available and their 
physical properties are compared in Table 1.4. 
  
 IVUS OCT Near infrared spectroscopy 
Energy source Ultrasound Infrared Near infrared 
Wavelength (µm) 35-80 1.3 0.8-2.5 
Penetration (mm) 10 1-2.5 1-2 
Resolution (µm) 100-200 20-40 NA 
Pullback speed (mm/s) 0.5-1 10-40 0.5 
Table 1.4 Comparison of the different modalities of intravascular imaging 
IVUS has a greater penetration than OCT or near-infrared spectroscopy (NIRS) and can therefore 
evaluate deep plaque structures, but has a poorer resolution than OCT and cannot image the thin fibrous 
cap of a TCFA. OCT has a faster imaging speed than either IVUS or NIRS. 
 
1.2.3.1 Other Radiofrequency Analysis IVUS Algorithms 
Two other technologies utilize radiofrequency ultrasound data to generate colour IVUS 
images: integrated backscatter-IVUS (IB-IVUS, Terumo, Tokyo, Japan) and iMap 
(Boston Scientific, MA, USA). IB-IVUS uses just one radiofrequency parameter to 
define tissue types, making it easier to provide feedback for misclassifications, but 
rendering it essentially a colour representation of the grayscale intensities within the 
IVUS image75. IB-IVUS was marginally more accurate than an older version of the VH 
IVUS algorithm in an ex vivo study against histology in identifying all 4 plaque 
components (IB-IVUS: κ=0.83, 95% CI 0.75-0.91, VH IVUS: κ=0.73, 95% CI 0.63-
0.83)76. However, formalin-fixed tissue was imaged in the study, which is known to 
alter spectral properties of IVUS backscatter77, 78. 
 
iMap is the most complex of the three radiofrequency analysis technologies. It 
measures 40 different spectral parameters and compares how close the 
radiofrequency signal is to a database previously obtained from histological analysis, 
24 
 
giving a “confidence level” for identifying each tissue type79. iMap had only a moderate 
agreement with IB-IVUS in identifying fibrous (R2=0.522, p<0.001) and calcific 
(R2=0.560, p<0.001) plaque, with no agreement for the areas of lipid pool (R2=0.071, 
p=0.149)80. 
 
1.2.3.2 Optical Coherence Tomography 
OCT provides complementary information to VH IVUS. It has a superior resolution (10-
40µm) but poorer penetration (2.5mm) (Table 1.4), and is therefore unable to quantify 
plaque burden (one of the main predictors of adverse events after ACS), deep lipid 
pools, necrotic regions or large calcium deposits81.  
 
Table 1.5 shows the studies that have evaluated VH IVUS as a diagnostic test for 
individual plaque subtypes against the “gold-standard” of OCT. However, using OCT 
as the gold-standard for identification of both FA and TCFA is flawed due to the 
limitations in penetration, and both studies used a wider definition of a VH IVUS-
defined TCFA82 than subsequently proposed by Garcia-Garcia53. Fujii et al assessed 
the combined accuracy of OCT and grayscale IVUS against histology in identifying 
TCFA in an ex vivo study of 165 arteries from 60 patients who had died from non-
cardiac causes83. Of 685 imaged plaques, 8% met the IVUS criteria for TCFA, 4% met 
the OCT criteria, and only 2% met both. Respectively, the sensitivity, specificity, PPV, 
negative predictive value (NPV) and accuracy of the combined OCT and IVUS criteria 













Sawada et al, 
200884 
TCFA 78% 63% 46% 88% 67% 
Kubo et al, 
201185 
TCFA 89% 86% 59% 97% 86% 
Kashiwagi et al, 
201486 
FA 71% 45% 56% 63% 58% 
Table 1.5 Summary of studies comparing OCT and VH IVUS identification of 
TCFA/FA 
Studies comparing the accuracy of VH IVUS against OCT for the identification of TCFA have been 
mixed. VH IVUS tends to “over-diagnose” TCFA when compared to OCT. 
 
Combining the criteria for VH-defined FA and fibrous cap <85µm for three frames on 
OCT improved diagnostic accuracy to 89% for histologically-proven TCFA87. False 
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positive TCFA on VH IVUS were most commonly caused by heavy calcification, and 
false negatives on OCT were caused by under-estimation of the lipid pool and over-
estimation of the fibrous cap thickness87. High negative predictive values84, 85, 88 for VH 
IVUS may mean that it is used as a “rule-out” test for TCFA in the future, with OCT 
providing confirmation of the presence of a TCFA. A combination catheter that 
automatically co-registers OCT and IVUS data has been proposed89 and could 
potentially be the key to accurately identifying TCFA. 
 
1.2.3.3 Near-Infrared Spectroscopy 
Near-infrared spectroscopy (NIRS) provides information about the lipid composition of 
a plaque, but cannot measure the thickness of the overlying fibrous tissue. A 
comparison of NIRS and VH IVUS in 31 stable and unstable patients demonstrated 
that the agreement between NC on VH IVUS and a high probability of lipid pool on 
NIRS was only 14.2%90. This was confirmed in a subsequent study, demonstrating that 
the relationship between VH IVUS-derived NC and NIRS-derived lipid core burden 
index was not significant (rs=0.16, p=0.11)91. A key reason for this observation could 
be that the NC classification by VH IVUS is specific to late NC with micro-
calcifications44, 47, whereas NIRS detects the chemical signature of lipids, which can 
be present at both early and late stages of plaque progression. However, NIRS is not 
affected by the presence of calcium and may provide more accurate information 
regarding the lipid content in highly calcified plaques than VH IVUS, as there is an 
overlap in the VH IVUS classification of NC and DC44, 79. 
 
1.2.3.4 Computed Tomography 
Non-invasive imaging appears promising for identifying vulnerable coronary plaques 
without the risk of minimally-invasive imaging. Obaid et al imaged 108 plaques from 
57 patients with ACS and stable angina with both computed tomography (CT) and VH 
IVUS to determine attenuation ranges for individual plaque components56. These 
plaque maps were then validated in a separate cohort of 47 patients, and showed good 
correlation between CT and VH IVUS (NC: r=0.41, p=0.002; fibrous plaque: r=0.54, 
p<0.001; DC: r=0.59, p<0.001)72. However, the spatial resolution precluded direct 
identification of TCFA. Joshi et al performed VH IVUS and positron-emission 
tomography-CT on 40 patients with stable angina92. High 18F-sodium fluoride uptake 
on positron-emission tomography-CT (postulated to be a marker of plaque activity) 
correlated with VH IVUS features such as microcalcification (73 vs. 21%, p=0.002) and 
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higher mean NC burden (24.6 vs. 18.0, p=0.001), which may be markers of plaque 
vulnerability92. There was also a non-significant trend towards a higher incidence of 
VH-TCFA in 18F-sodium fluoride positive plaques (47 vs. 16%, p=0.068)92. However, 
no VH IVUS data were reported from the MI sub-group of this study, and there was no 
correlation with adverse outcomes.  Further studies are necessary before this non-
invasive technique supplants minimally-invasive coronary imaging for the identification 
of vulnerable plaques.  
 
1.2.4 Limitations of VH IVUS 
The main technical limitation of VH IVUS is that it lacks the resolution to accurately 
identify a TCFA cap thickness of <65µm. Furthermore, VH IVUS lacks an algorithm for 
identifying thrombus, which may be misidentified as fibrous plaque unless care is taken 
to exclude it from the analysis61. The presence of thrombus at the site of TCFA might 
therefore appear as a thick-cap FA. It can also be difficult to analyse radiofrequency 
data in the acoustic shadow behind superficial calcium. More than 80% of regions of 
interest in this acoustic shadow had a radiofrequency signal greater than the 
background noise, but the accuracy of the VH plaque component classification within 
these regions requires further research93. It is unclear whether these signals are 
reflections from the ultrasound wave passing through “cracks” in the calcium (or around 
the edges) or just secondary echoes against the calcium itself. Use of a novel masking 
algorithm to prevent misclassification of the shadow behind the calcium improved the 
correlation between VH IVUS and quantitative computed tomography angiography in 
one study94. 
 
VH IVUS also has significant limitations that currently prevent it from being utilised 
routinely in clinical practice. Three-vessel VH IVUS imaging is time consuming and 
does carry a small but measurable risk of adverse events for the patient (1.6% of 
patients in PROSPECT had complications attributable to IVUS imaging), although the 
results from ATHEROREMO-IVUS suggest that imaging of one non-culprit vessel may 
be enough to predict adverse outcomes. Analysis of VH IVUS images currently 
requires manual verification of the lumen and vessel contours for each frame, which 
limits the application of VH IVUS in determining the individual patient’s treatment at the 
time of angioplasty. Finally, there are no studies to show that utilising VH IVUS to alter 
patient management can improve clinical outcomes, and such studies may require 
such large patient numbers and extended follow up as to be prohibitive. In the absence 
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of such studies, invasive imaging studies utilising technology such as VH IVUS may 
be better targeted at evaluating the effect of novel therapies on “soft” end points such 
as plaque composition or phenotype49. 
 
1.2.5 Conclusion 
Despite its limitations, VH IVUS is a useful tool in identifying high risk plaque features 
and vulnerable lesions in patients with ACS in a research setting. The advent of 
combination imaging catheters and higher resolution IVUS may improve its predictive 
capabilities, especially in identifying the thin fibrous cap characteristic of TCFA95. 
Measurement of plaque components is relatively simple, objective and accurate, but 
does not perform as well in identifying patients at risk of adverse outcomes as 
conventional grayscale IVUS measurements. In contrast, lesion-level based analysis 
correlates better with adverse cardiovascular outcomes, but lesion classification is 
more subjective, requires time and experienced operators. In addition, focusing on 
local detection of vulnerable plaque does not address the systemic nature of 
atherosclerosis. The evidence is mounting that VH-TCFA adversely affect patient 
outcomes and this may lead to more aggressive therapy for these vulnerable plaques. 
However, despite the technology being available for over a decade, evidence for the 
use of VH IVUS in modifying patient outcomes is lacking, and this requires further 
evaluation in future studies.  
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1.3 Optical Coherence Tomography In ACS 
 
OCT is an intravascular imaging modality that uses the reflection of near-infrared light 
to generate an image. OCT was first described over two decades ago when it was 
used to image the peri-papillary area of the human retina in vitro96. Eleven years later, 
OCT was used to image atherosclerotic plaques in human coronary arteries97. The 
image resolution achievable with OCT (axial: 10µm, lateral: 20-40µm) far surpasses 
that of IVUS (100-200µm). Histological studies have demonstrated that certain adverse 
plaque phenotypes are associated with the onset of an ACS95. With its excellent spatial 
resolution, OCT is ideally placed to identify vulnerable plaque that could result in ACS. 
 
1.3.1 OCT Technology 
To generate an image, a low coherence, near infrared (wavelength of 1.3µm) light 
source is directed at the tissue (Figure 1.8). The light beam is split into two arms, a 
sample arm and a reference arm, by an interferometer. The reference arm is directed 
to a mirror, which reflects the light directly back to the interferometer. The light of the 
sample arm is absorbed, refracted, or reflected from the sample tissue, scattering the 
light at large angles from its surface and sub-surface. Reflected light travels back to 
the interferometer and interacts with the reference arm light. The interaction between 
these two light waves determines the OCT image, depending on whether there is 
constructive or destructive interference between the waves96. Because red blood cells 
strongly scatter the light waves and hence attenuate the image, OCT requires a 
bloodless field. The OCT catheter is connected to a rotary junction, which utilises a 
motor to rotate the optical fibre in the catheter and couples light from this rotating fibre 
to light from the reference arm. The rotary junction is mounted to an automated 





Figure 1.8 Diagrammatic representation of OCT technologies 
Panel A: Time domain OCT 
Panel B: Frequency domain OCT 
 
There are two types of OCT systems: time domain (TD, Figure 1.8A) and frequency 
domain (FD, Figure 1.8B). The first generation TD-OCT system required sequential 
measurement of optical echoes from different depths by moving the reference mirror98. 
This initially required the use of a balloon to occlude coronary blood flow, and the slow 
pullback speed of 1-5mm/s led to image acquisition times of 3-45 seconds98. 
Subsequently, a blood-free imaging field was obtained by controlled intracoronary 
infusion of iso-osmolar contrast, negating the need for an occlusive balloon99. This 
reduced the procedure time, although the length of the analysed segments of artery 
were shorter99. Second generation FD-OCT systems employ a light source that is 
rapidly swept in time across wavelengths from 1.25-1.35µm, allowing simultaneous 
recording of reflections from different depths without movement of the reference 
mirror100. Depth profiles are then reconstructed by Fourier transformation. This speeds 
up image acquisition 10-fold, with achievable pullback speeds of up to 40mm/s and 
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imaging runs of up to 150mm in length with a 3-5 second flush of saline or contrast, 
without the need for prolonged vessel occlusion100. 
 
1.3.1.1 OCT Image Features 
The normal coronary artery is seen as a three layered structure on OCT (Figure 
1.9A)101. The internal elastic lamina appears as a signal-rich 20µm thick band that lies 
inside the dark band of the media and the further signal-rich band of the external elastic 
lamina101. An atherosclerotic lesion is seen on OCT as a mass lesion within the arterial 
wall, with focal intimal thickening or loss of the normal vessel architecture102. Fibrous 
plaque produces a relatively homogenous and highly backscattering signal102 (Figure 
1.9B). Calcified plaques appear as a signal-poor area with sharply delineated borders 
(Figure 1.9C). However, this only applies to larger regions of calcification; smaller 
areas and microcalcifications have yet to be validated against histology102. Necrotic 
core (and the broader histopathological category of a lipid pool) is seen as a signal-
poor region with poorly defined borders and fast OCT signal drop-off (Figure 1.9D)102. 
Because light does not penetrate through these areas, OCT cannot be used to 




Figure 1.9 OCT image examples of plaque composition 
A) Composition of the normal coronary artery, with white arrows depicting the internal elastic lamina, 
media and external elastic lamina 
B) Concentric fibrous plaque 
C) Calcified plaque 
D) Necrotic core 
* Guidewire artefact 
 
Macrophage accumulations can sometimes be seen at the border of the fibrous cap 
and necrotic core and can appear as punctate signal-rich spots that exceed the 
background noise of the image102. Cholesterol crystals (ChC) are linear regions of high 
intensity, often associated with a lipid pool (Figure 1.10C)102. OCT can differentiate 
between white and red thrombus (Figure 1.11) due to the high proportion of red blood 
cells in red thrombi, which causes greater attenuation of the OCT signal and a lower 
half-width (the distance from peak signal intensity to its half-intensity). Kume et al 
demonstrated that a cut off of 250µm in the half-width could accurately discriminate 




Figure 1.10 Cholesterol crystals on OCT 
Images from an 80 year old female patient, with hypertension and hypercholesterolaemia, who 
presented with a NSTEMI.  
A) Angiogram demonstrating a tight stenosis with thrombus in the mid-LAD artery (white arrow) 
B) OCT image of red (red arrow) and white (white arrow) thrombus in the culprit lesion  
C) OCT image of cholesterol crystals (white arrows) and macrophage accumulation (red arrow) 
* Guidewire artefact 
 
 
Figure 1.11 Red and white thrombus on OCT 
A) Red thrombus (red arrow) with high attenuation, associated with a calcified plaque (yellow arrow) 
B) Stent thrombosis with homogenous, low attenuation white thrombus (white arrow) 
* Guidewire artefact 
 
1.3.1.2 Histological Validation Of OCT 
OCT was first validated for plaque characterisation in vitro in 2002104. Agreement 
between the histopathological and OCT findings were high (κ=0.83-0.84), and inter-
observer and intra-observer reliability were good (κ=0.88 and κ=0.91, respectively)104. 
Intimal thickness measured by OCT also correlated well with histology (r=0.98, 
p<0.001)105. However, there were a number of false negative diagnoses of lipid pools, 
which could be attributed to the limited penetration of OCT, leading to deep lipid pools 




In addition, OCT images are prone to artefacts; 30.9% of images contained artefact in 
one study, although this improved with operator experience106. Seam line artefacts 
cause apparent breaks in the lumen contour on the cross-sectional image (6.0% of 
images), decentration artefacts are caused by eccentric positioning of the imaging 
catheter within the artery and lead to image attenuation in remote structures (30.9%), 
calibre artefacts are caused by an arterial diameter greater than the penetration limit 
of the OCT and are a particular problem in vein grafts and in the LMS107 (15.0%), and 
flow artefacts are caused by failure to clear blood from either the vessel or imaging 
catheter by flushing (19.6%)106.  
 
1.3.2 OCT And Vulnerable Plaque 
1.3.2.1 Definition Of Thin-Cap Fibroatheroma 
Given the high image resolution with OCT, it is well placed to identify these high-risk 
plaques in vivo (Figure 1.12). However, there is still debate over the exact definition 
of a TCFA on OCT (OCT-TCFA), as histological specimens of TCFA differ from OCT 
images (likely due to shrinkage of pathological specimens). Using a cut-off of 70µm 
(as the axial resolution of OCT is >10µm), only 67% of ruptured plaques in one study 
of 72 patients with ACS were defined as having a thin fibrous cap108. Therefore, the 
fibrous cap of a TCFA may be thicker in vivo than on histology. There is a higher 
proportion of lipid-rich plaque on OCT in patients with ACS compared to stable 
angina109, and some studies have used an additional parameter to define a TCFA: that 
the arc of the lipid pool should subtend an angle >90o102. However, there is no 
consensus on the exact cut-off value for the fibrous cap or arc of lipid pool for the 
identification of an OCT-TCFA, only that the definition of an OCT-TCFA should reflect 






Figure 1.12 Thin-cap fibroatheroma on multi-modality imaging 
Images from an 83 year old male ex-smoker, who presented with a NSTEMI. He underwent PCI to a 
culprit lesion in the LAD artery, but intravascular imaging of the RCA revealed a non-obstructive VH-
TCFA in the non-culprit artery. 
A) Angiogram with a non-obstructive lesion in the RCA (red bar)  
B) OCT image of the thin-cap fibroatheroma (white arrow) 
C) VH-IVUS image of the thin-cap fibroatheroma (white arrow) 
* Guidewire artefact 
 
1.3.2.2 Thin-Cap Fibroatheroma in ACS 
OCT-TCFA are more common in patients with an acute or unstable clinical 
presentation than in stable angina. A comparison of 26 STEMI patients with 16 stable 
angina patients demonstrated that STEMI patients had a higher proportion of OCT-
TCFA in the culprit lesion (85% vs. 13%, p<0.001) and a thinner fibrous cap (57±12 
vs. 180±65µm, p<0.001)110. Patients with STEMI also had a higher prevalence of OCT-
TCFA compared to patients with NSTEACS (78% vs. 49%, p=0.008)111. Similar results 
have been demonstrated in patients with UA compared to patients with stable angina 
(incidence of OCT-TCFA 81% vs. 47%, p=0.002; fibrous cap thickness of 56±20 µm 
vs. 75±30 µm, p<0.001)112.  Patients with ACS also have a higher proportion of OCT-
TCFA, and thinner fibrous caps, in non-culprit lesions110, 113. In a single-centre study of 
150 lesions on OCT (73 ACS culprit lesions, 32 ACS non-culprit lesions and 45 stable 
angina culprit lesions), there was a higher incidence of OCT-TCFA (67% vs. 41% vs. 
20%, p<0.01) and a thinner fibrous cap (60 vs. 82 vs. 114µm, p<0.001) in the ACS 
culprit lesions compared to the other two groups114. 
 
In patients with ACS, OCT-TCFA are more commonly found in the proximal segments 
of the culprit vessel115, 116. OCT has been utilised to confirm findings from histological 
studies that plaque rupture of TCFA occurs more often away from the site of MLA in 
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patients with STEMI and NSTEMI (mean distance of site of rupture from MLA = 
2.34±2.31mm)117.  
 
1.3.2.3 Effects Of Therapy On TCFA 
Methods to stabilise these vulnerable TCFA have been assessed using serial OCT 
studies. Patients taking statin therapy had an increased cap thickness of OCT-TCFA 
compared to patients not taking statins (an increase of 192±41µm vs. 25±8µm, 
p<0.001) at 9 months post-ACS118. In a prospective study of 42 patients with stable 
angina, statin therapy resulted in an increase in fibrous cap thickness when compared 
to dietary modification alone (+52±32µm vs. 2±22µm, p<0.001)119. Another study 
enrolled 30 patients (56.6% with ACS) with untreated dyslipidaemia and OCT-TCFA 
on baseline imaging and randomised them to either statin therapy alone or statin + 
eicosapentaenoic acid120. Despite similar levels of low density lipoprotein at follow up, 
those who received eicosapentaenoic acid had a greater increase in fibrous cap 
thickness (54.8±27.9µm vs. 23.5±11.6µm, p<0.0001)120. However, it remains to be 
seen whether stabilising these plaques actually improves clinical outcomes. 
 
1.3.2.4 Plaque Rupture 
Plaque rupture on OCT is associated with adverse outcomes in ACS121, 122. Ruptured 
plaques with thrombus have thinner fibrous caps than those without thrombus 
(57±17µm vs. 96±48µm, p=0.0076)123. Intracoronary thrombus is well visualised by 
OCT and is almost universally seen in STEMI110.  However, care must be taken with 
interpretation of these results, as overlying thrombus may interfere with OCT 
characterisation of the lesion, and performing thrombus aspiration prior to OCT 
imaging may alter the underlying plaque anatomy.  
 
Patients with ACS caused by ruptured culprit plaques are more likely to have non-
culprit plaques with a higher lipid index (mean lipid arc multiplied by lipid length 
measured in the longitudinal view: 1196.9±700.5 vs. 747.7±377.3, p=0.001), higher 
incidence of OCT-TCFA (52.9% vs. 19.0%, p=0.029), and thinner fibrous caps 
(107.0±56.5mm vs. 137.3±69.8mm, p=0.035) on OCT than those with non-ruptured 
culprit plaques124. In addition, plaque ruptures in patients with ACS differ from those 
seen in patients with asymptomatic coronary artery disease with a greater lipid arc 
(171±71o vs. 133±71o, p=0.037), higher incidence of thrombus (78% vs. 9%, p<0.001) 
and a smaller minimum lumen area of the culprit lesion (1.79±0.92mm vs. 
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2.75±0.99mm, p<0.001), suggesting that the morphology of the plaque rupture may 
influence whether it heals asymptomatically or causes an adverse cardiovascular 
event125. 
 
Patients with ruptured culprit plaques were also more likely to have secondary, non-
culprit plaques ruptures (35.3% vs. 4.8%, p=0.016)124. This suggests that these 
patients have increased pan-coronary vulnerability and may be at higher risk of future 
adverse events. In a study of 261 patients (41% with ACS), 20% had multiple plaque 
ruptures in non-culprit lesions126. The presence of OCT-TCFA, microchannels, and 
macrophage accumulations were independent predictors of multiple plaque 
ruptures126. 
 
1.3.2.5 Plaque Erosion 
Contrary to plaque rupture, plaque erosion is characterised by luminal thrombus and 
absence of the endothelium, without evidence of fibrous cap disruption95. In one 
histological study, erosions were responsible for over 40% of thrombotic sudden 
cardiac deaths and were more prevalent in women127. Although OCT does not have 
the resolution necessary to identify the absence of the endothelium, OCT-identified 
plaque erosion has been defined as the presence of thrombus and an irregular luminal 
surface in the absence of cap rupture102. In a cohort of patients with STEMI (n=30), 
plaque erosions were more often seen by OCT than by IVUS or angioscopy (23% vs. 
3% vs. 0%, p=0.003)88. In a previous study, OCT was performed in 126 patients with 
ACS and demonstrated plaque rupture in 43.7%, erosions in 31% and calcified nodules 
in 7.9%128. Plaque erosions were more commonly observed in younger patients 
(53.8±13.1 years vs. 60.6±11.5 years, p=0.005), and were more commonly associated 
with NSTEMI than STEMI (61.5% of patients with NSTEMI had a plaque erosion vs. 
29.1% of STEMI patients, p=0.008). Patients with plaque erosion had a less severe 
diameter culprit stenosis than those with plaque rupture (55.4±14.7% vs. 68.8±12.9%, 
p<0.001)128. Plaque erosion on OCT was associated with a higher level of serum 
myeloperoxidase, a haemoprotein released on neutrophil activation, than plaque 
rupture (2500ng/ml vs. 707ng/ml, p=0.001)129.  
 
Prati et al performed OCT after thrombus aspiration in patients with STEMI and 
followed up 31 patients with plaque erosion for one year130. Twelve patients were 
managed with thombus aspiration only, and 19 had thrombus aspiration plus 
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angioplasty. There were no significant differences in outcomes (death, MI, and target 
vessel revascularisation) between the groups130. Although this study raised the 
possibility of using OCT to influence the management of patients with ACS, this study 
is limited in that it consisted of too small a sample size to draw definitive conclusions, 
and treatment was not randomised (patients managed conservatively were younger 
and had fewer cardiac risk factors). 
 
1.3.2.6 Calcified Nodules 
Plaques with superficial calcified nodules are also considered prone to rupture131, 132. 
The pattern of plaque calcification on OCT was evaluated in 187 patients with acute 
MI, unstable and stable angina. Patients with acute MI and UA had less overall calcium 
(measured by arc, area, and length, p<0.001 for all measurements) than those with 
stable angina, but were more likely to have spotty calcium deposits closer to the 
surface of the plaque133. The incidence of calcified nodules in ACS in one study was 
8%, but was more common with increasing age128. However, the accuracy of OCT in 
identifying smaller areas of calcification has also yet to be validated against 
histology102. 
 
1.3.2.7 Macrophage Infiltration  
The resolution of OCT may allow identification of macrophages within an 
atherosclerotic plaque. In ACS patients, a higher prevalence of macrophage infiltration 
in non-culprit plaques was seen compared with non-ACS patients (82.4% vs. 37.9%, 
p=0.001)113. A study of diabetic patients also found those with poorly controlled 
diabetes (glycated haemoglobin ≥8%) had greater macrophage infiltration than non-
diabetics or well-controlled diabetics (37.9% vs. 11.0%, p=0.037)134. Plaques that 
exhibited an increase in luminal stenosis over time were more likely to have higher 
numbers of macrophages (OR 9.6, p=0.001), TCFA (OR 20, p<0.001), intimal 
laceration (OR 10.2, p<0.001), and/or microchannels (OR 20, p<0.001)135.  
 
1.3.2.8 Microchannel Formation 
Plaque neovascularisation and microchannel formation (Figure 1.13) are known to be 
markers of plaque vulnerability and rupture, as well as intraplaque haemorrhage, which 
can contribute to plaque progression136. Patients with microchannels in the culprit 
lesion were more likely to have presented with unstable than stable angina (83% vs. 
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17%), have a thinner fibrous cap (60µm vs. 100µm, p=0.001), and had a trend towards 
a higher incidence of plaque rupture (50% vs. 28%, p=0.11)137. In addition, in patients 
with early coronary artery disease (diameter stenosis <30%) patients with 
microchannels were more likely to have underlying coronary endothelial dysfunction 
as measured by the coronary artery diameter change in response to acetylcholine 
(−15.9±15.9% vs. −6.4±13.5%, p<0.01)138. 
 
 
Figure 1.13 Microchannel 
OCT image showing a microchannel (yellow arrow) associated with a non-obstructive lesion with a large 
necrotic core (white arrow) 
* Guidewire artefact 
† Seam line artefact 
 
1.3.2.9 Cholesterol Crystals 
In a study of 101 patients with stable coronary artery disease, 38.6% had ChC in the 
culprit lesion139. Patients with ChC were older (69.5 ± 8.0 vs. 65.3 ± 10.7 years, 
p=0.04) and had a higher glycated haemoglobin (7.0 ± 1.4 vs. 6.4 ± 1.2%, p=0.04) than 
those without. In addition, those with ChC had a higher frequency of spotty calcification 
(58.9 vs. 25.8%, p<0.001), microchannels (69.2 vs. 38.7%, p=0.003), and lipid-rich 
plaques (53.8 vs. 29.0%, p=0.01). Dai et al performed balloon-occlusion OCT in culprit 
lesions of 206 patients with STEMI (28.6%) or NSTEACS (71.4%) and demonstrated 
a ChC prevalence of 39.3%140. Patients with ChC were more likely to have presented 
with a STEMI (37.0% vs. 23.2%, p=0.032) and have a greater % diameter stenosis in 
the culprit lesion (68.1 ± 18.3% vs. 61.0 ± 19.1%, p=0.015)140. Lipid index 
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(3826.1 ± 2111.4 vs. 2855.0 ± 1753.0, p=0.001), macrophage accumulation (77.8% 
vs. 40.0%, p<0.001), microchannels (67.9% vs. 24.8%, p<0.001), plaque rupture 
(58.0% vs. 36.0%, p=0.001), and spotty calcification (35.8% vs. 10.4%, p<0.001) were 
all more common in those with ChC, but the prevalence of OCT-TCFA did not differ 
between groups (56.8% vs. 47.2%, p=0.179)140. However, it is unclear by what 
mechanism ChC potentially increase plaque vulnerability. 
 
1.3.3 Comparison With Other Intravascular Imaging Modalities 
1.3.3.1 Fractional Flow Reserve 
Although OCT is a structural imaging technique, there have been attempts to correlate 
it with functional measures of stenosis severity, such as fractional flow reserve (FFR). 
Table 1.6 summarises the studies that have correlated MLA (measured by OCT) and 
FFR and demonstrates a wide range of cut-offs for OCT-MLA in diagnosing functionally 
significant lesions. In a study of 106 patients with stable angina, an FFR <0.8 was 
associated with a smaller MLA (1.3 ± 0.5 vs. 2.9 ± 1.1mm2, p<0.001), greater area 
stenosis (80.0 ± 11.4 vs. 63.6 ± 9.2%, p<0.001), greater lipid arc (145.1 ± 63.0 vs. 
120.7 ± 48.9, p=0.047), and the presence of macrophage accumulations (45.0 vs 
22.9%, p=0.016) and ChC (17.5 vs. 2.9%, p=0.011)141. However, it was not associated 
with the presence of OCT-TCFA (10.0 vs. 11.4%, p=1.000) or microchannels (27.5 vs. 
22.9%, p=0.586)141. The ILUMIEN 1 study was designed to ascertain whether a 
combined OCT and FFR device aided peri-procedural decision making, and 
demonstrated over two thirds of physician decisions were influenced by either pre or 
post PCI OCT/FFR evaluation and there were low rates of post procedure MACE142. 
The COMBINE study aims to determine whether the addition of OCT evaluation to FFR 








































FD-OCT <0.75 <1.39mm2 54.4% 80.5% 69.0% 68.9% 




FD-OCT <0.80 <1.62mm2 89% 91% 97% 70% 








































<0.75 <1.91mm2 80.6% 92.3% 93.5% 77.4% 
Table 1.6 Summary of studies comparing OCT and FFR in intermediate 
coronary lesions 
There is a wide variation in values of MLA on OCT in functionally significant intermediate stenoses. 
Unlike on IVUS, there is no consensus on a value of MLA on OCT that would be considered flow-limiting.  
 
1.3.3.2 Near-Infrared Spectroscopy 
NIRS can only quantify the lipid content of the plaque, but the signal can pass through 
calcium and accurately quantify lipid behind this90. NIRS provides only compositional 
information regarding the plaque, but does not require a bloodless field152 and can help 
discriminate between calcium and necrotic core, which can often be misinterpreted on 
OCT153. A comparison of a hybrid NIRS-IVUS catheter with OCT demonstrated that 
plaque burden, positive remodelling and lipid index measured by the hybrid catheter 
were associated with OCT-TCFA154. A hybrid NIRS-OCT catheter is in development 
and a proof-of-concept demonstration has been published, successfully imaging a 3cm 
section of one human coronary artery ex vivo to provide simultaneous structural and 
compositional information155. 
 
1.3.3.3 3-Dimensional Reconstruction 
As the technology of OCT becomes more refined, and image acquisition faster, it has 
become possible to perform 3D reconstructions of the coronary anatomy by fusing X-
ray and OCT data156, 157. This allows assessment of local haemodynamic flow patterns 
and hence the effects of endothelial shear stress on the risk of plaque progression and 
rupture158. Three-dimensional IVUS studies have demonstrated that localised 
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elevation of shear stress is correlated with the plaque rupture site in patients with ACS 
(ĸ=0.79)159. However, this has not yet been studied using OCT. 
 
1.3.3.4 Computed Tomography 
Several studies have attempted to correlate vulnerable lesions seen on invasive 
imaging such as OCT with markers on non-invasive imaging such as CT. Nakazato et 
al demonstrated, in a study of 68 coronary plaques in 45 patients, that OCT-TCFA with 
macrophage infiltration were associated with a higher prevalence of positive 
remodelling (71% vs. 11%, p<0.001) and low attenuation plaque (59% vs. 11%, 
p<0.001) on CT versus those without160. A study of 102 patients (24 with UA, 78 with 
stable angina) demonstrated that plaques exhibiting both positive remodelling and low 
attenuation on CT had significantly thinner fibrous caps (76 ± 24 vs. 192 ± 49μm, 
p<0.001) and had a higher prevalence of OCT-TCFA (38% vs. 0%, p<0.001)161. The 
diagnostic accuracy of these two CT characteristics in identifying OCT-TCFA was 
78%161. Low attenuation plaque and napkin ring sign on CT were associated with OCT-
TCFA on multi-variate analysis in a more recent study of 28 symptomatic patients162. 
Thus, CT may prove a viable adjunct in the identification of vulnerable lesions in 
patients for whom invasive intra-coronary imaging may hold higher risk. 
 
1.3.4 Limitations Of OCT 
A major limitation of OCT is its requirement for a blood-free field, necessitating flushing 
with either saline or contrast during image acquisition. Any contamination with blood 
during pullback results in loss of image data due to backscattering. Differentiation of 
calcium and lipid pool is more challenging than with IVUS, as both give low attenuation 
signals163. Moreover, the limited ranging depth of OCT (5-6mm) means that imaging of 
the LMS and vein grafts is limited107, and calculation of plaque volume may be 
inaccurate101. Poor penetration of light through lipid-rich tissue also limits its use in 
quantifying certain plaque components. Imaging artefacts plague up to a third of OCT 
images and thrombus obscures the morphology of the underlying lesion. Plaque 
analysis of OCT images for features of vulnerability is currently done on a frame-by-
frame basis and is therefore time consuming and not feasible in real time in the catheter 
laboratory, although automated processes for luminal border detection and plaque 





The detailed spatial resolution provided by OCT has allowed detailed in vivo correlation 
of those histopathological features thought to underlie plaque vulnerability. This has 
led to greater insight into the prevalence of vulnerable plaques in patients presenting 
with acute coronary syndrome, particularly in non-culprit vessels. Although there is lack 
of clinical data to guide the management of vulnerable lesions, a greater understanding 
of their natural history and temporal response to pharmacological or invasive 














I propose that the composition of coronary atherosclerotic plaque in older patients with 
NSTEACS differs to that found in previous studies in younger patients. I hypothesise 
that previously identified patient-level risk factors (age, sex, and frailty) are associated 
with different patterns of vulnerable plaque, and that certain plaque phenotypes 
observed on intravascular imaging are associated with a higher rate of adverse 
outcomes in this cohort. This will not only further our understanding of the 
pathophysiology of advanced and unstable coronary disease, but could lead to more 
individualised management of these high risk patients. 
 
2.2 Aims 
1. To evaluate the vulnerable plaque burden among high-risk older patients 
presenting with NSTEACS and determine its association with previously 
identified patient-level risk factors: age, sex and frailty. 
 
2. To determine the association of previously identified vulnerable plaque 
phenotypes both with each other and with patient characteristics: 
a) Angiographic lesion calcification 
b) Culprit vs. non culprit lesions 
c) Dense calcium 
d) VH-TCFA 
e) Liverpool Active Plaque Score 
f) Plaque rupture 
g) Macrophage accumulation 
h) Microchannels 
i) Cholesterol crystals 
j) OCT-TCFA 
 
3.  To identify the lesion-related factors that put this cohort at higher risk of adverse 












3.1 Author Statement 
 
The subject of this thesis is data obtained from patients recruited to the invasive 
imaging sub-study of the Study to Improve Cardiovascular Outcomes in High Risk 
PatieNts (the ICON1 Study), a multi-centre prospective observational study of older 
patients with ACS165. A number of members of the research team were involved in the 
running of this study, but the author was personally responsible for the following: 
 
 Ethics and Trust Research and Development study protocol amendments 
 Provision of recruitment updates to the NIHR portfolio database 
 Patient screening at Freeman Hospital, Newcastle Upon Tyne 
 Patient consent and recruitment to the main study at both sites 
 Collection of demographic data for the screening log 
 Collection of blood samples at time of angiography 
 Extraction of peripheral blood mononuclear cells for telomere analysis 
 Support for the treating interventional cardiologist during invasive coronary 
imaging acquisition 
 Obtaining anonymised imaging data on CD/DVD for offline analysis 
 Collecting the clinical information from patients at baseline on standardised 
case report forms, including demographics, frailty scoring, quality of life indices, 
functional status, and cognitive function 
 Performing non-invasive measures of vascular function such as 
echocardiography, ankle-brachial index, vascular stiffness, carotid intima media 
thickness, and endothelial function 
 Writing standard operating protocols for the analysis of angiographic and VH 
IVUS data  
 Offline analysis of angiographic data, and training members of the core lab in 
performing these analyses 
 Offline analysis of all VH IVUS data 
 Offline analysis of all OCT data 
 Collecting the clinical information from patients, GPs and electronic health 
records at 1 year follow up on standardised case report forms 
 Entering data into study databases 
 All statistical analysis 
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3.2 Ethical Approval 
 
The ICON1 study is registered on the UK Clinical Research Network portfolio (ID 
number 12742) and with clinicaltrials.gov (ID number NCT01933581). It was granted 
ethical approval by the North East Research Ethics Committee, Sunderland (ID 
number 12/NE/0160) on 25 May 2012 and was monitored by this Committee. Approval 
for the research to be carried out at the Newcastle Upon Tyne NHS Foundation Trust 
was granted by the Research and Development department at the Royal Victoria 
Infirmary. The study was performed in accordance with guidelines on Good Clinical 
Practice. 
 
3.3 Patient Screening And Recruitment 
 
The prospective observational ICON1 study recruited patients referred to the two 
tertiary cardiac centres in the North East of England: The Freeman Hospital in 
Newcastle upon Tyne, UK and The James Cook University Hospital in Middlesbrough, 
UK. In Freeman Hospital, approximately 3,000 PCI procedures are carried out every 
year and, in the James Cook University Hospital, approximately 1,750 PCI procedures 
are performed every year. All patients aged ≥75 years on the urgent/ACS PCI cardiac 
catheter laboratory list were screened by the study team. 
 
3.3.1 Inclusion And Exclusion Criteria 
The inclusion and exclusion criteria are detailed in Table 3.1. Patients with cardiac 
arrest and cardiogenic shock were excluded because it would not have been possible 
to obtain valid consent in these urgent cases. Ventricular arrhythmias and significant 
valvular disease were excluded as they may have been the primary cause for 
admission rather than NSTEACS. Patients with a life expectancy of <1 year were not 
included as it would preclude measurement of adverse outcomes, and patients with 
active infection were excluded as measurement of inflammatory markers would be 
confounded. Previous CABG was an exclusion criterion until a protocol amendment 
was approved by the ethics committee to include these patients on 18 October 2013. 
However, these patients were not included in the invasive imaging sub-study as OCT 
imaging would not have been possible in vein grafts due to the limitations in penetration 
of the technology, and it was felt that atheroma in CABG grafts may have a different 
pattern to native vessels.  
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Inclusion Criteria Exclusion Criteria 
1. ≥ 75 years of age 
2. Initial presentation with NSTEACS 
(UA, NSTEMI) 
3. Planned for angiography ± PCI 
1. Cardiac arrest at presentation or during admission 
2. Cardiogenic shock at presentation or during admission 
3. Ventricular arrhythmia at presentation or during admission 
4. Moderate or severe valvular disease 
5. Malignancy with <1 year expected survival 
6. Active infection during admission 
7. Previous CABG  
Table 3.1 Inclusion and exclusion criteria for the ICON1 study 
 
3.3.2 Consent And Information 
Potential participants were approached on their arrival to the ward and the study 
explained in detail. They were given an opportunity to ask questions, and were given 
a written information sheet before the researcher returned to answer any further 
questions and to obtain informed consent. In patients with visual impairment, the 
researchers read the information sheet and consent form to the patient. Patients who 
were unable to consent, e.g. due to lack of capacity, were not recruited. The date of 
birth and gender of every patient who was screened for potential participation in the 
study was entered into a password protected screening log. Baseline demographic 
data for patients entered in the screening log was collected retrospectively from the 
local British Cardiovascular Intervention Society database, to which all patients 
undergoing angiography with a view to PCI consent to have data stored for audit 
purposes. 
 
3.3.3 Study Protocol 
The study flow chart is displayed in Figure 3.1. Participation in the study did not alter 
the contemporary treatment of NSTEACS (PCI, CABG or medical therapy) offered by 
the treating interventional cardiologist166. Each patient was assigned an anonymised 
study ID number and data was collected on standardised case report forms by 
members of the research team (Appendix A). 
 
In total, the ICON1 study aimed to recruit 300 patients, with 100 patients undergoing 
invasive coronary imaging with VH-IVUS alone, and 30 patients undergoing both VH 







Figure 3.1 Flow diagram of the invasive imaging sub-study protocol 
 
3.4 Quantitative Coronary Angiography 
 
Angiography was performed according to local practice at 15 frames/second. Each 
angiogram was anonymised and transferred to optical disc for offline analysis by the 
ICON1 angiographic core lab. Readers were blinded to patient demographics. All 
readers were trained in QCA analysis by an experienced interventional cardiologist 
and followed the ICON1 QCA Standard Operating Protocol (Appendix B). Each 
angiogram was analysed by 2 readers and, in the case of any major discrepancies, a 
third reader adjudicated. 
 
To gain an overview of the burden of coronary artery disease, the SYNTAX score167 
and BCIS Jeopardy Score (a semi-quantative assessment of the amount of 
myocardium at risk from coronary stenoses)168 were calculated. All culprit lesions and 
all lesions that were subsequently intervened on were analysed (irrespective of % 
stenosis). Other lesions were analysed if the diameter stenosis was >40% in a 
vessel >1.5mm in diameter. Lesions were considered separately if they were >3 vessel 
reference diameters apart.  
 
Specific lesion location, calcification score and lesion complexity were recorded. In 
addition, measurements of lesion length, minimum lumen diameter (MLD), MLA, 
maximum diameter and area % stenosis, and vessel reference diameter (RD) were 
Consenting patients aged ≥75 years admitted with UA/NSTEMI 
On clinical grounds – coronary angiography ± PCI 
Blood samples for FBC, U&Es, glucose, cholesterol, vitamin D, hsCRP 
If decision for PCI: VH IVUS ± OCT in all 3 coronary arteries where possible 
If decision not for PCI: no VH IVUS or OCT 
& 
Frailty scoring, co-morbidity assessment 
Cath lab 
Day after PCI 




made using the Medis software, QAngioXA version 7.3. Finally, post-PCI lesion 
characteristics and any post-intervention complications were recorded. Residual 




 𝑥 100) were calculated169, 170. 
 
A PCI procedure was considered a complete success if the post-procedure residual 
diameter stenosis was <30% with TIMI grade 3 flow. A procedure was classified as a 
partial success if there was either a ≥30% residual stenosis by QCA or if TIMI grade 2 
flow was attained. A procedure was classified a failure if there was a persistent total 
occlusion, if the lesion could not be crossed, or if there was persistent abrupt closure.  
 
3.5 Invasive Coronary Imaging 
 
This PhD project utilised patient data from the invasive imaging sub-study of ICON1, 
recruited between 31 October 2012 and 26 August 2015. It was expected that not all 
patients enrolled in ICON1 would be eligible for invasive imaging thus it was anticipated 
that, for every patient undergoing invasive imaging, 2 patients would be entered into 
the non-invasive sub-study. We aimed to image 100 patients with VH IVUS, of which 
30 patients would be imaged with both VH IVUS and OCT. 
 
3.5.1 Virtual Histology Intravascular Ultrasound 
 
3.5.1.1 Acquisition 
Following diagnostic angiography and decision to proceed to PCI, a 20MHz, phased-
array Volcano Eagle Eye Platinum™ (EEP) catheter (Figure 3.2A) was mounted on 
an R-100 pullback device (Figure 3.2B) and connected to either an integrated S5i 
system or mobile S5 tower. Image acquisition was performed at a pullback speed of 
0.5mm/s and was ECG gated to ensure only one frame was acquired per cardiac cycle. 
The maximum length of all three coronary arteries was imaged, where feasible53. The 
data was anonymised, then transferred to a DVD for offline data analysis. The treating 














Figure 3.2 Eagle Eye Platinum catheter (A) and R-100 pullback device (B) 
 
3.5.1.2 Analysis 
VH IVUS intracoronary imaging analysis was performed using the Medis QIvus 
software, versions 2.2 and 3.0, which calculates the MLD and MLD, %stenosis, and 
absolute volume and percentage of each plaque component (fibrous, FF, NC and DC) 
after the reader had manually drawn the contours of the lumen and external elastic 
membrane in each frame (Appendix C). Percent atheroma volume was calculated as 
the proportion of the vessel wall occupied by plaque, as previously described171. RI 
was calculated by dividing the external elastic membrane (EEM) area at the site of 
maximal plaque burden by the EEM area at the reference site (the site of smallest 
plaque burden 10mm proximal to the target site but distal to any side branches)172. 
 
A manual frame-by-frame analysis was then performed to classify the lesion sub-type 
present according to definitions from a previously published consensus document 
(Figure 1.7)53. The percentage of frames containing each lesion sub-type, rather than 
number of separate lesions, was calculated, as the high plaque burden in this cohort 
led to relatively low prevalence of separate lesions when classified as per the 
consensus document (lesions separated longitudinally by >5mm of artery with a plaque 
burden of <40% should be considered separate lesions53, but few of the ICON1 cohort 
of patients had long enough segments of “normal” coronary artery without 
atherosclerosis). The LAPS (= –2.149 + (0.68×
𝑁𝐶
𝐷𝐶
) + (3.39 if MLA <4) + (5.1 if 





3.5.2 Optical Coherence Tomography 
 
3.5.2.1 Acquisition 
OCT images were obtained using a Dragonfly catheter (St Jude Medical, Minnesota, 
USA) connected to the Ilumien™ PCI Optimization System. Immediately prior to image 
acquisition, a short flush of iso-osmolar contrast was administered to ensure the guide 
catheter was well engaged with the coronary artery and the catheter was clear of blood. 
The system was calibrated and the OCT pullback initiated with a flush of iso-osmolar 
contrast (10ml in the right coronary artery, 15ml in the left coronary artery). OCT 
images were obtained in 54mm segments at a pullback rate of 20mm/s in all three 
coronary arteries where feasible. Data was transferred anonymously to a DVD for 
offline analysis and the operator was blinded to this data during the procedure. 
 
3.5.2.2 Analysis 
OCT data was analysed using the Medis QIvus software, version 2.2. Contours were 
drawn around the lumen to generate data on the MLA and MLD. The whole vessel was 
then analysed frame-by-frame to identify lesion sub-types. An atherosclerotic lesion 
was defined on OCT as a mass lesion within the arterial wall, with focal intimal 
thickening or loss of the normal vessel architecture102. The number of frames 
containing significant lipid or calcium accumulations were recorded for each vessel, as 
were the presence or absence of other pathologies such as plaque rupture, thrombus, 
OCT-TCFA, microchannels, macrophage accumulations and ChC.  
 
3.6 Frailty Assessment 
 
The day following PCI, frailty was assessed by the Fried Frailty Criteria (Table 1.2, 
Appendix B)17. Nutritional status, endurance and physical activity were assessed by 
asking the patient pre-specified questions. Strength was assessed by grip 
dynamometer in the dominant hand (average of 3 readings), and mobility was 
assessed by timing the patient walking over 4.5m (15 feet). The patient was 
categorised as frail if 3 or more criteria were present, pre-frail if 1 or 2 criteria were 




3.7 Biomarker Analysis 
 
Full blood count, renal function, blood glucose, cholesterol and troponin levels were 
measured in all patients as part of routine normal care and were recorded in the case 
report form. At the time of coronary angiography, before administration of any heparin, 
30ml of blood was collected from the arterial sheath. Highly sensitive C-reactive protein 
(hsCRP) and vitamin D were analysed in real time. Vitamin D was stratified into 
deficient (<25nmol/L), insufficient (25-49nmol/L) and sufficient (≥50nmol/L) categories 




Patients were followed up in the research clinic at 1 year from the recruitment date and 
data was collected on standardised case report forms (Appendix D). If this was not 
possible, the patient was contacted by telephone and primary outcome measures 
recorded from this. If the patient was unwilling or unable to be contacted directly, the 
patient’s General Practitioner was contacted and a list of all medical consultations from 
the date of recruitment was obtained. 
 
Primary outcome measures were defined as death, ACS, stroke, repeat unplanned 
revascularisation, and Bleeding Academic Research Consortium (BARC) defined 
bleeding (grade 2 and above)173. Time to first primary endpoint was recorded.  
 
3.9 Statistical Analysis 
 
The sample size was calculated to provide adequate power to detect whether the 
presence of TCFA are associated with a composite of the 1-year primary outcomes in 
this population. This required several assumptions taken from previous studies: a 
27.9% rate of adverse outcomes in patients ≥75 years following interventional 
treatment for ACS22, a 20% incidence of TCFA in patients ≥65 years174, and a HR of 
3.35 for a TCFA to cause an adverse event in patients of all ages69. Using the method 
described by Kelsey et al, a sample size of 97 patients is required to provide 80% 




Normality of the distribution of continuous variables was checked with the Shapiro-Wilk 
test. Continuous variables are expressed as mean ± standard deviation (SD) if 
normally distributed or median and IQR if not normally distributed. Discrete variables 
are expressed as numbers and percentages  
 
Results of patient-level, vessel-level and lesion-level data are presented. Where both 
independent and dependent variables were measured at the same level, they were 
analysed using unpaired Student’s t-test or ANOVA test if continuous and normally 
distributed, Mann-Whitney U test or Kruskal-Wallis test if continuous but not normally 
distributed, Pearson’s Chi Square test or Fisher’s Exact Test (if any cell count was <5) 
if categorical. 
 
Where the independent variable was measured at a patient-level but the dependent 
variable was measured at a vessel or lesion-level, a linear mixed-effects model was 
used, nesting lesions or vessels within patient identifiers. This model handles 
correlated data and unequal variances, and also allows an unequal number of 
measurement repetitions between subjects (as patients had differing numbers of 
vessels imaged by VH IVUS and OCT). It also estimates fixed (i.e. affects the 
population mean) and random (i.e. associated with the sampling procedure) effects 
and thus adjusts for the covariance structure of the data. 
 
Predictors of plaque phenotypes were investigated by performing multiple regression 
analyses (for continuous dependent variables e.g. %NC) or multivariate logistic 
regression (for categorical dependent variables e.g. presence of VH-TCFA). 
Covariates for the multivariate analyses were chosen by purposeful selection, with any 
independent variable having a significant univariate test (with a p value cut-off point of 
0.25) entered into an automated stepwise regression analysis with the non-candidate 
inclusion level set to 0.15. This is a method which has been shown to result in a more 
accurate model when risk factor modelling rather than just predicting events, as it 
identifies and retains confounders at a greater rate than other automated selection 
algorithms176. 
 
The Statistical Package for Social Sciences version 21.0 (SPSS Inc, Chicago, IL) and 







CHAPTER 4: RESULTS – Demographics, 




The data presented here is a sub-study of a larger prospective observational study of 
older patients with ACS. I evaluate the recruitment of older patients to this invasive 
imaging sub-study and quantify the challenges of three-vessel intravascular imaging 
in this complex cohort. 
 
4.1 Recruitment  
 
Recruitment is summarised in Figure 4.1. Of the 629 patients initially screened for 
participation in ICON1, 457 (72.7%) were eligible and approached to take part in the 
study. The average age of those screened was 81.2 ± 4.8 years and 43.6% were 
female. Of those approached, 319 (69.8%) consented to participation. Following 
coronary angiography, 20 (6.3%) of these patients were excluded from the study due 
to a non-NSTEACS final diagnosis, and one patient withdrew their consent.  
 
In total, 99/298 (33.2%) underwent invasive imaging. Five of these patients were 
recruited after August 2015 and two patients were <75 years, so are therefore not 
included in this work. In addition, there were 8 patients that underwent VH IVUS 
evaluation with the Volcano Revolution® catheter as the EEP catheters were not 
available; these patients are also not included in the VH IVUS analysis (although 7 did 
have OCT imaging alone), as previous validation studies have shown that the EEP 
phased-array catheter demonstrates systematically higher volumetric measurements 
and therefore cannot be directly compared with the 45MHz rotational imaging 
catheter177.  
 
This leaves a final total of 91 patients recruited over 34 months from November 2012 














































Figure 4.1 CONSORT flow diagram of study recruitment 
 
Not recruited:   n = 21/319, 6.6% 
 Non-ACS diagnosis  n = 20 














Recruited to ICON1 
(n = 298) 
Recruited to invasive sub-study 





















Not recruited:   n = 207/298, 69.5% 
 Unfavourable coronary anatomy n = 53 
 No PCI performed  n = 38 
 Recruited after August 2015 n = 27 
 Under 75 years  n = 18 
 Previous CABG  n = 16 
 Operator decision  n = 13 
 Time pressure on list  n = 10 
 Previous PCI   n = 9 
 Unknown   n = 9 
 Awaiting unstable patient  n = 5 
 No trained operator  n = 4 
 Equipment unavailable  n = 3 
 Declined invasive imaging n = 2 
 
Provided written, informed consent 









Patients excluded:   n = 172/629, 27.3% 
 Severe valvular disease  n = 50 
 Ventricular arrhythmia  n = 21 
 Active infection  n = 23 
 Patient unwell   n = 18 
 Malignancy   n = 12 
 Cardiac arrest   n = 9 
 Recruitment to another study n = 9 
 Cardiogenic shock  n = 3 
 Declined PCI   n = 1 
 Other   n = 26 
Satisfied ICON1 inclusion criteria 




























Unable to provide informed consent: n = 59/457, 12.9% 
 Lack of capacity  n = 45 
 Severe visual impairment n = 7 
 Language issues  n = 4 
 Severe hearing impairment n = 2 
 Illiteracy   n = 1 
Declined to participate:  n = 79/457, 17.3% 
Total number of patients screened 
(n = 629) 
VH IVUS and OCT n = 19 
VH IVUS only n = 65 
OCT only n = 7 
58 
 
Table 4.1 details the baseline characteristics of patients in the eligible and recruited 
populations to August 2015 (both to the main ICON1 study and to the invasive imaging 
sub-study). The ICON1 study cohort was slightly younger than the eligible population 
and had fewer females. This is because female patients were more likely to decline to 
participate than male (25.6% vs. 10.0% of eligible patients approached, p<0.001), and 
those who were unable to consent were older than those able to consent (83.0 ± 4.7 
vs. 81.0 ± 4.7 years, p=0.002). The cardiovascular risk factor profile was similar other 
than family history of IHD. The invasive imaging sub-study cohort did not differ 
significantly from the ICON1 population other than lower incidences of hypertension, 
hyperlipidaemia and renal disease. This may reflect a higher incidence of unfavourable 














A vs B B vs C 
Age (years ± SD) 81.5 ± 4.4 81.1 ± 4.1 80.9 ± 3.8 *0.020 0.693 
Male, n (%) 213 (51.8) 152 (58.9) 58 (63.7) *<0.001 0.245 
Presentation: 
 NSTEMI, n (%) 
 Unstable angina, n (%) 














Hypertension, n (%) 307 (74.7) 196 (76.0) 60 (65.9) 0.441 *0.005 
Diabetes, n (%) 103 (25.1) 63 (24.4) 18 (19.8) 0.696 0.200 
Smoking status: 
 Current smoker, n (%) 
 Ex-smoker, n (%) 














Hyperlipidaemia, n (%) 234 (56.9) 155 (60.1) 45 (49.5) 0.095 *0.010 
Family history of IHD, n (%) 110 (26.9) 81 (31.6) 28 (31.5) *0.005 0.964 
Renal disease, n (%) 92 (22.4) 56 (21.7) 13 (14.3) 0.668 *0.033 
Peripheral vascular disease, n (%) 39 (9.5) 25 (9.7) 6 (6.6) 0.857 0.215 
Cerebrovascular disease, n (%) 55 (13.4) 42 (16.3) 12 (13.2) *0.025 0.321 










4.2 Baseline Demographics 
 
Tables 4.2 and 4.3 demonstrate that there were few differences between the age 
groups in terms of patient demographics and baseline blood results. GRACE score 
and creatinine clearance both include age as one of their variables and therefore it was 
expected that there would be significant differences between the age groups. There 
was a non-significant trend towards higher frailty with increasing age, and older 
patients were more likely to have had a previous MI or PCI, and therefore a higher 
incidence of congestive cardiac failure (CCF). Body mass index (BMI) was lowest in 
the middle age group. Older patients were more likely to have a lower haemoglobin, in 
keeping with the known age-related decline in erythropoiesis178. 
 
Table 4.4 demonstrates that baseline demographics did not differ significantly between 
the sexes other than a higher number of male ex-smokers, and a higher incidence of 
previous stroke or transient ischaemic attack in males. In keeping with previous large 
studies of age related changes in peripheral blood counts, female patients had lower 
haemoglobin levels but higher platelet counts (Table 4.5)178. Female patients had a 
higher total cholesterol level, again in keeping with the known increase in cholesterol 
in post-menopausal women179, and this may also reflect the higher rate of statin 
prescription pre-PCI in male patients (96.6% vs. 87.9% in this cohort). Vitamin D was 
lower in women than men, in line with a large meta-analysis of studies on vitamin D 
and cardiovascular disease in Europe and the USA180. 
 
Unsurprisingly, frailty was associated with increasing age (Table 4.6). Frailty was also 
significantly associated with GRACE risk score, in keeping with previous results from 
the Trilogy ACS trial21. Frail patients had a higher rate of diabetes, atrial fibrillation, 
angina and cerebrovascular disease, these conditions are likely the cause of the higher 
frailty rather than an effect. Other conditions that could be expected to cause increased 
frailty include chronic obstructive pulmonary disease (COPD), CCF, peripheral 
vascular disease (PVD) and anaemia, but these were present in very low numbers in 
this cohort, likely due to selection bias prior to referral for PCI. There were no significant 






































NSTEMI, n (%) 










GRACE score, ± SD 129.4 ± 17.2 118.0 ± 14.2 129.9 ± 15.2 141.5 ± 13.8 *<0.001 
BMI (IQR) 26.6 (24.0, 28.8) 27.9 (25.2, 32.3) 24.9 (23.5, 27.3) 26.1 (22.0, 28.1) *0.005 
Hypertension, n (%) 60 (65.9) 20 (66.7) 19 (57.6) 21 (75.0) 0.357 
Diabetes, n (%) 18 (19.8) 5 (16.7) 7 (21.2) 6 (21.4) 0.872 
Smoking status: 
 Current smoker, n (%) 
 Ex-smoker, n (%) 


















Hyperlipidaemia, n (%) 45 (49.5) 12 (40.0) 18 (54.5) 15 (53.6) 0.448 
Family history of IHD, n (%) 28 (31.5) 12 (42.9) 9 (27.3) 7 (25.0) 0.287 
Renal disease, n (%) 13 (14.3) 2 (6.7) 5 (15.2) 6 (21.4) 0.271 
Previous MI, n (%) 18 (19.8) 7 (23.3) 2 (6.1) 9 (32.1) *0.033 
Previous angina, n (%) 26 (28.6) 9 (30.0) 5 (15.2) 12 (42.9) 0.057 
Previous PCI, n (%) 11 (12.1) 3 (10.0) 1 (3.0) 7 (25.0) *0.029 
Atrial fibrillation, n (%) 13 (14.3) 3 (10.0) 6 (18.2) 4 (14.3) 0.651 
PVD, n (%) 6 (6.6) 2 (6.7) 2 (6.1) 2 (7.1) 0.986 
Cerebrovascular disease, n (%) 12 (13.2) 3 (10.0) 3 (9.1) 6 (21.4) 0.300 
COPD, n (%) 13 (14.3) 3 (10.0) 6 (18.2) 4 (14.3) 0.651 
CCF, n (%) 5 (5.5) 0 0 5 (17.9) *0.003 
Anaemia, n (%) 3 (3.3) 0 1 (3.0) 2 (7.1) 0.312 












Haemoglobin (g/dL ± SD) 13.4 ± 1.8 14.1 ± 1.3 13.5 ± 1.3 12.6 ± 2.4 *0.004 
White cell count (x109 ± SD) 8.4 ± 2.1 8.1 ± 1.8 8.4 ± 2.1 8.9 ± 2.3 0.338 
Platelets (x109 ± SD) 242 ± 83 233 ± 53 260 ± 95 230 ± 91 0.283 
Creatinine clearance (ml/min ± SD) 58.5 ± 20.5 70.3 ± 22.7 56.4 ± 19.0 48.3 ± 12.6 *<0.001 
Glucose, mmol/L (IQR) 6.2 (5.3, 7.1) 5.9 (5.75, 7.0) 6.2 (5.1, 7.5) 6.3 (5.3, 7.5) 0.956 
Cholesterol (mmol/L ± SD) 4.22 ± 0.99 4.43 ± 1.10 4.28 ± 0.96 3.91 ± 0.84 0.210 
Peak troponin, ng/L (IQR) 150 (44, 504) 335 (32, 894) 88 (15, 246) 194 (29, 428) 0.707 
Vitamin D, nmol/L (IQR) 39 (24, 53) 40 (23, 65) 28 (21, 46) 40 (30, 63) 0.570 
hsCRP, mg/L (IQR) 4.8 (1.7, 15.1) 3.5 (1.2, 8.5) 9.2 (3.5, 21.9) 4.2 (1.3, 14.9) 0.098 

































NSTEMI, n (%) 








GRACE score, ± SD 129.4 ± 17.2 128.5 ± 15.6 131.0 ± 19.8 0.531 
BMI (IQR) 26.6 (24.0, 28.8) 26.7 (24.0, 28.7) 26.6 (23.6, 30.2) 0.650 
Hypertension, n (%) 60 (65.9) 37 (63.8) 23 (69.7) 0.568 
Diabetes, n (%) 18 (19.8) 12 (20.7) 6 (18.2) 0.773 
Smoking status: 
 Current smoker, n (%) 
 Ex-smoker, n (%) 














Hyperlipidaemia, n (%) 45 (49.5) 27 (46.6) 18 (54.5) 0.463 
Family history of IHD, n (%) 28 (31.5) 14 (24.6) 14 (43.8) 0.061 
Renal disease, n (%) 13 (14.3) 7 (12.1) 6 (18.2) 0.535 
Previous MI, n (%) 18 (19.8) 12 (20.7) 6 (18.2) 0.773 
Previous angina, n (%) 26 (28.6) 17 (29.3) 9 (27.3) 0.836 
Previous PCI, n (%) 11 (12.1) 7 (12.1) 4 (12.1) 1.000 
Atrial fibrillation, n (%) 13 (14.3) 11 (19.0) 2 (6.1) 0.123 
PVD, n (%) 6 (6.6) 6 (10.3) 0 0.083 
Cerebrovascular disease, n (%) 12 (13.2) 11 (19.0) 1 (3.0) *0.050 
COPD, n (%) 13 (14.3) 7 (12.1) 6 (18.2) 0.535 
CCF, n (%) 5 (5.5) 3 (5.2) 2 (6.1) 1.000 
Anaemia, n (%) 3 (3.3) 2 (3.4) 1 (3.0) 1.000 










Haemoglobin (g/dL ± SD) 13.4 ± 1.8 14.0 ± 1.4 12.5 ± 2.1 *<0.001 
White cell count (x109 ± SD) 8.4 ± 2.1 8.3 ± 1.8 8.6 ± 2.5 0.586 
Platelets (x109 ± SD) 242 ± 83 218 ± 59 287 ± 100 *<0.001 
Creatinine clearance (ml/min ± SD) 58.5 ± 20.5 60.9 ± 19.5 54.2 ± 21.9 0.137 
Glucose, mmol/L (IQR) 6.2 (5.3, 7.1) 6.2 (5.1, 7.0) 6.4 (5.8, 7.5) 0.435 
Cholesterol (mmol/L ± SD) 4.2 ± 1.0 4.0 ± 0.8 4.6 ± 1.1 *0.015 
Peak troponin, ng/L (IQR) 150 (44, 504) 189 (44, 708) 116 (40, 364) 0.583 
Vitamin D, nmol/L (IQR) 39 (24, 53) 41 (28, 64) 29 (13, 40) *0.002 
hsCRP, mg/L (IQR) 4.8 (1.7, 15.1) 5.2 (2.2, 15.3) 4.5 (1.5, 14.9) 0.492 

















Age (years ± SD) 80.8 ± 3.9 79.1 ± 2.9 81.2 ± 4.0 82.6 ± 3.8 *0.011 
Male, n (%) 58 (63.7) 14 (56.0) 36 (70.6) 8 (53.3) 0.303 
NSTEMI, n (%) 










GRACE score, ± SD 129.4 ± 17.2 124.2 ± 14.4 128.8 ± 16.9 140.6 ± 18.5 *0.014 
BMI (IQR) 26.6 (24.0, 28.8) 27.3 (24.2, 27.3) 25.7 (23.8, 29.4) 26.6 (23.1, 28.2) 0.327 
Hypertension, n (%) 60 (65.9) 16 (64.0) 32 (62.7) 12 (80.0) 0.451 
Diabetes, n (%) 18 (19.8) 2 (8.0) 10 (19.6) 6 (40.0) *0.049 
Smoking Status: 
 Current smoker, n (%) 
 Ex-smoker, n (%) 


















Hyperlipidaemia, n (%) 45 (49.5) 11 (44.0) 27 (52.9) 7 (46.7) 0.744 
Family history of IHD, n (%) 28 (31.5) 10 (43.5) 11 (21.6) 7 (46.7) 0.065 
Renal disease, n (%) 13 (14.3) 3 (12.0) 7 (13.7) 3 (20.0) 0.771 
Previous MI, n (%) 18 (19.8) 6 (24.0) 8 (15.7) 4 (26.7) 0.531 
Previous angina, n (%) 26 (28.6) 3 (12.0) 17 (33.3) 6 (40.0) 0.087 
Previous PCI, n (%) 11 (12.1) 3 (12.0) 5 (9.8) 3 (20.0) 0.567 
Atrial fibrillation, n (%) 13 (14.3) 2 (8.0) 6 (11.8) 5 (33.3) 0.063 
PVD, n (%) 6 (6.6) 0 4 (7.8) 2 (13.3) 0.223 
Cerebrovascular disease, n (%) 12 (13.2) 0 8 (15.7) 4 (26.7) *0.040 
COPD, n (%) 13 (14.3) 2 (8.0) 8 (15.7) 3 (20.0) 0.525 
CCF, n (%) 5 (5.5) 1 (4.0) 3 (5.9) 1 (6.7) 0.922 
Anaemia, n (%) 3 (3.3) 0 2 (3.9) 1 (6.7) 0.485 












Haemoglobin (g/dL ± SD) 13.4 ± 1.8 13.7 ± 1.2 13.5 ± 2.1 12.7 ± 1.5 0.190 
White cell count (x109 ± SD) 8.4 ± 2.1 7.9 ± 2.1 8.7 ± 2.1 8.2 ± 2.0 0.271 
Platelets (x109 ± SD) 242 ± 83 251 ± 94 245 ± 83 217 ± 59 0.411 
Creatinine clearance (ml/min ± SD) 58.5 ± 20.5 60.2 ± 17.4 59.6 ± 22.9 51.9 ± 16.3 0.397 
Glucose, mmol/L (IQR) 6.2 (5.3, 7.1) 6.9 (5.8, 7.5) 5.9 (5.3, 6.9) 6.4 (4.9, 11.2) 0.284 
Cholesterol (mmol/L ± SD) 4.2 ± 1.0 4.6 ± 1.1 4.1 ± 0.9 4.3 ± 1.1 0.274 
Peak troponin, ng/L (IQR) 150 (44, 504) 152 (36, 426) 197 (49, 696) 85 (32, 172) 0.251 
Vitamin D, nmol/L (IQR) 39 (24, 53) 35 (24, 58) 35 (23, 52) 40 (22, 50) 0.868 
hsCRP, mg/L (IQR) 4.8 (1.7, 15.1) 4.0 (1.7, 17.6) 5.4 (2.4, 15.8) 6.7 (1.1, 11.6) 0.666 








4.3 Safety and Feasibility of Three Vessel Intravascular Imaging 
 
VH IVUS and OCT intravascular imaging in this cohort was safe, with no complications 
attributable to VH IVUS imaging. There was only one complication of imaging during 
the study, and this occurred during OCT imaging. Ventricular fibrillation was induced 
by contrast flushing of the LAD artery in a patient with a CTO of the RCA and was 
successfully treated with defibrillation with no sequelae for the patient.  
 
The feasibility of VH IVUS and OCT imaging in an older cohort is shown in Table 4.8. 
Overall, there was a high success rate, with successful imaging performed in 80.6% of 
anatomically suitable vessels with VH IVUS and 74.7% with OCT. The success rate 
was similar between the LAD and RCA but the success rate in the Cx artery was slightly 
lower, due to the higher number of non-dominant or tortuous vessels in this group. 
 
The definition of unsuitable coronary anatomy included CTO, tortuous vessels or heavy 
calcification, which would preclude the imaging catheter being delivered into the artery 
(as determined by the operator). It also included previous stenting, which would 
prevent VH IVUS or OCT analysis behind the stent struts. Failure to cross the lesion 
with the imaging catheter and unsuitable anatomy for intravascular imaging defined by 
the operator was more common with the VH IVUS EEP catheter, as the transducer 
has a 3.5F external diameter, compared to 2.7F for the Dragonfly OCT catheter.  
 
Only one set of OCT acquisitions was affected by a technical problem; the optical lens 
of the imaging catheter was damaged when introducing it into the guide catheter. 
“Sufficient quality for analysis” was defined as acquisition of >70% of the region of 
interest and satisfactory blood clearing with visibility of >3 quadrants in >70% of the 
pullback length. Three VH IVUS pullbacks were unable to be analysed, as the imaging 
catheter “stuck” in tortuous and calcified vessels, leading to non-continuous automated 
pullback, and 6 arteries imaged by OCT had insufficient blood clearing. 
 
Prolonged catheterisation time was defined  as  premature  termination  of  the  3-
vessel imaging  procedure  due  to  patient  discomfort . This was a particular concern 
prior to the commencement of the study, due to the nature of the patient cohort, but 
occurred in a very small number of patients. It was marginally more common in the 
OCT imaging sub-study (6.7 vs. 5.5%), as this imaging modality tended to be 
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performed second. Cath lab time constraints included premature termination of the 3-
vessel imaging procedure due to arrival of an unscheduled emergency or if the imaging 
had a detrimental effect of the timely running of the list and was unavoidable, as all 
cases were scheduled on “urgent” lists rather than in a dedicated research lab. 
 
 LAD Cx RCA 
 VH IVUS OCT VH IVUS OCT VH IVUS OCT 
Number of vessels 84 27 84 27 84 27 
Unsuitable coronary artery anatomy (%) 4 (4.8) 0 14 (16.7) 2 (7.4) 18 (21.4) 4  (14.8) 
Number of vessels available for imaging 80 27 70 25 66 23 
Successful imaging (%) 67 (83.8) 20 (74.1) 53 (75.7) 18 (72.0) 54 (81.8) 18 (78.3) 
Unsuccessful imaging: 
 Failure to cross lesion (%) 
 Technical problem (%) 
 Insufficient quality for analysis (%) 
 Prolonged catheterisation time (%) 
 Cath lab time constraints (%) 











































Table 4.8 Feasibility of VH IVUS and OCT imaging 
 
Because of the reasons for unsuccessful imaging of an artery outlined in Table 4.8, 
<30% of patients underwent 3 vessel imaging using either VH IVUS or OCT (Table 
4.9). However, >75% of patients had at least 2 epicardial vessels imaged by either 
technology. OCT image runs were shorter than VH IVUS acquisitions as the automatic 
pullback device had a 56mm limit; two imaging runs were done in some patients but 







Number of epicardial arteries imaged: 
 Three (%) 
 Two (%) 









Culprit vessel length imaged (mm ± SD) 47.5 ± 27.4 33.9 ± 18.0 
Non-culprit vessel length imaged (mm ± SD) 71.9 ± 37.2 53.9 ± 24.5 
Total length imaged per patient (mm ± SD) 105.2 ± 54.5 75.3 ± 31.1 
 LMS (mm ± SD) 
 LAD (mm ± SD) 
 Cx  (mm ± SD) 
 RCA (mm ± SD) 
9.4 ± 7.1 
46.1 ± 24.0 
41.7 ± 17.9 
58.4 ± 25.8 
7.2 ± 4.8 
34.0 ± 14.6 
32.6 ± 14.0 
39.1 ± 17.9 




There was a small increase in contrast volume (Figure 4.2A) and procedure duration 
(Figure 4.2B) for patients undergoing PCI with invasive imaging compared to those 
undergoing PCI alone, but no difference in radiation dose (Figure 4.2C). Median 
contrast volume increased by 40ml with the addition of invasive imaging, and median 
procedure duration increased by 15 mins. The increase in contrast use persisted even 
when patients undergoing only VH IVUS were analysed (i.e. disregarding patients who 
underwent OCT imaging, during which contrast is administered). This increase in 
contrast use can be explained by the need for additional angiography of non-target 
vessels when positioning guide catheters for invasive imaging, or at the end of imaging 
when demonstrating that there were no adverse sequelae following removal of the 
imaging catheter. Although the increase in time and contrast used are small, this has 














Figure 4.2 Procedure characteristics for patients undergoing PCI + invasive 
imaging vs. PCI alone 
Patients in the invasive imaging sub-study had a longer procedure duration and increase in the volume 
of radio-opaque contrast, but no difference in the radiation dose, in comparison to patients in the ICON1 
study undergoing PCI but no invasive imaging. Data presented as median (central line), interquartile 

















4.4 Reproducibility of Measurements 
 
Following training in the use of the analytical software (QAngio and QIvus) by Medis 
Product Support Specialists, I analysed 15 patients’ data (angiographic, VH IVUS and 
OCT) which was then checked by the study’s Chief Investigator for accuracy. After this 
learning phase was approved, the official analysis was then commenced. A random 
sample of 8 lesions/arteries was re-analysed for each imaging modality several months 
later to provide data on intra-observer variability. 
 
4.4.1 Quantitative Coronary Angiography 
Figure 4.3 details the intra-observer variability on selected measurements on QCA. All 
show a very strong correlation between measurements, as denoted by the intraclass 


























































































































4.4.2 VH IVUS 
In total, 636 frames from 8 patients were analysed twice to provide data on area and 
volumetric measurements (Figure 4.4), plaque composition (Figure 4.5) and lesion 
classification (Figure 4.6). Again, there was excellent reproducibility. 
Figure 4.4 Intra-observer variability in grayscale IVUS measurements 






































































Figure 4.6 Intra-observer variability in VH IVUS lesion classification 
 
The outlier in Figure 4.6B represents an artery with very little plaque (measurements 
of 2/54 and 0/54 frames with VH-TCFA), therefore the absolute agreement between 
measurements remains good. 
 
4.4.3 OCT 
There was very little intra-observer variability in OCT measurements (Figure 4.7). 

















































4.5.1 Feasibility of Recruiting Older Patients with ACS to Research Studies 
 
Historically, the recruitment of older patients to clinical research has represented a 
significant challenge. In this study, we have demonstrated that the majority of patients 
meeting the inclusion criteria (69.8%) were recruited to participate in the ICON1 study, 
with a low rate of patients declining to participate (17.3%). Those who declined were 
more likely to be female, and those unable to consent were older than those who could.  
 
Despite a recent focus on the importance of recruiting older people to cardiovascular 
research, the majority of RCTs and observational studies fail to recruit older patients 
with ACS, and a significant minority actively exclude them. This leads to the continuing 
paucity of data in this age group. A systematic review of RCTs in ACS showed that, 
although enrolment of older patients has increased through the decades, only 10.3% 
of patients fell into this age category in the RCTs published between 1996 and 200035. 
In one meta-analysis of trials in heart failure, the use of arbitrary age cut-offs was more 
common in European studies than those conducted in the USA181. Of the 44 published 
RCTs in ACS in 2014, 10 studies (22.7%) had upper age limits (4 RCTs excluded 
patients >75 years, 4 excluded >80 years, 1 excluded >85 years and 1 excluded >90 
years) and the average age of participants across all RCTs was 62.0 ± 6.8 years. Only 
two RCTs (4.5%) specifically recruited older patients32, 37. Of the 70 published 
prospective observational studies, 11 (15.7%) had upper age limits (1 study 
excluded >55 years, 3 excluded >75 years, 5 excluded >80 years and 2 excluded >85 
years) and the average age of participants was 61.3 ± 5.9 years. Six prospective 
observational studies did not define whether there were any exclusion criteria related 
to age. Two observational studies (2.9%) specifically recruited older patients38, 39. 
However, at least in RCTs, the percentage of trials actively excluding older patients 
does seem to be falling, from 31.9% in 1996-200135 to 22.7% in 2014.  
 
Recruiting older patients to this cardiovascular research study has been a very positive 
experience. The recruitment rate of 69.8% compares favourably to that of the 
Newcastle 85+ study (71.7%)36, which recruited from a similar geographic population, 
but recruited in the community and did not involve patients undergoing invasive 
investigations. Patients who were approached to participate in this study were 
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generally enthusiastic about taking part in research, citing their wish to “give something 
back” and to improve the treatment of patients presenting in the future.  
 
Several cardiovascular studies have exclusively recruited older patients, with mixed 
success. The Italian Elderly ACS study recruited a population comparable to ICON1, 
patients with NSTEACS, aged ≥75 years22. Initially planning to recruit 504 patients, the 
trial design was amended due to a slower-than-expected recruitment rate and recruited 
313 patients in total. The investigators attributed slow recruitment to a number of 
factors, including difficulty in obtaining informed consent and significant co-morbidity 
burden, making many patients ineligible for recruitment due to exclusion criteria. More 
recently, the After Eighty study patients recruited aged ≥75 years, and also evaluated 
conservative versus invasive management of NSTEACS23. Out of 4,187 patients in this 
age group with NSTEACS, 1,973 patients met the inclusion criteria but only 457 
(23.2%) were recruited. The authors credit the low recruitment rate to logistical reasons 
(1011 patients, mainly due to lack of funding in community hospitals for 24/7 
recruitment) and refusal to participate (402 patients, 20.4%).  
 
A previous cardiovascular RCT in patients aged 70-82 years found that the most 
common reason for taking part in research was self-interest (52.9%) such as for “health 
checks” or “peace of mind”, followed by a sense of altruism (39.6%) to “help research” 
or “help others”182. Several patients mentioned the importance of as few clinic visits as 
possible after the initial recruitment in hospital, citing a lack of transport and 
unwillingness to “bother” family members. Five patients cited distance from the 
research venue as a reason for declining, and previous research has demonstrated an 
inverse correlation between distance from the older patient’s residence to the research 
venue and their likelihood of participation in a clinical trial183. 
 
Several patients expressed anxiety regarding the PCI procedure and felt unable to 
consider any additional procedures at that time. Care was taken by the researchers 
not to overwhelm the patient and to provide them with adequate time to assimilate the 
information given, often with multiple conversations with them and their family. Older 
patients who agree to participate in research often take more time to make the 
decision184 and patients who feel they have sufficient time to consider the information 
are more likely to consent185. This is time-consuming for the research team and 
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requires dedicated researchers who are able to develop a rapport with the patient and 
their family. 
 
Guidance on ethical research for and with older people has stipulated that studies 
recruiting older people should aim to recruit a majority of women in order to reflect the 
general population43. However, women approached for participation were much more 
likely to decline than men. There was an anxiety among older patients, not just about 
research, but about the wider experience of having PCI that prevented them from 
agreeing to take part in the study. The research team therefore had to be 
knowledgeable not just about the study, but about the whole in-patient journey. In 
addition, 3 female patients declined to participate in ICON1 because of concerns that 
taking part in research would affect their ability to care for their spouse. Although a 
greater proportion of men than women over the age of 75 years are unpaid carers, this 
figure may be skewed as more women in this age group are likely to be widowed186. 
Indeed, two female patients screened for inclusion declined because of a recent 
bereavement. Therefore it is important for researchers to be sensitive to these issues 
when approaching older patients for participation in studies. 
 
Patients approached for participation in ICON1 who were unable to provide informed 
consent were, on average, older than those who could. The most common reason for 
being unable to consent was a lack of capacity due to cognitive impairment (70%). 
Around 10% of the population over 85 have dementia187; all research involving older 
patients should take due consideration of mental capacity and the process of informed 
consent. However, it is still possible to recruit patients without mental capacity whilst 
still protecting them from coercion, allowing them to take part and benefit from the 
advances brought about by such research. In the UK, specific Research Ethics 
Committees consider the involvement of patients without capacity on an individual 
study basis188. Other reasons for being unable to consent included hearing or visual 
impairment. The patient information sheet was written in plain English in a large font 
size to facilitate reading, and researchers often took time to read it aloud to patients 
with visual impairment. 
 
Therefore, if older patients are willing to participate, is the poor recruitment rate the 
fault of the study investigators? In a study of patients with breast cancer eligible to 
participate in research, 51% of patients <65 years of age were offered the chance to 
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participate, compared with 35% of those ≥65 years (p=0.006)189. Age was not a 
predictor of consenting to participate in a study once it was offered (56% of younger 
patients vs. 50% of older, p=0.67)189. The most common reasons given by physicians 
for not offering a trial to older patients were that they believed treatment was too toxic 
for the patient (33%), the best treatment was not available in the trials (27%), the 
physician was unaware that the patient was eligible (21%), and the physician thought 
that the patient was not eligible (18%)189. A further study of patients with breast cancer 
demonstrated that physicians cited age as a factor in deciding not to discuss a trial in 
17% of patients ≥65 years vs. 3% of younger patients (p=0.04) and, if a trial was 
discussed, cited age as a factor in not enrolling the patient in 11% of older vs. 3% of 
younger patients (p=0.04)190. A change in attitudes towards older patients in research 
is required if we are to see substantial improvements in their recruitment rates. 
 
Recently, the PREDICT Consortium, a group funded by the European Union to study 
and help boost the number of elderly people taking part in research, has compiled a 
charter for the rights of older patients in clinical trials, aiming to narrow the gap between 
populations recruited to clinical trials and real clinical practice42. Guidelines published 
by the Geriatric Working Party of the European Forum for Good Clinical Practice 
suggest that research in older people should: 1)  actively recruit patients over 75 years 
with no upper age limit, 2) recruit a majority of women, and 3) justify exclusion co-
morbidities in order to accurately reflect the population studied43. 
 
The recruitment rate of older patients to studies in ACS remains low even in the 
contemporary era, resulting in a paucity of data in this high-risk cohort. However, the 
contribution of older patients must not be ignored, particularly in the setting of an ever-
ageing population, in whom cardiovascular disease burden is high. The recruitment of 
older patients to the present study was robust, comparing favourably to previous 
longitudinal studies within this age group. Although enrolling older people to research 
remains challenging and requires significant adaptation from the inception of study 
design, this cohort is generally enthusiastic to participate. By taking the time to build a 
rapport with the potential participant, identifying any consent issues, involving relatives 
in the decision making process, and minimising the burden of the study on the 
participant, researchers can ensure this valuable cohort of patients can contribute to 




4.5.2 Three Vessel Invasive Coronary Imaging In Older Patients with ACS 
 
This is the first study of multi-modality invasive coronary imaging in a “real world” older 
population with few exclusion criteria, and demonstrated an excellent rate of successful 
imaging. In this study, >75% of patients underwent invasive imaging in at least 2 
coronary vessels. This is a slightly lower success rate than a similarly-sized 
prospective cohort study utilising 3 vessel EEP VH IVUS and OCT imaging in young 
patients (n=103, mean age 58.2 ± 10.5 years) with STEMI, who were successful in 
imaging >90% of arteries, with no IVUS complications and <2% OCT complications191. 
However, as well as recruiting younger and less complex patients than ICON1, that 
study recruited at 5 separate hospitals in Switzerland, The Netherlands and Denmark 
so each site did not have the same pressures to recruit large numbers as in ICON1. 
Interestingly, this European study also demonstrated that 3 vessel multi-modality intra-
coronary imaging was associated with an increased use of contrast agent (268.3 ± 
109.8 vs. 197.9 ± 88.8ml in the PCI alone cohort)191. 
 
The number and length of arteries imaged by VH IVUS was also lower than in the 
PROSPECT (total length imaged per patient ≥65 years = 165.9mm)69, 174 or VIVA 
(181.7mm)70 studies, but these studies again recruited a much less complex patient 
cohort. In addition, the PROSPECT investigators explicitly excluded patients requiring 
3 vessel PCI, patients with LMS lesions, patients receiving unsuccessful PCI, and 
patients with marked calcification or tortuosity of their coronary vessels. Previous 
studies have demonstrated that vulnerable coronary lesions are more likely to be found 
in proximal vessels192, 193, therefore it may not be necessary to focus on longer 
pullbacks when performing intracoronary imaging in more complex patient groups such 
as this, but instead concentrate on good quality acquisitions. 
 
There was one complication due to invasive imaging during this study: ventricular 
fibrillation following contrast flush prior to OCT image acquisition. This is a recognised 
complication of OCT imaging, occurring in 1.1% of patients in a large registry194. In 
general, these additional imaging procedures are safe; in a prospective, single-centre 
study, 1142 OCT and 2476 IVUS imaging procedures were carried out with no 





The reproducibility of measurements for all three modalities presented here was 
excellent. Variability in the measurement of VH IVUS parameters has been of particular 
concern previously, due to the derived nature of many of the plaque composition values 
(Figure 1.4). Differences in the definition of the lumen or vessel contour, difficulty in 
distinguishing between the plaque margins and artefact or thrombus, and differences 
in segment length analysed (e.g. due to incorrect identification of proximal or distal 
landmarks, or repeated frames due to a “stuck” catheter in heavy calcification), can all 
contribute to a wide variation in the final calculation of plaque composition. A validation 
study of VH IVUS measurements in patients with ACS demonstrated that there was 
differences in the repeatability coefficient of up to 14% in vessel area and 31% for 
lumen area196. The intra-class correlation co-efficients reported here for VH IVUS 
plaque components are in keeping with those reported by previous validation studies, 
with all co-efficients >0.95 with the exception of fibro-fatty tissue, probably due to the 
difficulties in tracing the lumen border around soft plaque or thrombus196, 197.  
 
Although intracoronary invasive imaging in older patients with ACS has its challenges 
due mainly to their complex coronary anatomy, it is feasible, safe and yields 









CHAPTER 5: RESULTS – The Pattern of Coronary 
Plaque Burden on Multi-Modality Invasive Imaging in 




This high-risk, older patient cohort underwent rigorous examination of their coronary 
vasculature on three intravascular imaging modalities: invasive angiography, VH IVUS 
and OCT. Results from these modalities are stratified by both patient-level factors (age, 
sex and frailty) and vessel or lesion-related factors to attempt to gain a better 
understanding of the pattern of coronary artery disease in older patients with ACS. 
 
5.1  Quantitative Coronary Angiography 
 
5.1.1 Age  
In total, 217 lesions in 91 patients were identified on QCA (<79 years n=60, 79-82 
years n=85, >82 years n=72). 
 
Table 5.1 demonstrates that, overall, the complexity of coronary disease was higher 
than in previous studies of patients with NSTEACS. The overall median SYNTAX score 
was higher than in the sub-analysis of patients with NSTEACS in the ACUITY study 
(13 vs. 9)198, but did not increase with age in our cohort. Older patients did not have a 
higher rate of multi-vessel disease but were more likely to undergo multi-vessel PCI, 
suggesting that they were more likely to have their complex coronary disease treated 
with a single procedure. This is in keeping with a previous study, which demonstrated 
that octogenarians were more likely to undergo multi-vessel PCI than younger patients 
(35 vs. 27%, p=0.004)14. However, this did not increase the procedure duration, 
contrast volume used or radiation dose. 
 
There were high rates (>90%) of radial artery access for all age groups, higher than 
the national average of 80.5%199, in contrast to previous UK data demonstrating lower 
rates of radial access with increasing age26. Many older patients were still waiting 
longer than the 72 hour target for PCI, with a median time from presentation to 




















Time from presentation to angiography, 
days (IQR) 
5 (3, 6) 3 (3, 5) 5 (4, 7) 5 (3, 6) 0.381 
Radial arterial access, n (%) 85 (93.4) 27 (90.0) 32 (97.0) 26 (92.9) 0.533 
Culprit artery: 
 LMS, n (%) 
 LAD, n (%) 
 Cx, n (%) 






















Number of diseased vessels, (IQR) 2 (1, 3) 2 (1, 2) 2 (1, 3) 2 (2, 3) 0.507 
Number of lesions, (IQR) 3 (1, 3) 2 (1, 3) 3 (1, 4) 3 (2, 3) 0.222 
SYNTAX score, (IQR) 13 (7, 19) 9 (6, 16) 13 (7, 22) 16 (11, 24) 0.193 
BCIS Jeopardy Score, (IQR) 6 (4, 7) 6 (3, 6) 6 (4, 6) 6 (4, 10) 0.391 
Multi-vessel PCI (%) 27 (29.7) 3 (10.0) 13 (39.4) 11 (39.3) *0.016 
Number of stents (IQR) 1 (1, 3) 1 (1, 3) 2 (1, 2) 2 (1, 3) 0.304 
Contrast volume (ml ± SD) 196.1 ± 68.9 212.7 ± 63.2 181.7 ± 77.0 195.4 ± 62.7 0.205 










Procedure duration (mins ± SD) 75.5 ± 23.4 75.1 ± 23.1 71.8 ± 22.1 80.5 ± 25.3 0.381 










Table 5.1 Angiographic characteristics by age 
 
Figure 5.1 demonstrates no difference in QCA measurements between age groups 
either before or after PCI. Although the post-PCI % diameter stenosis is greater than 
that seen in studies of ACS such as the study of PLATelet inhibition and patient 
Outcomes (PLATO: which had a 6% residual diameter stenosis in almost 2000 patients 



























Figure 5.1 Median pre and post-PCI QCA measurements by age 
 
There was a trend towards older patients having fewer CTO lesions (p=0.077) but 
otherwise there were no differences in calcification score or complexity of lesion 
between age groups (Table 5.2). There was a higher complexity of lesions overall 
compared to the younger patients in the PLATO study (type A: 9.3%, type B1: 54.0%, 
type B2: 32.1%, type C: 4.6%)200 which, in part, is reflective of the higher overall level 
of calcification. There were no procedure failures in the whole cohort, and a high rate 
of complete angiographic success across all groups, which is comparable to previous 












CTO, n (%) 17 (8.1) 7 (12.1) 8 (9.5) 2 (2.9) 0.077 
Calcification: 
 None, n (%) 
 Mild, n (%) 
 Moderate, n (%) 























 Type A, n (%) 
 Type B1, n (%) 
 Type B2, n (%) 






















Procedure performed, n (%) 136 (62.7) 37 (61.7) 52 (61.2) 47 (65.3) 0.659 
Procedure success, n (%) 123 (90.4) 35 (94.6) 44 (84.6) 44 (93.6) 0.987 
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%






































5.1.2 Sex  
Of the 217 lesions, 148 were identified in men and 69 in women. 
 
Women were less likely than men to have multi-vessel disease, had fewer lesions, and 
less extensive disease on the SYNTAX and BCIS jeopardy scores (Table 5.3). 
Consequently, fewer stents were implanted in women and they had a lower procedural 
radiation dose (although the lower contrast volume and procedure duration in women 
did not reach statistical significance). Similar results were demonstrated in a sub-
analysis of the PROSPECT data (lower incidence of non-culprit lesions in women 
compared to men: 2.38 ± 1.84 vs. 2.72 ± 2.03, p=0.05201), and in a large registry 
(>100,000 patients) of Swedish ACS patients (lower incidence of 3 vessel/LMS disease 
in women: 20.9 vs. 30.4%, p<0.001202). Thus the sex differences in the extent of 










Time from presentation to angiography, 
days (IQR) 
5 (3, 6) 5 (3, 6) 5 (4,7) 0.248 
Radial arterial access, n (%) 85 (93.4) 56 (96.6) 29 (87.9) 0.185 
Culprit artery: 
 LMS, n (%) 
 LAD, n (%) 
 Cx, n (%) 

















Number of diseased vessels, (IQR) 2 (1, 3) 2 (2, 3) 1 (1, 2) *0.003 
Number of lesions, (IQR) 3 (1, 3) 3 (2, 3) 2 (1, 3) *0.045 
SYNTAX score, (IQR) 13 (7, 19) 13 (9, 23) 9 (5, 17) *0.037 
BCIS Jeopardy Score, (IQR) 6 (4, 7) 6 (4, 8) 6 (2, 6) *0.041 
Multi-vessel PCI (%) 27 (29.7) 21 (36.2) 6 (18.2) 0.070 
Number of stents (IQR) 1 (1, 3) 2 (2, 3) 2 (1, 3) *0.047 
Contrast volume (ml ± SD) 196.1 ± 68.9 201.9 ± 73.7 185.6 ± 59.1 0.285 
Radiation dose, cGycm2 (IQR) 6098 (4033, 10957) 7275 (4927, 10997) 4917 (3155, 6370) *<0.001 
Procedure duration (mins ± SD) 75.5 ± 23.4 77.8 ± 26.2 71.6 ± 17.0 0.188 
SYNTAX Revascularisation Index, (IQR) 75.0 (33.3, 100) 69.3 (33.3, 100) 77.1 (38.1, 100) 0.614 
Table 5.3 Angiographic characteristics by sex 
 
When analysed at a lesion level, male and female patients had similar measurements 
on QCA both pre and post-PCI (Figure 5.2). This differs from the PROSPECT sub-
analysis, which demonstrated that women have a smaller RD pre-PCI (2.2 vs. 2.3mm, 
p=0.01) but a similar diameter stenosis in non-culprit lesions201. However, there were 
no differences in pre-PCI measurements in culprit arteries in the PROSPECT study so, 
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overall, there may be no sex differences in lesion measurements. In contrast to 
PROSPECT, we demonstrated no difference in post-PCI measurements. This 
suggests that there may be a tendency to undersize stents in women, leading to the 
















Figure 5.2 Median pre and post PCI QCA measurements by sex 
 
The lesion complexity was similar between the sexes, and the procedure success 
remained high in both groups (Table 5.4). There was a non-significant trend towards 
less calcification in male patients. However, in the Assessment of Dual Anti-Platelet 
Therapy with Drug Eluting Stents (ADAPT-DES) study, angiographic calcification was 
more common in women vs. men in the younger cohort, but this relationship was not 
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CTO, n (%) 17 (8.1) 10 (7.0) 7 (10.4) 0.505 
Calcification: 
 None, n (%) 
 Mild, n (%) 
 Moderate, n (%) 


















 Type A, n (%) 
 Type B1, n (%) 
 Type B2, n (%) 

















Procedure performed, n (%) 136 (62.7) 96 (64.9) 40 (58.0) 0.394 
Procedure success, n (%) 123 (90.4) 86 (89.6) 37 (92.5) 0.600 
Table 5.4 Lesion characteristics on QCA by sex 
 
5.1.3 Frailty  
Of the 217 lesions, 67 were found in robust patients, 114 in pre-frail patients and 36 in 
the frail group. 
 
Femoral access was more common in frail patients (Table 5.5). All bar one (frail) 
patient had an attempt at radial access before conversion to femoral; the right radial 
artery was impalpable in the remaining patient and left radial access was not attempted 
before femoral puncture. Radial access failures were all due to failed radial artery 
punctures except in one frail patient, where the operator was unable to access the 
aortic root due a subclavian loop.  
 
In the ICON1 invasive imaging cohort, there were no differences in the extent of 
coronary disease or rate of multi-vessel PCI with frailty, in keeping with a previous 
study that demonstrated a higher rate of PCI to the LMS but no difference in number 




















Time from presentation to angiography, 
days (IQR) 
5 (3, 6) 5 (4, 7) 5 (3, 6) 4 (3, 8) 0.989 
Radial arterial access, n (%) 85 (93.4) 24 (96.0) 50 (98.0) 11 (73.3) *0.006 
Culprit artery: 
 LMS, n (%) 
 LAD, n (%) 
 Cx, n (%) 






















Number of diseased vessels, (IQR) 2 (1, 3) 2 (1, 2) 2 (1, 3) 2 (1, 3) 0.691 
Number of lesions, (IQR) 3 (1, 3) 3 (2, 4) 2 (1, 3) 3 (1, 3) 0.419 
SYNTAX score, (IQR) 13 (7, 19) 14 (7, 24) 12 (7, 21) 13 (10, 15) 0.737 
BCIS Jeopardy Score, (IQR) 6 (4, 7) 6 (4, 6) 6 (4, 8) 6 (4, 9) 0.825 
Multi-vessel PCI (%) 27 (29.7) 8 (32.0) 16 (31.4) 3 (20.0) 0.702 
Number of stents (IQR) 1 (1, 3) 2 (1, 3) 1 (1, 2) 1 (1, 3) 0.372 
Contrast volume (ml ± SD) 196.1 ± 68.9 194.4 ± 75.7 196.8 ± 66.0 196.7 ± 71.9 0.989 










Procedure duration (mins ± SD) 75.5 ± 23.4 77.4 ± 25.3 73.0 ± 21.4 80.6 ± 27.1 0.513 










Table 5.5 Angiographic characteristics by frailty 
 
Figure 5.3 demonstrates that pre-frail patients had a smaller pre-PCI reference 







































































Diameter stenosis Area stenosis
%
Robust (pre) Pre-frail (pre) Frail (pre) Robust (post) Pre-frail (post) Frail (post)
84 
 
There were no differences in angiographic calcification between frailty groups (Table 
5.6), in contrast to the results seen when calcification was measured by VH IVUS 
(Figure 5.8). However, angiographic calcification is a subjective observation rather 













CTO, n (%) 17 (8.1) 7 (10.8) 8 (7.3) 2 (5.6) 0.364 
Calcification: 
 None, n (%) 
 Mild, n (%) 
 Moderate, n (%) 























 Type A, n (%) 
 Type B1, n (%) 
 Type B2, n (%) 






















Procedure performed, n (%) 136 (62.7) 42 (62.7) 72 (63.2) 22 (61.1) 0.920 
Procedure success, n (%) 123 (90.4) 37 (88.1) 68 (94.4) 18 (81.8) 0.692 
Table 5.6 Lesion characteristics on QCA by frailty 
 
5.1.4 Key Findings From Angiographic Sub-Study 
 Angiographic success of PCI is high in this older age group 
 Older patients are not more likely to have multi-vessel disease, but are more 
likely to undergo multi-vessel PCI 
 Women are likely to have less extensive coronary disease than men, in keeping 
with studies in younger patients 




5.2 Virtual Histology Intravascular Ultrasound 
In total, 221 vessels were imaged in 84 patients with VH IVUS (20,078 frames). 
 
5.2.1 Age 
Overall, 74 vessels were imaged in patients aged <79 years (6161 frames), 76 in 
patients 79-82 years (7266 frames), and 71 in patients >82 years (6651 frames). 
 
With increasing age, there was a significant increase in coronary plaque burden, as 
measured by the maximum vessel stenosis and the percent atheroma volume (PAV) 
(Table 5.7). This is consistent with previous studies demonstrating an increase of 
plaque burden with age58, 204, 205. The sub-analysis of the PROSPECT data by age also 
demonstrated similar results, whereby plaque volume in non-culprit segments was 
greater in the older age cohort (<65 years: 49.0% [46.5, 51.9], ≥65 years: 49.7% [47.2, 
52.9], p=0.01)174. The results also demonstrate increasing LAPS with age, suggesting 












MLA (mm2 ± SD) 5.2 ± 2.4 5.7 ± 2.5 5.2 ± 2.5 4.8 ± 2.1 0.174 
MLD (mm ± SD) 2.5 ± 0.6 2.6 ± 0.6 2.5 ± 0.6 2.4 ± 0.5 0.167 
Maximum stenosis (% ± SD) 67.2 ± 12.2 63.7 ± 13.0 66.6 ± 12.1 71.5 ± 10.4 *0.003 
Remodeling index (± SD) 1.04 ± 0.13 1.04 ± 0.12 1.02 ± 0.13 1.07 ± 0.15 0.137 
Percent atheroma volume (± SD) 45.3 ± 10.9 42.7 ± 11.4 43.4 ± 10.9 50.0 ± 8.9 *<0.001 
Liverpool Active Plaque Score (± SD) 4.19 ± 3.57 3.32 ± 3.63 4.01 ± 3.24 5.24 ± 3.66 *0.015 
Table 5.7 Grayscale and VH IVUS parameters by age 
 
Figure 5.4 illustrates the proportion of plaque components in each age group and 
demonstrates that there was no difference between the groups, in contrast to the 
PROSPECT sub-analysis, which demonstrated more DC and less fibrous tissue in the 
older age group174. However, this cohort had a much higher proportion of DC overall 
(over twice as much) due to selection bias in the PROSPECT study, and a much older 
and narrower age range such that differences in plaque composition due to age may 
not be as apparent. A further retrospective, single-centre study of 553 patients 
undergoing VH IVUS imaging demonstrated that elderly patients (>70 years) had 
greater %NC and %DC than non-elderly patients. However, when results were broken 
down by clinical presentation, this only held true for patients with stable angina; those 




Figure 5.4 Proportion of plaque components by age 
 
Figure 5.5 demonstrates that there was a greater burden of advanced and vulnerable 
lesions (FA and VH-TCFA) with age. Interestingly, the PROSPECT investigators 
demonstrated greater FA in the older cohort (42.5 vs. 35.8%, p=0.0007) but a trend 
towards fewer VH-TCFA (23.2 vs. 20.3%, p=0.08)174. This may reflect the fact that they 
only reported non-culprit lesions and there was a trend in our cohort for a greater 
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Figure 5.5 Lesion classification by age 
 
5.2.2 Sex 
Overall, 138 vessels were imaged in men (11841 frames) and 83 in women (8237 
frames).  
 
Male patients had a higher burden of atheroma, as measured by the PAV and 
maximum vessel stenosis, than female patients (Table 5.8). This concurs with a Swiss 
VH IVUS study of patients with ACS and stable angina, which demonstrated that men 
had a higher plaque burden than women in every age tertile (p<0.001)205, and in a sub-
analysis of the ADAPT-DES study203. The PROSPECT investigators also showed a 











MLA (mm2 ± SD) 5.2 ± 2.4 5.2 ± 2.5 5.3 ± 2.2 0.203 
MLD (mm ± SD) 2.5 ± 0.6 2.5 ± 0.6 2.5 ± 0.5 0.298 
Maximum stenosis (% ± SD) 67.2 ± 12.2 69.1 ± 11.5 64.3 ± 12.9 *0.011 
Remodeling index (± SD) 1.04 ± 0.13 1.05 ± 0.13 1.02 ± 0.14 0.147 
Percent atheroma volume (± SD) 45.3 ± 10.9 47.6 ± 10.4 41.7 ± 10.8 *<0.001 
Liverpool Active Plaque Score (± SD) 4.19 ± 3.57 4.51 ± 3.73 3.66 ± 3.24 0.128 
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The proportion of plaque components between the sexes was similar (Figure 5.6). 
Previous studies have shown a blunting of sex differences in plaque composition with 
age. Although Shoenenberger et al demonstrated sex differences in plaque 
composition in younger patients, there were no differences between the sexes in the 
oldest age tertile205. An analysis of a registry of almost 1000 patients undergoing VH 
IVUS imaging also demonstrated attenuation of the sex differences in plaque 
components with increasing age204, and this phenomenon was also seen in a registry 
of patients with STEMI206. In contrast, the PROSPECT investigators demonstrated that 
older female patients had a higher proportion of NC and DC (and concomitantly less 
FF tissue) than male patients, but their “older” female group was actually significantly 
older than the male group (73.7 [68.8, 77.3] vs. 70.4 [67.3, 74.5] years, p=0.001)174 















Figure 5.6 Proportion of plaque components by sex 
 
There were no differences between the sexes in the vulnerability of the lesions (as 
measured by LAPS and %TCFA), although male patients had more FA present (Figure 
5.7). This is probably a reflection of the higher plaque burden seen in men, whereby 
the increase in plaque is predominantly with thick capped FA. This was not seen in the 
PROSPECT sub-analysis, with no differences in the lesion phenotypes between the 
sexes174. 
 
































Figure 5.7 Lesion classification by sex 
 
5.2.3 Frailty 
Of the 221 vessels imaged, 65 were in robust patients (4865 frames), 112 in pre-frail 
(11413 frames) and 44 in the frail group (3800 frames). 
 
Table 5.9 demonstrates a non-linear relationship between frailty and severity of 
stenosis, as measured by the MLA, MLD and maximum vessel stenosis. This is in 
keeping with the results seen in the QCA analysis, whereby pre-frail patients had a 
smaller reference diameter than robust or frail patients, although this was not seen 
when measured by the RI on IVUS, possibly because the site of tightest stenosis and 
highest remodeling was not always imaged due to failure to deliver the EEP catheter 












MLA (mm2 ± SD) 5.2 ± 2.4 5.7 ± 2.5 4.8 ± 2.2 5.7 ± 2.6 0.053 
MLD (mm ± SD) 2.5 ± 0.6 2.6 ± 0.6 2.4 ± 0.5 2.6 ± 0.6 *0.039 
Maximum stenosis (% ± SD) 67.2 ± 12.2 63.8 ± 13.6 69.5 ± 10.9 66.1 ± 12.5 *0.025 
Remodeling index (± SD) 1.04 ± 0.13 1.05 ± 0.15 1.03 ± 0.13 1.07 ± 0.13 0.432 
Percent atheroma volume (± SD) 45.3 ± 10.9 42.8 ± 11.5 46.7 ± 10.6 45.4 ± 10.6 0.139 
Liverpool Active Plaque Score (± SD) 4.19 ± 3.57 3.41 ± 3.60 4.70 ± 3.60 3.94 ± 3.29 0.115 




































This non-linear relationship may be related to the pattern of calcification (as discussed 
in Section 6.3), as frail patients had a higher proportion of dense calcium overall and 
proportionally less fibrous tissue (Figure 5.8), which may have affected how the vessel 















Figure 5.8 Proportion of plaque components by frailty 
 
With the increasing proportion of calcium, frail patients had a higher proportion of fibro-













































Figure 5.9 Lesion classification by frailty 
 
5.2.4 Culprit vs. Non-Culprit Artery  
As expected, culprit arteries had a greater degree of stenosis, higher plaque burden 
and a higher LAPS (Table 5.10). There were no differences in the proportions of plaque 
components between culprit and non-culprit arteries (FT: 51.4 ± 11.6% vs. 53.7 ± 
11.9%, p=0.289; FF: 14.6 ± 10.3% vs. 13.4 ± 8.5%, p=0.336; NC: 19.3 ± 5.9% vs. 19.2 
± 6.8%, p=0.995; DC: 14.7 ± 8.7% vs. 13.7 ± 8.0%, p=0.494). Culprit arteries had a 
higher proportion of plaque categorised as FA (42.8 ± 23.1% vs. 35.3 ± 24.6%, 
p=0.034) but the proportions of TCFA were not statistically different (10.5 ± 11.5% vs. 
9.0 ± 11.8%, p=0.145). These results are similar to those demonstrated by 
Schoenenberger et al, with a higher plaque burden in culprit arteries but no differences 





















































MLA (mm2 ± SD) 5.22 ± 2.37 4.82 ± 2.29 5.51 ± 2.40 *0.033 
MLD (mm ± SD) 2.52 ± 0.55 2.42 ± 0.53 2.59 ± 0.56 *0.032 
Maximum stenosis (% ± SD) 67.2 ± 12.2 71.2 ± 10.8 64.4 ± 12.5 *<0.001 
Remodeling index (± SD) 1.04 ± 0.13 1.07 ± 0.16 1.03 ± 0.11 0.137 
Percent atheroma volume (± SD) 45.3 ± 10.9 48.5 ± 10.0 43.0 ± 11.0 *0.001 
Liverpool Active Plaque Score (± SD) 4.19 ± 3.57 4.92 ± 4.06 3.67 ± 3.09 *0.034 
Table 5.10 Grayscale and VH IVUS parameters by culprit vs. non-culprit vessel 
 
5.2.5 VH-TCFA 
Using the standard definition of VH-TCFA53, there were 79 vessels with VH-TCFA 
present and 95 without. In the univariate analysis of baseline patient characteristics, 
presence of VH-TCFA was correlated (p<0.25) with age, frailty, NSTEMI, GRACE 
score, BMI, hyperlipidaemia, family history of IHD, cerebrovascular disease, platelets, 
cholesterol, troponin and vitamin D level. These variables were entered into a 
multivariate logistic regression analysis and increasing age, presentation with 
NSTEMI, and increasing vitamin D level were demonstrated to be independent 











Age 0.207 0.096 0.031 1.229 (1.019, 1.483) 
NSTEMI 2.158 0.772 0.005 8.650 (1.903, 39.315) 
Vitamin D 0.038 0.012 0.002 1.038 (1.014, 1.063) 
Intercept -22.961 7.822 0.003  
Table 5.11 Multiple regression analysis for VH-TCFA 
 
Table 5.12 demonstrates the association of VH-TCFA with other vessel 
characteristics. VH-TCFA were more common in the RCA and were associated with 


















 LAD, n (%) 
 Cx, n (%) 










Culprit, n (%) 37 (38.9) 35 (44.3) 0.475 
Calcification: 
 None, n (%) 
 Mild, n (%) 
 Moderate, n (%) 













 Type A, n (%) 
 Type B1, n (%) 
 Type B2, n (%) 












Procedure success, n (%) 36 (87.8) 43 (87.8) 0.626 
VH IVUS 
MLA, mm2 (IQR) 4.8 (3.4, 6.5) 4.6 (3.5, 6.5) 0.987 
Maximum stenosis, % (IQR) 64.2 (53.3, 71.4) 72.5 (65.7, 80.2) *<0.001 
Remodeling index (IQR) 1.03 (0.95, 1.10) 1.02 (0.97, 1.13) 0.914 
Percent atheroma volume (IQR) 41.3 (32.9, 49.9) 51.7 (45.5, 57.0) *<0.001 
OCT 
MLA, mm2 (IQR) 3.2 (1.5, 5.6) 2.8 (1.9, 4.6) 0.988 
Minimum fibrous cap, µm (IQR) 87 (58, 118) 79 (61, 115) 0.960 
% fibroatheroma frames (IQR) 41.5 (16.6, 100) 29.1 (12.3, 75.2) 0.398 
% fibrocalcific frames (IQR) 60.6 (32.9, 100) 70.2 (45.0, 96.7) 0.816 
Rupture, n (%) 6 (28.6) 3 (18.8) 0.702 
Macrophage, n (%) 12 (54.4) 7 (43.8) 0.511 
Microchannel, n (%) 9 (40.9) 7 (43.8) 0.861 
ChC, n (%) 6 (27.3) 5 (31.3) 1.000 
OCT-TCFA, n (%) 6 (28.6) 4 (25.0) 0.809 
Table 5.12 Association of VH-TCFA with other vessel characteristics 
 
5.2.6 Liverpool Active Plaque Score 
In the univariate analysis of baseline patient characteristics, LAPS was correlated 
(p<0.25) with age, sex, presentation with NSTEMI, white cell count, creatinine 
clearance and cholesterol level. These variables were entered into a multiple linear 
regression analysis and only increasing age and male sex were independent predictors 












Age 0.305 0.095 0.002 
Male 1.983 0.698 0.005 
Intercept -19.267 7.642 0.013 
Table 5.13 Multiple regression analysis for LAPS 
 
A LAPS >6 has been previously shown to correlate with an active plaque phenotype64. 
Table 5.14 demonstrates the association between LAPS and other vessel 
characteristics (not including those that make up the score itself, i.e. MLA, RI and VH-
TCFA). It was significantly associated with the culprit artery, maximum stenosis and 
PAV, and a thinner fibrous cap on OCT. There was also a non-significant association 










 LAD, n (%) 
 Cx, n (%) 










Culprit, n (%) 39 (33.9) 33 (56.9) *0.004 
Calcification: 
 None, n (%) 
 Mild, n (%) 
 Moderate, n (%) 













 Type A, n (%) 
 Type B1, n (%) 
 Type B2, n (%) 












Procedure success, n (%) 46 (90.2) 33 (84.6) 0.522 
VH IVUS  
Maximum stenosis, % (IQR) 65.4 (56.5, 72.8) 72.7 (66.3, 81.2) *<0.001 
Percent atheroma volume (IQR) 42.3 (33.8, 50.8) 52.6 (46.2, 57.1) *<0.001 
OCT 
MLA, mm2 (IQR) 3.2 (2.1, 5.2) 2.4 (1.4, 3.9) 0.270 
Minimum fibrous cap, µm (IQR) 94 (72, 140) 60 (56, 80) *0.005 
% fibroatheroma frames (IQR) 32.6 (10.7, 100) 33.2 (22.1, 71.2) 0.902 
% fibrocalcific frames (IQR) 58.3 (32.7, 100) 73.9 (44.5, 100) 0.768 
Rupture, n (%) 4 (17.4) 5 (35.7) 0.255 
Macrophage, n (%) 11 (45.8) 8 (57.1) 0.501 
Microchannel, n (%) 8 (33.3) 8 (57.1) 0.152 
ChC, n (%) 7 (29.2) 4 (28.6) 0.969 
OCT-TCFA, n (%) 4 (17.4) 6 (42.9) 0.096 
Table 5.14 Association of LAPS with other vessel characteristics 
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In a validation cohort, LAPS was demonstrated to have good diagnostic ability in 
discriminating between ACS and stable angina culprit lesions64. In this study, many 
had multi-vessel coronary disease, and we hypothesised that LAPS may be a useful 
diagnostic test to confirm the culprit artery if there was diagnostic uncertainty. It had a 
PPV of 56.9% (95% CI 43.2-69.8%), NPV of 66.1% (95% CI 56.7-69.8%), sensitivity 
of 43.8% (95% CI 34.0-58.0%), specificity of 75.3% (95% CI 65.7-83.3%) and an 
accuracy of 63%. The most discriminatory cut-off LAPS was >5.74 for predicting the 
culprit artery (similar to the LAPS of >6 for predicting an active plaque phenotype in 
the original study64). However, Figure 5.10 displays the receiver operating 
characteristic curve for LAPS, demonstrating a poor diagnostic ability (area under the 
curve = 0.594) for culprit vs. non-culprit arteries in NSTEACS in older patients.  
 
 
Figure 5.10 ROC curve for LAPS in predicting culprit artery 
Although LAPS has previously been shown to have good discriminatory ability between plaques from 
patients with stable angina vs. ACS, results here demonstrate that it would be less useful as a tool to 
aid identification of the culprit lesion in patients presenting with NSTEACS and multiple coronary lesions. 
 
5.2.7 Key Findings From VH IVUS Sub-Study 
 Plaque burden, but not plaque composition, increases with age 
 Men have a greater plaque burden than women, but there were no differences 
in plaque composition between the sexes 
 Pre-frail patients have the greatest severity of stenosis on VH IVUS 
 Calcification increases with increasing frailty 
AUC = 0.594 
 




 VH-TCFA are associated with increasing plaque burden, but not with OCT-
TCFA 
 LAPS is a poor diagnostic test to discriminate between culprit and non-culprit 





5.3 Optical Coherence Tomography 
 
The sub-group of patients who underwent OCT imaging was small (n=26 with 
analysable data) and therefore these results should be treated as exploratory and 
hypothesis-generating only. In total, 65 vessels in 26 patients were imaged on OCT 
(9142 frames). 
 
5.3.1 Age  
32 vessels were imaged in patients <80 years (4429 frames) and 33 were imaged in 
patients ≥80 years (4713 frames). 
 
Due to the smaller numbers in the OCT sub-analysis, the cohort was split into just 2 
age categories. As in the VH IVUS cohort, there was no difference in MLA or MLD with 
age on OCT (Table 5.15). There was a non-significant trend towards a greater 
proportion of fibroatheroma and OCT-TCFA present with increasing age but no 
differences in the other potential markers of plaque vulnerability. This correlates with 
the results seen in the larger group who underwent VH IVUS imaging. Data from a 
large registry of patients with ACS showed a similar non-significant trend for younger 
(<50 years) patients to have a greater prevalence of OCT-TCFA (70 vs. 58%, p=0.06) 










MLA, mm2 (IQR) 3.0 (1.7, 5.6) 3.0 (2.1, 5.7) 3.0 (1.5, 5.5) 0.449 
MLD, mm (IQR) 1.9 (1.5, 2.7) 1.9 (1.6, 2.7) 2.0 (1.4, 3.4) 0.317 
Minimum fibrous cap, µm (IQR) 83 (60, 116) 94 (72, 124) 71 (57, 98) 0.283 
% fibroatheroma frames (IQR) 24.3 (14.4, 40.5) 20.3 (9.2, 31.1) 29.0 (19.2, 52.0) 0.066 
% fibrocalcific frames (IQR) 37.3 (15.8, 57.3) 42.8 (18.4, 65.1) 32.3 (15.8, 56.8) 0.864 
Rupture, n (%) 11 (22.0) 4 (16.0) 7 (28.0) 0.333 
Macrophage, n (%) 30 (56.6) 15 (55.6) 15 (57.7) 0.875 
Microchannel, n (%) 21 (39.6) 9 (33.3) 12 (46.1) 0.433 
ChC, n (%) 13 (24.5) 4 (14.8) 9 (34.6) 0.102 
OCT-TCFA, n (%) 14 (26.9) 3 (11.5) 11 (42.3) 0.060 
Table 5.15 OCT parameters by age 
 
5.3.2 Sex 




There were no significant differences in OCT measurements or plaque characteristics 
when stratified by sex (Table 5.16). This is similar to results previously reported by 
Chia et al, who demonstrated no sex differences in incidence of lipid-rich plaque, OCT-
TCFA, minimum fibrous cap or plaque rupture208. A study of patients with STEMI 










MLA, mm2 (IQR) 3.0 (1.7, 5.6) 2.8 (1.7, 5.6) 3.7 (2.2, 5.4) 0.838 
MLD, mm (IQR) 1.9 (1.5, 2.7) 1.9 (1.5, 2.7) 2.2 (1.7, 2.6) 0.955 
Minimum Fibrous Cap, µm (IQR) 83 (60, 116) 85.0 (60.0, 112.0) 81.0 (59.0, 112.0) 0.721 
% fibroatheroma frames (IQR) 24.3 (14.4, 40.5) 27.0 (16.2, 40.3) 21.8 (14.4, 35.9) 0.809 
% fibrocalcific frames (IQR) 37.3 (15.8, 57.3) 48.3 (24.6, 58.3) 30.9 (6.9, 41.7) 0.127 
Rupture, n (%) 11 (22.0) 8 (26.7) 3 (15.0) 0.356 
Macrophage, n (%) 30 (56.6) 18 (56.3)  12 (57.1) 0.949 
Microchannel, n (%) 21 (39.6) 11 (34.4) 10 (47.6) 0.346 
ChC, n (%) 13 (24.5) 8 (25.0) 5 (23.8) 0.922 
OCT-TCFA, n (%) 14 (26.9) 9 (29.0) 5 (23.8) 0.651 
Table 5.16 OCT parameters by sex 
 
5.3.3 Frailty 
Of the 65 vessels imaged, 16 were in robust patients (1693 frames), 35 in pre-frail 
(5515 frames) and 14 in the frail group (1934 frames). 
 
Although not statistically significant, there were trends towards more calcium and a 
thicker fibrous cap in frail patients (Table 5.17). This suggests that frail patients may 
have more stable coronary plaque than robust patients (and, indeed, no OCT-TCFA 












MLA, mm2 (IQR) 3.0 (1.7, 5.6) 4.1 (1.6, 5.6) 2.7 (1.4, 4.1) 3.7 (2.7, 6.9) 0.505 
MLD, mm (IQR) 1.9 (1.5, 2.7) 2.3 (1.4, 2.7) 1.8 (1.4, 2.3) 2.2 (1.9, 3.0) 0.324 
Minimum Fibrous Cap, µm (IQR) 83 (60, 116) 72 (58, 140) 82 (57, 98) 114 (84, 155) 0.055 
% fibroatheroma frames (IQR) 24.3 (14.4, 40.5) 21.8 (14.8, 48.3) 27.0 (19.9, 41.6) 15.5 (7.6, 34.3) 0.521 
% fibrocalcific frames (IQR) 37.3 (15.8, 57.3) 22.8 (2.2, 44.2) 42.2 (19.4, 58.9) 49.6 (31.3, 85.0) 0.101 
Rupture, n (%) 11 (22.0) 4 (30.8) 6 (24.0) 1 (8.3) 0.187 
Macrophage, n (%) 30 (56.6) 5 (35.7) 19 (70.4) 6 (50.0) 0.400 
Microchannel, n (%) 21 (39.6) 5 (35.7) 13 (48.1) 3 (25.0) 0.814 
ChC, n (%) 13 (24.5) 4 (28.6) 8 (29.6) 1 (8.3) 0.257 
OCT-TCFA, n (%) 14 (26.9) 3 (23.1) 11 (40.7) 0 0.294 
Table 5.17 OCT parameters by frailty 
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5.3.4 Plaque Rupture 
There were 11 plaque ruptures seen in the OCT sub-study. In the univariate analysis 
of baseline patient characteristics, presence of plaque rupture on OCT was correlated 
(p<0.25) with male sex, NSTEMI, GRACE score, hypertension, diabetes, smoking 
status, family history of IHD, cerebrovascular disease, platelets, glucose and 
cholesterol. These variables were entered into a multivariate logistic regression 
analysis. However, no patient baseline characteristics were independently associated 
with plaque rupture. Age, diabetes, hypertension and hyperlipidaemia were 
independent predictors of plaque rupture in a previous meta-analysis of NSTEACS210 
but the ICON1 sample size is likely too small to demonstrate these associations due 
to the small regression coefficients reported. 
 
Plaque rupture was more common in lesions with higher angiographic complexity but 
not necessarily more common in the culprit artery (Table 5.18). This confirms that 
patients with NSTEACS may have multiple asymptomatic plaque ruptures at the time 
of their coronary event. The MLA and MLD were smaller in the plaque rupture group 
(although this did not reach significance when measured on IVUS), suggesting that 
rupture occurs in more tightly stenosed vessels. There was also a greater degree of 
lipid present in vessels with plaque rupture, as well as a higher incidence of 






















Angiography    
Vessel: 
 LAD, n (%) 
 Cx, n (%) 










Culprit, n (%) 14 (35.9) 7 (63.6) 0.166 
Calcification: 
 None, n (%) 
 Mild, n (%) 
 Moderate, n (%) 













 Type A, n (%) 
 Type B1, n (%) 
 Type B2, n (%) 












Procedure success, n (%) 17 (85.0) 6 (75.0) 0.606 
VH IVUS    
MLA, mm2 (IQR) 4.4 (3.2, 6.0) 3.7 (2.5, 6.5) 0.519 
Maximum stenosis, % ± SD 69.8 ± 9.5 73.6 ± 14.4 0.375 
Remodeling index, ± SD 1.03 ± 0.18 1.03 ± 0.10 0.927 
Percent atheroma volume (IQR) 50.3 (42.8, 57.2) 59.3 (50.3, 61.3) 0.116 
% Fibrous tissue, ± SD 54.1 ± 10.3 52.3 ± 16.6 0.767 
% Fibro-fatty tissue, ± SD 10.6 ± 4.4 11.6 ± 5.4 0.588 
% Necrotic core, ± SD 21.4 ± 6.3 21.6 ± 10.2 0.957 
% Dense calcium, ± SD 13.8 ± 6.7 14.5 ± 10.2 0.861 
% frames VH-TCFA (IQR) 9.9 (0.7, 12.7) 6.0 (0.9, 20.3) 0.614 
LAPS, ± SD 3.75 ± 3.61 5.95 ± 2.92 0.107 
OCT    
MLA, mm2 (IQR) 3.2 (2.2, 6.1) 1.5 (1.0, 3.3) *0.006 
Minimum fibrous cap, µm (IQR) 92 (68, 123) 64 (53, 94) 0.106 
% fibroatheroma frames (IQR) 17.0 (7.5, 28.0) 35.3 (27.7, 53.7) *0.001 
% fibrocalcific frames (IQR) 39.7 (22.8, 68.8) 27.2 (9.6, 54.2) 0.292 
Macrophage, n (%) 21 (53.8) 8 (72.7) 0.319 
Microchannel, n (%) 12 (30.8) 7 (63.6) *0.047 
ChC, n (%) 7 (17.9) 6 (54.5) *0.023 
OCT-TCFA, n (%) 7 (17.9) 5 (45.5) 0.059 
Table 5.18 Association of plaque rupture with other vessel characteristics 
 
5.3.5 Macrophage Accumulation 
There were 30 vessels with macrophage accumulations on OCT. In the univariate 
analysis of baseline characteristics, their presence was correlated (p<0.25) with frailty, 
BMI, hypertension, diabetes, previous MI, atrial fibrillation, and troponin. These 
variables were entered into a multivariate logistic regression analysis but no patient 
characteristics were independently associated with macrophage accumulations. 
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Table 5.19 demonstrates that macrophage accumulations were associated with a 
greater degree of stenosis and with greater %lipid on OCT (but not VH IVUS). There 
were non-significant trends towards the presence of other markers of plaque 








Angiography    
Vessel: 
 LAD, n (%) 
 Cx, n (%) 










Culprit, n (%) 9 (39.1) 13 (43.3) 0.758 
Calcification: 
 None, n (%) 
 Mild, n (%) 
 Moderate, n (%) 













 Type A, n (%) 
 Type B1, n (%) 
 Type B2, n (%) 












Procedure success, n (%) 11 (84.6) 13 (81.3) 1.000 
VH IVUS 
MLA, mm2 (IQR) 5.3 (3.8, 6.5) 3.6 (2.8, 5.3) *0.030 
Maximum stenosis, % ± SD 67.1 ± 11.0 74.0 ± 9.6 *0.045 
Remodeling index, ± SD 1.04 ± 0.11 1.03 ± 0.14 0.780 
Percent atheroma volume (IQR) 50.5 (45.5, 56.9) 55.8 (42.4, 61.1) 0.246 
% Fibrous tissue, ± SD 54.6 ± 12.0 52.6 ± 11.7 0.614 
% Fibro-fatty tissue, ± SD 10.6 ± 4.3 11.3 ± 4.9 0.668 
% Necrotic core, ± SD 21.1 ± 6.8 21.7 ± 7.7 0.820 
% Dense calcium, ± SD 13.7 ± 7.0 14.5 ± 8.1 0.756 
% frames VH-TCFA (IQR) 4.8 (0, 16.2) 8.3 (1.7, 12.6) 0.506 
LAPS, ± SD 3.50 ± 3.33 5.05 ± 3.58 0.175 
OCT 
MLA, mm2 (IQR) 4.0 (2.6, 6.1) 2.5 (1.4, 3.4) *0.021 
Minimum fibrous cap, µm (IQR) 98 (68, 137) 81 (57, 101) *0.043 
% fibroatheroma frames (IQR) 10.7 (3.9, 44.2) 27.0 (19.9, 36.5) *0.011 
% fibrocalcific frames (IQR) 76.2 (46.2, 86.7) 36.8 (15.1, 55.4) 0.524 
Microchannel, n (%) 6 (26.1) 15 (50.0) 0.078 
ChC, n (%) 3 (13.0) 10 (33.3) 0.089 
OCT-TCFA, n (%) 4 (18.2) 10 (33.3) 0.224 





5.3.6 Microchannel Formation 
There were 21 vessels with macrophage accumulations seen in the OCT sub-study. In 
the univariate analysis of baseline patient characteristics, presence of microchannels 
on OCT was correlated (p<0.25) with NSTEMI, hypertension, platelets, and troponin. 
These variables were entered into a multivariate logistic regression analysis. Platelet 
count was the only variable independently associated with presence of microchannels. 










Platelet count 0.07 0.003 0.045 1.007 (1.00,1.014) 
Intercept -2.564 1.000 0.010  
Table 5.20 Multiple regression analysis for microchannels 
 
Table 5.21 demonstrates that microchannels were associated with the burden of 
coronary disease on IVUS and OCT (maximum stenosis, PAV, and MLA/MLD on 
OCT), and negatively associated with % fibrous tissue on VH IVUS. They were also 
significantly associated with the burden of VH-TCFA and OCT-TCFA. Microchannels 
were also associated with other markers of plaque vulnerability on OCT such as 



























 LAD, n (%) 
 Cx, n (%) 










Culprit, n (%) 12 (37.5) 10 (47.6) 0.465 
Calcification: 
 None, n (%) 
 Mild, n (%) 
 Moderate, n (%) 













 Type A, n (%) 
 Type B1, n (%) 
 Type B2, n (%) 












Procedure success, n (%) 11 (78.6) 13 (86.7) 0.651 
VH IVUS 
MLA, mm2 (IQR) 4.7 (3.3, 5.6) 3.7 (2.8, 6.4) 0.569 
Maximum stenosis, % ± SD 68.4 ± 11.7 73.5 ± 8.7 0.150 
Remodeling index, ± SD 1.02 ± 0.10 1.06 ± 0.15 0.341 
Percent atheroma volume (IQR) 50.8 (38.4, 56.0) 58.5 (47.7, 60.7) *0.022 
% Fibrous tissue, ± SD 56.8 ± 11.3 49.2 ± 11.1 *0.046 
% Fibro-fatty tissue, ± SD 11.4 ± 3.7 10.3 ± 5.6 0.510 
% Necrotic core, ± SD 19.4 ± 5.6 24.1 ± 8.3 *0.048 
% Dense calcium, ± SD 12.3 ± 6.5 16.4 ± 8.2 0.096 
% frames VH-TCFA (IQR) 3.7 (0, 11.5) 10.0 (6.4, 25.2) 0.069 
LAPS, ± SD 3.18 ± 3.26 5.78 ± 3.35 *0.022 
OCT 
MLA, mm2 (IQR) 3.2 (2.1, 6.0) 2.4 (1.2, 4.0) 0.089 
Minimum Fibrous Cap, µm (IQR) 93 (69, 133) 72 (58, 99) 0.118 
% fibroatheroma frames (IQR) 17.0 (7.6, 30.0) 30.3 (19.5 (51.0) *0.018 
% fibrocalcific frames (IQR) 34.5 (17.0, 56.1) 73.8 (44.6, 73.8) 0.585 
ChC, n (%) 5 (15.6) 8 (38.1) 0.063 
OCT-TCFA, n (%) 6 (18.8) 8 (40.0) 0.093 
Table 5.21 Association of microchannels with other vessel characteristics 
 
5.3.7 Cholesterol Crystals 
There were 13 vessels with ChC in the OCT sub-study. In the univariate analysis of 
baseline patient characteristics, presence of ChC on OCT was correlated (p<0.25) with 
age, NSTEMI, BMI, hypertension, diabetes, family history of IHD, troponin and hsCRP. 
These variables were entered into a multivariate logistic regression analysis. However, 




Table 5.22 demonstrates that presence of ChC was associated with a greater degree 
of stenosis on both IVUS and OCT (consistent with results from Tian et al, who 
demonstrated the association of ChC with greater angiographic lesion severity211), as 
well as with a thinner fibrous cap and greater prevalence of OCT-TCFA (and a trend 










 LAD, n (%) 
 Cx, n (%) 










Culprit, n (%) 14 (35.0) 8 (61.5) 0.092 
Calcification: 
 None, n (%) 
 Mild, n (%) 
 Moderate, n (%) 













 Type A, n (%) 
 Type B1, n (%) 
 Type B2, n (%) 












Procedure success, n (%) 16 (84.2) 8 (80.0) 1.000 
VH IVUS 
MLA, mm2 (IQR) 5.1 (3.4, 6.4) 3.3 (2.4, 5.3) *0.045 
Maximum stenosis, % ± SD 67.5 ± 10.5 78.0 ± 7.4 *0.005 
Remodeling index, ± SD 1.05 ± 0.12 0.99 ± 0.13 0.172 
Percent atheroma volume (IQR) 49.3 (41.6, 57.5) 55.8 (51.9, 61.2) *0.049 
% Fibrous tissue, ± SD 54.3 ± 13.2 51.8 ± 7.3 0.562 
% Fibro-fatty tissue, ± SD 10.8 ± 4.6 11.2 ± 4.7 0.826 
% Necrotic core, ± SD 20.8 ± 8.0 22.9 ± 4.4 0.413 
% Dense calcium, ± SD 14.1 ± 8.2 14.1 ± 5.6 0.993 
% frames VH-TCFA (IQR) 4.8 (0, 11.4) 10.9 (8.0, 23.1) 0.088 
LAPS, ± SD 4.15 ± 3.54 4.60 ± 3.56 0.723 
OCT 
MLA, mm2 (IQR) 3.2 (2.2, 6.0) 1.3 (0.9, 3.4) *0.002 
Minimum Fibrous Cap, µm (IQR) 92 (67, 122) 64 (55, 97) *0.037 
% fibroatheroma frames (IQR) 19.6 (7.6, 34.3) 30.3 (15.8, 66.7) 0.069 
% fibrocalcific frames (IQR) 35.5 (15.8, 66.7) 44.6 (12.4, 56.8) 1.000 
OCT-TCFA, n (%) 6 (15.4) 8 (61.5) *0.001 





There were 14 vessels with OCT-TCFA identified in the OCT sub-study. In the 
univariate analysis of baseline patient characteristics, presence of OCT-TCFA on OCT 
was correlated (p<0.25) with age, frailty, NSTEMI, BMI, hypertension, diabetes, family 
history of IHD, previous MI, atrial fibrillation, cerebrovascular disease, platelet count, 
glucose level, cholesterol level, peak troponin and hsCRP. These variables were 
entered into a multivariate logistic regression analysis. However, no patient baseline 
characteristics were independently associated with the presence of OCT-TCFA.  
 
OCT-TCFA were evenly distributed between culprit and non-culprit vessels (Table 
5.23). They were associated with higher degrees of stenosis within the vessel on both 
OCT and VH IVUS, and there was a trend towards less %DC in vessels with OCT-
TCFA. Presence of OCT-TCFA was also significantly associated with plaque rupture 
(p=0.020), presence of thrombus (p=0.005), microchannel formation (p=0.021) and 































 LAD, n (%) 
 Cx, n (%) 










Culprit, n (%) 14 (36.8) 7 (50.0) 0.391 
Calcification: 
 None, n (%) 
 Mild, n (%) 
 Moderate, n (%) 













 Type A, n (%) 
 Type B1, n (%) 
 Type B2, n (%) 












Procedure success, n (%) 15 (83.3) 8 (80.0) 1.000 
VH IVUS 
MLA, mm2 (IQR) 4.4 (3.4, 6.4) 2.8 (2.3, 5.5) 0.072 
Maximum Stenosis, % ± SD 68.9 ± 9.3 75.8 ± 13.4 0.085 
Remodeling Index, ± SD 1.01 ± 0.12 1.07 ± 0.10 0.242 
Percent Atheroma Volume (IQR) 50.1 (43.9, 57.5) 55.1 (49.5, 61.6) 0.158 
% Fibrous Tissue, ± SD 52.7 ± 12.2 56.2 ± 11.2 0.435 
% Fibro-Fatty Tissue, ± SD 10.6 ± 4.3 11.6 ± 5.7 0.555 
% Necrotic Core, ± SD 21.4 ± 7.0 21.6 ± 8.5 0.938 
% Dense Calcium, ± SD 15.3 ± 7.9 10.5 ± 3.6 0.090 
% frames VH-TCFA (IQR) 7.8 (0.5, 11.8) 9.7 (1.3, 24.8) 0.468 
LAPS, ± SD 3.67 ± 3.58 5.97 ± 3.02 0.079 
OCT 
MLA, mm2 (IQR) 3.3 (2.1, 5.9) 1.6 (1.1, 3.1) *0.029 
Minimum Fibrous Cap, µm (IQR) 97 (81, 140) 57 (51, 61) *<0.001 
% fibroatheroma frames (IQR) 17.0 (7.5, 27.8) 36.7 (29.0, 54.3) *<0.001 
% fibrocalcific frames (IQR) 38.0 (21.0, 70.0) 30.9 (8.9, 53.6) 0.327 
Table 5.23 Association of OCT-TCFA with other vessel characteristics 
 
5.3.9 Key Findings From OCT Sub-Study 
 There was a trend for more OCT-TCFA with advancing age 
 Markers of plaque vulnerability tend to cluster together, suggesting an element 









5.4.1 Patient-Level Factors And Pattern Of Plaque Burden 
It was the “English Hippocrates”, Thomas Sydenham, who declared that “a man is as 
old as his arteries”. This is the first prospective study utilising advanced intracoronary 
imaging techniques to explore the pattern of coronary artery disease in older patients 
presenting with NSTEACS. It has provided unique insights into the progression of 
advanced atherosclerosis, and revealed a population with high levels of so-called 
“vulnerable” plaque characteristics who could prove a valuable resource for future 
research studies. Overall, across all 3 imaging modalities, the study cohort had a 
higher plaque burden and greater levels of advanced and vulnerable plaque than other 
contemporary studies in patients with NSTEACS, but comparably excellent levels of 
procedural success, low complication rate and a lower than expected adverse event 
rate.  
 
This ICON1 invasive imaging sub-study confirms multiple previous observational and 
randomised controlled studies that early invasive management is both feasible and 
safe in older patients with NSTEACS. The results presented here should reassure 
clinicians that, even in the presence of frailty, comorbidities and complex coronary 
disease, patients ≥75 years of age should be referred for PCI in the absence of any 
absolute contraindications. Indeed, the current UK guidelines state that all patients with 
≥3% risk of mortality at 6 months after ACS should be referred for PCI within 72 
hours212; all patients aged ≥75 years, regardless of any other clinical measurement, 
fall into this category on the most widely used risk score, GRACE 2.0. The European 
Society of Cardiology guidelines state that “elderly patients should be considered for 
an invasive strategy and, if appropriate, revascularisation after careful evaluation of 
risks and benefits”213. I would argue that this statement does not go far enough and 
that all patients with NSTEACS should be considered for an early invasive strategy, 
regardless of age. The recently commenced SENIOR-RITA trial will hopefully put this 
question of conservative vs. early invasive strategy to bed once and for all214. 
 
The data presented here corroborates the findings of previous studies in younger 
patients in demonstrating that ageing is associated with a higher plaque burden, 
greater severity of stenosis, and increasing incidence of advanced plaque sub-types 
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such as FA and TCFA. It would therefore appear that at no age does the acquisition of 
more atherosclerotic plaque plateau or cease.  
 
Figure 5.1 demonstrates the commonly held theory of atherosclerotic plaque 
progression based on historical ex vivo histological studies, proposed by Stary et al215. 
The loop between types V and VI illustrates the repeated rupture and healing of 
atherosclerotic plaques, sometimes silently, leading to an increasing burden of 
complex plaque. These in vivo imaging results support this theory of plaque 
progression, as they clearly show increasing proportions of FA and TCFA, alongside 
high numbers of plaque rupture and thrombus in both culprit and non-culprit lesions 
(the OCT sub-study was underpowered to show any differences between age groups). 
Advanced plaque features suggestive of repeated rupture such as macrophage 
accumulations, microchannels and ChC clearly clustered together within lesions, 





Nomenclature and histology 
 




Type I (initial) lesion 





Type II (fatty streak) lesion 
Intracellular lipid accumulation 
 
 
Type III (intermediate) lesion 
Small extracellular lipid pools 
 
 
Type IV (atheroma) lesion 
Necrotic core of extracellular lipid 
 
 
Type V (fibroatheroma) lesion 
Single or multiple lipid cores and fibrotic 
layers or 




muscle and collagen 
increase 
Type VI (complicated) lesion 





Figure 5.11 Atherosclerotic plaque progression with age 
Flow diagram demonstrating progression of atherosclerosis with age215. From types I-IV, lipid 
accumulation is the main reason for plaque growth, facilitated by inflammatory insults to the 
endothelium, migration of monocytes into the intima, and transformation of those monocytes into 
macrophages. These macrophages then engulf lipid and form foam cells, eventually aggregating into 
fatty streaks and lipid pools. In more advanced lesions (types V and VI), incomplete clearance of 
apoptotic foam cells and migration of vascular smooth muscle cells into the intima forms necrotic cores 
with overlying fibrotic caps. Rupture or erosion of the cap can lead to thrombus and subsequent acute 
coronary syndrome, or healing with deposition of calcium within the plaque216. 
 
When the results were analysed by sex, they supported previous studies that 
suggested that the sex differences in plaque composition in younger age groups 
disappear in later life, but the plaque burden differential (men>women) persists. Men 
and women were evenly matched from the point of view of cardiovascular risk factors 
and GRACE risk score (Table 4.6), in contrast to previous studies that have 
demonstrated a worse cardiovascular risk profile in younger women217. It has been 
proposed that oestrogen has a cardio-protective effect in pre-menopausal women, 
stabilising and thickening the fibrous cap of coronary plaques218 and potentially 
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interrupting the plaque rupture/healing loop. A sub-analysis of the PROSPECT data 
demonstrated that younger women had more fibrous tissue on VH IVUS (61.1 vs. 
60.0%, p<0.05) and less FF (19.1 vs. 21.6%, p<0.05)174. All the women in this study 
had been post-menopausal for many years and none were taking hormone 
replacement therapy, thus lacked this protective effect. Women in the oldest age 
groups therefore “catch up” with men as they age from the point of view of plaque 
composition and fibrous cap thickness, but not plaque burden. 
 
It is becoming increasingly apparent that biological age, i.e. frailty, is a better predictor 
of adverse outcomes after NSTEACS than chronological age219. Recently published 
results from the full ICON1 study cohort (n=279) demonstrate that frailty is associated 
with increased adverse outcomes at 1 year, driven by all-cause mortality, MI and repeat 
hospitalisation220. Although there were no differences in overall in-hospital or 30-day 
outcomes, frailty was associated with higher arterial complications following 
angiography ± PCI (robust: 0, pre-frail: 1.3%, frail: 5.2%, p=0.049)220, concordant with 
the data presented here, demonstrating a higher rate of femoral access in frail patients 
(robust: 4.0%, pre-frail: 2.0%, frail: 26.7%, p=0.006). This may help to explain the 
higher rate of major bleeding post-ACS in frail patients in previous studies18, 221 and 
would certainly increase the time-to-ambulation post-procedure, increasing the risk of 
adverse events. Yet again, this illustrates the treatment paradox for frail patients 
whereby the patients at highest risk of complications are undergoing angiography/PCI 
via the riskiest route. It is a clear indication that, if an invasive strategy is followed in 
frail patients, radial access must be treated as a priority. 
 
Frailty (but not age alone) was also associated with increasing intimal calcification on 
VH IVUS imaging. This is the first study to show this association in patients with 
symptomatic cardiovascular disease and has wide ranging implications for both 
invasive treatment strategies in individual patients, and future research into vascular 
calcification, as previous studies demonstrating an increase in coronary calcium with 
age174 have failed to take frailty into account. Two previous studies have utilised CT 
calcium scoring to explore if there is an association between frailty and vascular 
calcification. The first recruited 42 institutionalised patients and classified them by Fried 
frailty status, excluding pre-frail patients222. They demonstrated no differences 
between robust and frail patients in coronary artery calcium score. However, this was 
a small study in asymptomatic patients, and CT calcium score measurement does not 
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discriminate between intimal or adventitial calcification. Indeed, the angiographic 
results presented here did not show any difference in calcification between frailty 
groups, suggesting that it is only intimal calcification that is associated with frailty. The 
second, larger study utilising CT calcium scoring recruited 374 asymptomatic men and 
again classified them according to Fried frailty status, but combined the robust and 
pre-frail groups223. They demonstrated that frail patients had a 53% increased 
prevalence of coronary artery calcification, which remained significant even after 
adjustment for traditional cardiovascular risk factors (prevalence ratio 1.27, 95% CI 
1.02-1.59, p<0.05)223. As these patients were asymptomatic, it may suggest that there 
is something about the frailty phenotype that is independently involved in causing 
coronary calcification, rather than the other way around. 
 
It seems intuitive that an increasing burden of coronary artery disease causes frailty. 
However, neither the angiographic nor the VH IVUS results presented here have 
shown that plaque burden or disease extent increases with frailty. Thus, the 
association of coronary calcification with frailty is not necessarily due solely to 
increasing burden of disease. There are several other plausible explanations. Firstly, 
coronary calcification may be a marker of subclinical vascular disease elsewhere in 
the body, thus decreasing overall physiological reserve without necessarily having 
overt clinical events (e.g. stroke, intermittent claudication). Idoate et al demonstrated 
greater femoral artery calcification in frail vs. robust nonagenarians, which was 
associated with lower bone mineral density and leg muscle mass and could, in turn, 
be associated with sarcopenia224. Secondly, plaque rupture and healing is known to 
be a process associated with inflammation225 and a state of chronic inflammation could 
lead to a systemic catabolic phenomenon leading to frailty. Our data did not show an 
association between frailty or calcification and hsCRP, but other inflammatory markers 
such as interleukin-6, myeloperoxidase and lipoprotein-associated phospholipase A2 
are worthy of investigation in future studies226, 227. Thirdly, frailty and coronary 
calcification may be mediated by a confounding factor such as vitamin D.  
 
In practical terms, coronary calcification matters when planning PCI. It often requires 
specialised kit and advanced techniques such as high maximum inflation pressures, 
cutting and scoring balloons, laser, rotational atherectomy and, more recently, 
intravascular lithotripsy, not all of which are available at all centres by all operators228. 
Knowing the frailty status of a patient would go some way to stratifying their risk of 
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coronary calcification prior to the procedure, allowing scheduling of the individual 
patient on an appropriate procedure list. Angiographic results presented here 
demonstrated that moderately calcified lesions had the highest residual %diameter 
stenosis post-PCI, leaving them at risk of adverse outcomes such as MI and repeat 
revascularisation, so adequate lesion preparation is paramount229. 
 
Although age and male sex were associated with increased atherosclerotic plaque 
burden on multi-modality imaging it is frailty, not age alone, that predicts coronary 
arterial calcification and poor outcomes following PCI for NSTEACS. 
 
5.4.2 Vulnerable Plaque In The Older Patient With ACS 
Due to the high-risk nature of the patient cohort examined in this ICON1 sub-study, 
there was a high prevalence of vulnerable plaque sub-types identified on intracoronary 
imaging. On VH IVUS, 45.4% of vessels imaged had a VH-TCFA present (more than 
double the prevalence of 21.6% in the PROSPECT study69) and, on OCT, 26.9% of 
vessels imaged had an OCT-TCFA present. However, there was significant 
discordance between imaging modalities in the identification of TCFA, both when using 
the standard definition of VH-TCFA53 or when measuring the overall burden of VH 
IVUS frames with VH-TCFA present. 
 
Several studies have shown a poor correlation between OCT-TCFA and VH-TCFA83, 
86, 87. As discussed previously, VH IVUS lacks the resolution to accurately identify the 
thin fibrous cap, and OCT lacks the penetration to accurately measure deep lipid pools. 
Increasing calcium (a particular issue in this cohort) may lead to false positives, as it is 
associated with increasing necrotic core, a key component in the decision tree for 
lesion classification. Microcalcifications can also lead to false positives on OCT83. 
Combining OCT and VH IVUS imaging is one method of improving diagnostic accuracy 
ex vivo87 but there are no commercially available in vivo catheters capable of this at 
present230. Although there was no correlation between burden of VH-TCFA and OCT-
TCFA, there was a non-significant trend towards higher LAPS in the presence of OCT-
TCFA (p=0.079). Refining this type of VH IVUS score may circumvent the need for 
combined imaging catheters. 
 
We found no association between the presence of TCFA on either imaging modality 
with markers of inflammation such as hsCRP. In previous studies, there has been 
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discord as to whether inflammatory markers such as hsCRP, interleukin-6 or pentraxin 
3 are associated with TCFA on VH IVUS or OCT115, 231-233. However, our results have 
shown that vulnerable plaque features identified on OCT did seem to be co-localised: 
OCT-TCFA, plaque rupture, thrombus, microchannels and ChC were all significantly 
correlated with each other, even in non-culprit arteries. This higher pancoronary 
vulnerability in patients with ACS has been reported in several previous 
studies124,234,140, suggesting that ACS is a syndrome of multi-focal instability throughout 
the coronary tree. Although one particular lesion is the culprit for an ACS event, the 
factors that have led to that lesion rupturing at that time are also responsible for the 
destabilisation of non-culprit lesions and subsequent progression of coronary 
atheroma.  
 
Specifically, we have demonstrated a strong association between microchannels and 
atheroma burden, and platelet count was the only factor independently associated with 
presence of microchannels. This is consistent with previous studies showing a higher 
prevalence in lesions of greater angiographic severity211 and an association with rapid 
angiographic progression of previously non-significant lesions, possibly by promoting 
inflammation and plaque haemorrahge/rupture135. 
 
Older patients with NSTEACS have a high prevalence of previously identified 
vulnerable plaque characteristics, and they may prove to be a valuable resource in 
future studies into potential plaque stabilisation therapies. However, the complexity of 
coronary disease in this population has exposed the limitations of current definitions of 
vulnerable plaque, in particular TCFA identification on VH IVUS, and further work is 







CHAPTER 6: RESULTS – Multi-Modality 




One of the striking features of the analysis of the pattern of plaque burden in older 
patients with ACS was the high burden of coronary calcification. This group of patients 
is therefore ideal to investigate the hypothesis that calcium plays an important role in 
the response to atheroma deposition in these patients. 
 
6.1 Angiographic Calcification 
 
In the univariate analysis of baseline patient characteristics, angiographic lesion 
calcification was correlated (p<0.25) with sex, frailty, NSTEMI, GRACE score, smoking 
status, family history of IHD, renal impairment, previous angina, CCF, and glucose 
level. These variables were entered into an ordinal logistic regression analysis and 
history of angina and being a current smoker (vs. never smoked) were demonstrated 





Standard error P value 
Odds ratio 
(95% CI) 
No history of angina -1.433 0.463 0.002 0.239 (0.096, 0.591) 
Non smoker -1.291 0.555 0.020 0.275 (0.093, 0.817) 
Table 6.1 Multiple regression analysis for angiographic calcification 
 
Figure 6.1 demonstrates the association between angiographic lesion calcification and 
QCA measurements. Actual MLD increases at a greater rate (p<0.001) than the 
derived RD (p=0.003), so %stenosis initially decreases. However, this reaches a limit 
when calcification is severe so % stenosis starts to increase again (p=0.003). These 
results are similar to those demonstrated by Genereux et al in the pooled analysis of 
two major ACS trials: pre-PCI RD increased as calcification of the target lesion 
increased. They demonstrated that % diameter stenosis was similar between the 






Figure 6.1 Pre-PCI QCA measurements by lesion calcification 
There is a non-linear relationship between lesion calcification and severity of % stenosis. This is likely 
to be mediated by positive remodeling in the early stages of calcification. 
 
The procedure success was similar between calcification groups (no calcification: 
93.2%, mild: 91.7%, moderate: 82.4%, severe: 89.5%, p=0.624), but there was a 
significant difference in residual % diameter stenosis post-PCI (no calcification: 14.2%, 
mild: 17.0%, moderate: 23.1%, severe: 19.0%, p=0.014). This may suggest that 
moderately calcified lesions are stiffer and more resistant to stretching by PCI, or that 
heavily calcified lesions were more likely to be prepared better pre-stent e.g. by 
rotablation/laser/repeated balloon angioplasty. 
 
6.2 VH IVUS Dense Calcium 
 
Previous studies with VH IVUS have expressed concerns regarding the accuracy of 
measurement of NC in the presence of heavy calcification. Figure 6.3 demonstrates 
that %DC was strongly correlated with %NC (r=0.725, p<0.001). This association was 
also present when correlating angiographic calcification and %NC (p=0.004). This 
illustrates a major limitation of VH IVUS in accurately assessing heavily calcified 
arteries, as large areas of calcified plaque are a barrier to IVUS assessment of deeper 








































Figure 6.2 Association of %NC with %DC 
There was a strong linear association of DC and NC on VH IVUS, leading to overestimation of %NC in 
the presence of high calcification. 
 
In the univariate analysis of baseline patient characteristics, %DC was correlated 
(p<0.25) with frailty, GRACE score, family history of IHD, previous MI, atrial fibrillation, 
cerebrovascular disease, white cell count and vitamin D level. These variables were 
entered into a multiple linear regression analysis and increasing GRACE score, 
presence of atrial fibrillation, previous MI, and increasing vitamin D level were 
demonstrated to be independent predictors of higher %DC. Table 6.2 shows the output 








GRACE Score 0.113 0.037 0.003 
Atrial fibrillation 4.417 1.649 0.008 
Previous MI 5.494 1.547 0.001 
Vitamin D 0.088 0.025 <0.001 
Intercept -7.037 4.966 0.159 
Table 6.2 Multiple regression analysis for %DC 
 
When analysed by vitamin D category, there was a clear association between 



















This association between increasing vitamin D and calcification held true even when 














Figure 6.3 Proportion of plaque components by vitamin D status 
Increasing vitamin D was associated with a decreasing proportion of fibrous tissue and an increasing 
proportion of NC and DC. Deficient n=25, insufficient n=38, sufficient n=28. 
 
The imaged vessels were then split into 3 equal tertiles by %DC: low (<9.4%), 
intermediate (9.4-16.7%) and high (>16.7%) calcification. Table 6.3 demonstrates that 
%DC was significantly associated with maximum stenosis, PAV and %VH-TCFA 
frames on IVUS, suggesting that calcification increases with overall burden, severity 
and complexity of atherosclerotic plaque. %DC on VH IVUS correlated well with 
angiographic calcification, although a proportion of vessels had significant amounts of 
calcium on VH IVUS but very little visible angiographically.  
 
There were 7 vessels that required complex PCI techniques (rotablation or laser 
atherectomy) in this cohort. All were vessels in the high %DC tertile (mean %DC in 








 Low %DC Intermediate %DC High %DC P value 
Angiography 
Vessel: 
 LAD, n (%) 
 Cx, n (%) 














Culprit, n (%) 23 (39.7) 25 (43.1) 24 (41.4) 0.981 
Calcification: 
 None, n (%) 
 Mild, n (%) 
 Moderate, n (%) 


















 Type A, n (%) 
 Type B1, n (%) 
 Type B2, n (%) 

















Procedure success, n (%) 23 (85.2) 29 (93.5) 27 (84.4) 0.515 
VH IVUS 
MLA, mm2 (IQR) 4.9 (2.7, 6.9) 5.1 (3.3, 6.4) 4.4 (3.4, 5.9) 0.488 
Maximum stenosis, % (IQR) 66.0 (53.0, 72.9) 67.0 (60.3, 76.1) 71.1 (62.4, 78.4) *0.036 
Remodeling index (IQR) 1.02 (0.93, 1.13) 1.04 (0.99, 1.11) 1.02 (0.95, 1.13) 0.507 
Percent atheroma volume (IQR) 41.7 (31.7, 47.5) 45.7 (36.2, 53.2) 52.3 (41.9, 57.8) *<0.001 
% frames VH-TCFA (IQR) 2.0 (0, 10.0) 5.1 (0.5, 16.2) 9.1 (4.2, 20.4) *<0.001 
OCT 
MLA, mm2 (IQR) 3.3 (1.7, 5.8) 2.8 (1.3, 4.0) 3.2 (2.2, 5.2) 0.526 
Minimum fibrous cap, µm (IQR) 76 (57, 92) 72 (57, 112) 94 (61, 140) 0.339 
% fibroatheroma frames (IQR) 39.7 (27.1, 100) 24.3 (7.5, 65.3) 60.9 (14.7, 100) 0.198 
% fibrocalcific frames (IQR) 45.7 (12.6, 100) 55.9 (38.1, 90) 86.6 (61.5, 100) 0.095 
Rupture, n (%) 3 (30.0) 2 (12.5) 4 (36.4) 0.347 
Macrophage, n (%) 6 (60.0) 7 (41.2) 6 (54.5) 0.706 
Microchannel, n (%) 4 (40.0) 5 (29.4) 7 (63.6) 0.216 
ChC, n (%) 1 (10.0) 8 (47.1) 2 (18.2) 0.113 
OCT-TCFA, n (%) 3 (30.0) 6 (37.5) 1 (9.1) 0.294 
Table 6.3 Association of %DC with other vessel characteristics 
 
The results from the angiographic sub-study suggested that there may be an 
association between calcification and vessel remodeling. Although there was no 
association of whole vessel %DC with RI, deeper analysis of the site of MLA in vessels 
with a stenosis ≥50% revealed a non-linear positive association between DC area and 





Figure 6.4 Association of DC area at MLA with remodeling index 
Increasing DC area at the site of the MLA is associated with increasing RI in vessels with a maximum 
stenosis ≥50. The data was best fit by a quadratic curve, with severely calcified MLA sites more limited 

























6.3.1 Predictors Of Coronary Calcification 
The older population studied in ICON1 has given us a unique opportunity to investigate 
the pathophysiology of coronary artery calcification. Although calcification measured 
on angiography and VH IVUS were broadly associated with each other, they differed 
in terms of patient-level predictive factors and this may be due to the fact that 
angiographic calcification is a subjective “eyeball” assessment whereas the VH IVUS 
algorithm is arguably a more objective measurement. 
 
In terms of patient-level factors, previous angina or MI was a predictor of both 
angiographic and VH IVUS calcification, concurring with the pooled analysis of 2 large 
ACS studies, which demonstrated that previous IHD was associated with angiographic 
calcification (p=0.005)28. This lends further weight to the theory that calcification 
accumulates following coronary events due to plaque rupture and healing. There were 
no consistent cardiovascular risk factors that predicted coronary calcification, 
contradicting a large meta-analysis of >12,000 symptomatic patients (although not 
necessarily patients with ACS) that demonstrated that hypertension (OR 1.71, 
p<0.001) and diabetes (OR 1.34, p=0.03), but not smoking (OR 1.42, p=0.13) predicted 
the presence and extent of coronary calcification235. However, it may be that age and/or 
frailty attenuates these relationships such that they were not apparent in our smaller 
cohort size. 
 
Interestingly, vitamin D level independently predicted calcification on VH IVUS in this 
study. Zitterman et al proposed a biphasic dose-response curve between vascular 
calcification and vitamin D, with both low and high levels associated with adverse 
effects (Figure 6.5)236. Physiological levels of vitamin D may inhibit calcification 
through modulating inflammatory cytokines, with vitamin D deficiency leading to pro-
inflammatory activity that subsequently drives calcification, and hyper-vitaminosis D 
leading to increased free calcium and phosphate levels and vascular mineralisation. In 
contrast to this theory, the results presented here demonstrated a linear positive 
relationship between vitamin D and coronary calcification, although the majority of the 
patients were deficient/insufficient in vitamin D (69.2%), only 4 were supra-therapeutic 
















Figure 6.5 Biphasic dose response curve for adverse effects of vitamin D 
Low vitamin D promotes arterial stiffness and calcification by increasing pro-inflammatory cytokines and 
metalloproteinases, whilst supra-therapeutic vitamin D has a direct effect on vascular calcification 
through hyperphosphataemia and hypercalcaemia. There may be an optimum level of vitamin D which 
has yet to be fully established. 
 
A recent systematic review of 10 studies found insufficient evidence to support an 
association between vitamin D level and the presence or severity of coronary artery 
calcification on CT237. Since then, two prospective studies have shown no association 
between vitamin D and CT coronary calcification238, 239, one study showed an inverse 
association in men only240, and two showed an inverse association in the whole 
cohort241, 242. However, these studies are all limited by the fact that they are small and 
often conducted in asymptomatic individuals, so the results may not be applicable to a 
“real-world” population. In addition, they have all utilised CT calcium scoring rather than 
invasive imaging. One study has evaluated coronary artery calcification on grayscale 
and VH IVUS and fibroblast growth factor 23, a regulator of vitamin D metabolism; it 
was associated with a non-significant increase in volume of DC on VH IVUS (p=0.063), 
but the %DC was not reported and the study excluded patients with ACS243. 
 
It has been postulated that vitamin D metabolism could be the mechanism linking frailty 
and coronary calcification. However, there was no difference in baseline vitamin D 
between frailty groups, which contradicts a large meta-analysis of >17,000 patients 
that demonstrated a significant association between vitamin D and frailty (pooled 
OR = 1.25, 95% CI = 1.14–1.37)244. The 7 studies analysed all utilised different 















































longitudinal study has demonstrated that cardiometabolic disease in older women 
attenuates the association between vitamin D and frailty245.  
 
The results presented here have demonstrated that the effects of previously 
demonstrated patient-related risk factors for coronary calcification may be attenuated 
in older patients, with calcification in this cohort more strongly associated with previous 
coronary events. The association between vitamin D metabolism and vascular 
calcification, if there is one, is complex and requires further investigation with large 
scale prospective clinical trials before widespread supplementation is advised for 
patients. 
 
6.3.2 The Vascular Effects Of Coronary Calcification 
By utilising multi-modality intracoronary imaging, it has been possible to investigate the 
effects of increasing calcification on the coronary vasculature. In this study, 
calcification was positively associated with plaque burden, vessel remodeling and VH-
TCFA, consistent with A VH IVUS sub-study of a large registry of “all-comer” PCI 
patients demonstrating that %DC was positively associated with plaque burden and 
VH-TCFA246. A study utilising serial grayscale IVUS also demonstrated that coronary 
artery calcification was associated with increasing total atheroma burden, and that 
patients with more calcification were less likely to have a reduction in atheroma burden 
in response to medical therapies targeting cardiovascular risk factors247. This supports 
the conventional theory that atheromatous plaques calcify in response to a chronic 
rupture and healing process, and that this is the end-stage of plaque evolution. 
 
On angiography, moderate calcification was associated with the lowest degree of 
stenosis pre-PCI, and analysis of the VH IVUS data demonstrated that calcification at 
the site of MLA increased the RI in a non-linear fashion. As plaque burden increased 
linearly with calcification, the lesion diameter stenosis initially decreased as the vessel 
remodeled quicker than plaque accumulated, then increased as the positive vessel 
remodeling slowed and the plaque continued to accumulate. Although the best-fit curve 
for the association of DC and RI was a quadratic curve, suggesting that very severe 
calcification leads to negative remodeling of the vessel at some point, the 
measurement of RI in the presence of large amounts of calcification may be inaccurate 
due to difficulty in determining the border of the vessel EEM in the acoustic shadow of 
the calcium (Figure 6.6). The QCA-measured RD also increased with increasing 
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calcification, but it should be remembered that RD is not a direct measure of arterial 
dimensions but is a computer estimate of the vessel diameter at the maximum stenosis 
site derived by an iterative linear regression technique, and therefore cannot be utilised 











Figure 6.6 Acoustic shadow of calcium obscures the EEM border 
In the presence of severe calcification, precise tracing of the EEM border of the vessel in the acoustic 
shadow of the calcium is often problematic and could lead to inaccuracies in the derivation of the RI. 
Panel A demonstrates a heavily calcified eccentric plaque (red arrow) with the acoustic shadow 
obscuring the EEM border (yellow arrow). Panel B demonstrates extrapolation of the circumference of 
the EEM (green line) as the cross section of the artery is roughly ovoid. 
 
These findings are consistent with the few previous studies looking at coronary 
calcification and vessel remodeling. In a small study (n=15) of minimally calcified 
lesions, calcification was associated with plaque shrinkage and luminal enlargement 
during a 5 year follow up249. In an analysis of 138 patients with ACS (NSTEACS and 
STEMI), calcification on serial OCT and IVUS (baseline and 12 months) was 
associated with a reduction in the expansive remodeling capacity250. Glagov et al 
postulated that coronary arteries enlarge as atheromatous plaque develops as a 
mechanism to preserve lumen cross-sectional area in a study of 136 histological 
specimens of the LMS artery251. Our data has demonstrated that, as calcium 
accumulates and the artery becomes stiffer, its capacity to positively remodel 
decreases, EEM enlargement slows and the severity of stenosis increases. 
 
In addition, previous research has demonstrated that arteries with positive remodeling 
are more likely to harbour adverse plaque characteristics such as plaque rupture and 




necrotic core254, 255, and thinning of the fibrous cap of the plaque on OCT253, 256. A 
positive RI was also shown to be predictive of troponin positive ACS culprit lesions in 
a study of VH IVUS in 70 patients257. Deposition of significant amounts of calcium may 
help to stabilise these plaques despite increasing the overall plaque burden, potentially 
reducing the risk of adverse cardiovascular events.  
 
It has been proposed that plaque vulnerability and risk of plaque rupture is modulated 
by accumulation of calcium in the vessel. A sub-analysis of VH IVUS data from the 
VIVA study in lesions with plaque burden ≥40%, plaque structural stress (PSS) was 
calculated using 3D reconstructions258. PSS increased with increasing calcification 
until it plateaued or even reduced with severe calcification258. It is postulated that PSS 
is highest at sites of interface between plaque components with different levels of 
stiffness i.e. calcified and non-calcified plaque259. As spotty calcium is deposited, the 
number of interfaces initially increases, increasing the PSS, but coalescence of areas 
of calcium in the latter stages of plaque formation leads to a decrease in the interface 














Figure 6.7 Relationship between calcium surface area and total mass  
In the early stages of calcification, discrete depositions of calcium have an increasing surface area and 
therefore an increasingly adverse effect on plaque structural stress. As the calcium deposits coalesce, 
the surface/interface area decreases with a corresponding decrease in the propensity for the plaque to 
rupture. Adapted from Abedin et al259 
 
Murray et al delved further into this relationship by looking for “blueprints” associated 
with plaque vulnerability and spotty calcification. They calculated a “calcified interface 
area” (CIA = 
𝑁𝐶+𝐷𝐶
𝐷𝐶
 ) as a mathematical surrogate for the interface between DC and 


















NC, and demonstrated that ACS culprit lesions had a higher CIA at the MLA site than 
stable plaques (5.38 ± 2.72 vs. 3.58 ± 2.26, p=0.001)257. There was a trend towards a 
positive correlation between CIA and remodelling index (p=0.07) but only in stable 
plaques257. However, we have demonstrated a strong linear relationship between DC 
and NC that is, in part, artefactual due to acoustic shadowing behind heavy 
calcification. In the presence of significant calcium, relying on ratios of plaque 
components to identify spotty calcification is therefore too simplistic. Joshi et al defined 
microcalcifications on VH IVUS as “spotty calcification in the absence of acoustic 
shadowing on 3 consecutive frames” and demonstrated that they were associated with 
high risk plaques in patients with stable angina (73 vs. 21%, p=0.002). A consistent 
definition of “spotty calcification” is required if future studies are to unpick the 
relationship between the deposition of calcium and the vulnerability of the plaque to 
rupture and cause adverse events.  
 
In addition to modulating lesion vulnerability, the pattern of plaque calcification has also 
been shown to influence the haemodynamic significance of the lesion. In a grayscale 
IVUS study of 70 coronary lesions in patients with stable angina and ACS, FFR was 
negatively correlated with the maximal thickness of calcification and calcification 
angle260. In addition, superficial calcification was associated with negative remodeling 
but deep calcification was associated with positive remodeling260. The relationship 
between the severity of coronary artery stenosis (measured by QCA) and 
haemodynamic significance (measured by FFR) is also influenced by the degree of 
coronary calcification, with no association between degree of stenosis and FFR in 
patients with heavy calcification261. It is clear that, not only is the amount of calcification 
important in predicting the haemodynamic significance of a lesion, but the geometry 
and location of the calcium plays an additional role, possibly by affecting arterial wall 
compliance.  
 
Although analysis of this patient cohort has yielded significant results, caution must be 
used when interpreting VH IVUS measurements in the presence of high calcification. 
In particular, the potential for the misclassification of NC could be a factor in the 
association of %DC with VH-TCFA seen here, and therefore the over-reporting of VH-
TCFA overall. A study utilising both NIRS and VH IVUS to characterise plaques 
demonstrated no correlation between %NC and lipid index by NIRS in calcified plaques 
(as NIRS assesses the chemical composition of plaque, measurement of lipid index is 
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not affected by calcification)91. Sales et al demonstrated that, when stent struts were 
used to simulate calcium, there was a linear increase in measured NC on VH IVUS262. 
This linear relationship suggests that it may be possible to mathematically correct for 
this overestimation. Masking algorithms have also been shown to improve the 
accuracy of VH IVUS classification behind calcified plaques94. 
 
These results demonstrate that the progressive deposition of calcium within coronary 
plaque results in dynamic positive remodeling of the vessel, initially preserving or even 
increasing the lumen size before increasing plaque burden subsequently encroaches 
on the lumen. Lesions with a moderate amount of calcium may be at highest risk of 
rupture and subsequent adverse events, as they have a high interface area between 













The primary aim of the ICON1 study was to describe the patient-level predictors of 
adverse outcomes at one year following NSTEACS in older patients. This thesis 
focusses on investigating the coronary plaque phenotypes associated with adverse 
outcomes in this patient group. 
 
7.1 Major Adverse Cardiovascular Events 
 
In total, there were 19 MACE in 17 patients: 3 deaths, 5 ACS, 2 unplanned 
revascularisations (both had already re-presented with ACS: one received PCI to an 
acute stent thrombosis in culprit vessel, and one had a CABG for severe ISR in culprit 
and non-culprit vessels), 1 stroke and 8 bleeding events. All bar one of the bleeding 
events were BARC grade 2 (the other was grade 3). Median follow up time was 364 
days (IQR 355 to 369 days) and there were no patients lost to follow up. Only 2 MACE 
occurred in the OCT sub-group therefore the association of adverse outcomes with 
plaque characteristics on OCT is not reported here due to lack of statistical power. 
 
Figure 7.1 details the Kaplan-Meier curves for the association of MACE at 1 year with 
age (Figure 7.1A), sex (Figure 7.1B) and frailty (Figure 7.1C). There were no 









Figure 7.1 Kaplan-Meier curves of MACE by patient-level factors 
 
Figure 7.2 displays the Kaplan-Meier curves for the association of MACE with 
angiographic and VH IVUS findings. There were no differences in adverse outcomes 
at one year between groups when classified by baseline SYNTAX score (Figure 7.2A), 
SYNTAX Revascularisation Index >70% (Figure 7.2B), overall %NC (Figure 7.2C), 
presence of VH-TCFA in a non-culprit vessel (Figure 7.2E), or presence of a high 
LAPS in a non-culprit vessel (Figure 7.2F). However, the intermediate %DC group was 










A) MACE event rate by age B) MACE event rate by sex 
























Figure 7.2 Kaplan-Meier curves of MACE by vessel-level factors 
Log rank 
*p=0.044 
D) MACE event rate by overall % DC tertile 
Log rank 
p=0.780 
A) MACE event rate by SYNTAX Score 
Log rank 
p=0.736 













Table 7.1 summarises the clinical outcomes at 1 year when stratified by %DC and 
demonstrates that the increase in adverse outcomes in the intermediate calcification 









Composite MACE, n (%) 2 (9.5) 12 (31.6) 3 (12.0) *0.044 
All-cause mortality, n (%) 0 2 (5.3) 1 (4.0) 0.523 
ACS, n (%) 0 5 (13.2) 0 *0.043 
Stroke, n (%) 0 1 (2.6) 0 0.477 
Bleeding, n (%) 2 (9.5) 4 (10.5) 2 (8.0) 0.879 
Unplanned revascularisation, n (%) 0 2 (5.3) 0 0.269 
Table 7.1 Clinical outcomes at 1 year by overall proportion of dense calcium 
 
Results from the PROSPECT, VIVA and ATHEROREMO-IVUS studies consistently 
demonstrated that the combination of MLA ≤4mm2 + plaque burden ≥70% + presence 
of VH-TCFA was associated with adverse outcomes69-71. However, when combining 
these variables in this cohort (Figure 7.3), there were no differences in outcomes at 1 
year. This persisted even when only taking into account non-culprit lesions (log rank 
p=0.473), or non-culprit lesions that were not intervened on (log rank p=0.101), 
although there were only 4 non-culprit lesions (4.8%) that had this combination of 
plaque characteristics and did not undergo PCI (similar to the prevalence in 





























Figure 7.3 MACE event rate for all lesions with MLA ≤4mm2 + plaque burden 




There was a consistently low adverse event rate at one year in older patients 
undergoing PCI for NSTEACS. The lack of difference in MACE between patient-level 
factors such as age, sex and frailty (factors that have previously been shown to be 
associated with poorer prognosis post NSTEACS14, 21, 202) is likely to be due to patient 
selection bias in this small, and largely homogenous, cohort. Indeed, results from the 
full ICON1 patient cohort (both invasive and non-invasive sub-studies, n=279) 
demonstrated that increasing frailty was associated with MACE and greater unplanned 
hospitalisations at 1 year (although not in-hospital or at 30 days)220.  
 
Utilising angiography and radiofrequency intravascular ultrasonographic imaging, we 
have also shown that previously identified lesion-related risk factors such as SYNTAX 
score, SYNTAX revascularisation index, lipid burden and VH-TCFA are not associated 
with MACE at one year in this cohort. Moreover, a previously validated scoring system 
designed to identify “active” plaque, LAPS64, was also not associated with adverse 
outcomes. However, moderate total vessel %DC was associated with higher MACE 





intermediate lesions that are highest risk. The event rate in this group was primarily 
driven by an excess of rehospitalisation for ACS. 
 
There could be multiple mechanisms by which moderate calcification is associated with 
adverse events. Firstly, although procedural success was similar between VH IVUS 
calcification tertiles (Table 6.3), the angiographic sub-study results demonstrated that 
moderately calcified lesions had a higher residual % diameter stenosis post-PCI than 
none/mildly and severely calcified lesions. Thus moderate/intermediate calcified 
lesions may not be prepared adequately prior to stenting (perhaps due to the perceived 
risks of using complex interventions such as rotablation/laser in an older patient 
cohort), and therefore may be at higher risk of restenosis and subsequent coronary 
events. Indeed, in a large analysis of outcomes stratified by angiographic calcification, 
moderate calcification was significantly associated with definite stent thrombosis at 1 
year (no/mild calcification: 1.7% vs. moderate: 2.9% vs. severe: 1.9%, p=0.01)28. As 
well as stent under-expansion, residual calcification following preparation of the lesion 
can be associated with structural damage during stent delivery, with stripping of the 
polymer from the drug eluting stent263. 
 
Secondly, the relationship between moderate calcification and high PSS has already 
been discussed here, and our results support the theory that high levels of calcification 
in the coronary tree could stabilise lesions and lower the risk of adverse events. Thirdly, 
a large retrospective study of patients with ACS demonstrated the association of 
coronary calcification and increased risk of major bleeding after PCI264. As well as 
calcification of the coronary arteries, it is expected that other peripheral arteries such 
as the femoral and radial arteries also undergo the same calcification, thus increasing 
the risk of bleeding from the access site265. In addition, the need for advanced PCI 
techniques such as rotablation in highly calcified lesion, and thus potentially more 
potent anti-thrombotic and anti-platelet regimens, further increases the risk of bleeding.  
 
The results presented here contrast previous prospective studies utilising VH IVUS to 
predict adverse outcomes in patients with ACS, which demonstrated that the 
combination of small lumen area, large plaque burden and the presence of VH-TCFA 
was associated with adverse events at one year69-71. However, there were only 4 
(4.8%) lesions with this combination in non-culprit arteries that did not receive PCI 
during the index admission. This may suggest that a policy of full revascularisation at 
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the time of PCI after NSTEACS negates the adverse effect of these previously 
identified vulnerable lesions, although a large RCT would be needed to test this 
hypothesis. Moreover, the pitfalls of TCFA identification on VH IVUS in a population 
with complex coronary disease have been discussed here previously and this lesion 
phenotype is simply not an accurate predictor of adverse outcomes in the real world. 
 
In an older, real-world population with NSTEACS, it is moderate calcification that was 
associated with the highest risk of adverse outcomes at one year, rather than 












8.1 Final Summary 
 
The results presented in this thesis demonstrate for the first time that recruitment of 
older patients to a study of invasive coronary imaging is safe, feasible, and has a high 
yield of advanced plaque phenotypes to study the pathophysiology of coronary disease 
following NSTEACS. We performed a comprehensive assessment of the pattern and 
burden of coronary plaque in this cohort, and identified that moderate coronary 
calcification is associated with adverse outcomes. 
 
8.1.1 Engaging Older Patients In Invasive Cardiovascular Research Is A 
Positive Experience  
The recruitment rate reported in this study was high and compared favourably to 
previous observational studies in community populations in this age group36. Overall, 
69.8% of patients consented after being approached and 33.2% of those were suitable 
for invasive imaging. 80.6% of anatomically suitable vessels were successfully imaged 
with VH IVUS and 74.7% with OCT. There was only one adverse event attributable to 
intracoronary imaging, concordant with the safety profile reported previously194, 195.  
 
Three-vessel intracoronary imaging in an older cohort does present challenges to the 
researcher due to issues in delivering the catheters through tortuous and calcified 
arteries, and the total length of coronary artery imaged here was lower than in previous 
3-vessel intracoronary imaging studies (e.g. 105.2mm on VH IVUS vs. 165.9mm in the 
older cohort in PROSPECT174). However, the majority of proximal arteries were 
imaged and the results presented focus on overall burden of plaque phenotypes rather 
than presence or absence of one lesion sub-type. The population studied were a “real-
world” population that are encountered every day in the coronary catheter laboratory, 
and exclusion co-morbidities were minimised to accurately reflect this. 
 
This body of work endeavoured to adhere to the PREDICT charter for research in older 
patients, paving the way for more individualised clinical decision-making in this cohort. 
Older age should not preclude enrolment in future studies of coronary pathophysiology 
and, indeed, should be encouraged as this population is enthusiastic about 
participating in research and have a lot to offer in terms of progressing the 
understanding of advanced coronary atherosclerosis. 
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8.1.2 Increasing Burden Of Atheroma Is Associated With Age And Male Sex, But 
Frailty Is Associated With Changes In Plaque Composition 
With increasing age, the angiographic severity and complexity of coronary disease did 
not change, but older patients were more likely to undergo multi-vessel PCI (<79 years: 
10% vs. 79-82 years: 39.4% vs. >82 years: 39.3%, p=0.016). Overall PAV on IVUS 
increased with age (42.7 ± 11.4% vs. 43.4 ± 10.9% vs. 50.0 ± 8.9%, p<0.001) and 
there was an increasing burden of advanced lesion phenotypes such as VH-TCFA 
(5.7% vs. 9.3% vs. 14.1% p<0.001). Men had a higher burden of coronary disease 
than women when measured by number of lesions (3 [2,3] vs. 2 [1,3], p=0.045), 
SYNTAX score (13 [9,23] vs. 9 [5,17], p=0.037), and PAV (47.6 ± 10.4% vs. 41.7 ± 
10.8%, p<0.001). This would suggest that at no age does the accumulation of coronary 
plaque cease to increase, with women lagging around 10 years behind men in the 
incidence of cardiac events266.  
 
It has been postulated that this consistent deposition of coronary plaque with ageing is 
regulated by a reduction in the repair mechanisms critical in maintaining arterial 
homeostasis in the face of cardiovascular risk factors. In an apolipoprotein-E deficient 
(hyperlipidaemic) mouse model, the capacity of bone marrow-derived progenitor cells 
to repair damaged arteries was reduced with ageing and atheroma deposition began 
with the loss of repair capacity rather than with onset of hyperlipidaemia267, 268. 
Senescent cells may also secrete cytokines, matrix metalloproteinases and other 
inflammatory biomarkers, which propagate the development of atherosclerosis269. 
Genetic factors that occur with ageing such as telomere shortening270 or development 
of clonal haematopoiesis of intermediate potential271 may contribute to the ongoing 
deposition of plaque via their association with inflammation and oxidative stress. 
 
Interestingly, neither age nor sex were associated with a difference in the proportion 
of plaque components, but frail patients had a higher burden of calcified plaque on VH 
IVUS (robust: 13.7%, vs. pre-frail: 13.0% vs. frail: 17.7%, p=0.018). This is the first time 
that this association has been demonstrated on invasive imaging and risk-stratification 
by frailty may therefore aid decision-making prior to PCI. Frailty was not associated 
with an increase in plaque burden or disease severity, suggesting that the association 
of calcification with frailty is not necessarily mediated by increasing burden of disease, 




Adverse features on OCT such as plaque rupture, microchannels, cholesterol crystals 
and TCFA were clustered together in vessels, suggesting that these features develop 
in tandem and may be representative of increased overall coronary vulnerability. 
Indeed, 36.4% of plaque ruptures seen in this study were in non-culprit arteries. A 
recent study utilising NIRS and OCT demonstrated the association of inflammatory 
CD14++CD16+ monocytes, previously shown to be associated with acute MI, with 
fibrous cap thickness, OCT-TCFA and thrombus272. A French study demonstrated that, 
in the immediate aftermath of an acute MI, 10% of patients had evidence of two areas 
of myocardial necrosis (one in a region not attributable to the culprit lesion) on magnetic 
resonance imaging (MRI) and, in 3.8% of patients, this corresponded to a coronary 
vessel with normal flow273. Thus, pancoronary instability in NSTEACS may be related 
to a systemic inflammatory process and contribute to accelerated accumulation of 
coronary atheroma through repeated rupture and healing of plaques.  
 
8.1.3 Moderate Coronary Calcification Is Associated With Positive Remodeling 
And Adverse Outcomes 
The high burden of coronary calcification in our cohort provided an invaluable 
opportunity to investigate the causes and effects of this important plaque component. 
Calcification on angiography and VH IVUS was associated with previous coronary 
events such as angina and previous MI, and with PAV (low %DC: 41.7%, vs. 
intermediate %DC: 45.7%, vs. high %DC: 52.3%, p<0.001), which would suggest that 
calcification accumulates with repeated plaque rupture and healing. Calcification was 
also independently associated with vitamin D in a positive linear fashion (VH 
IVUS %DC: β=0.088, p<0.001), in contrast to previous theories suggesting a biphasic 
association between vascular calcium and vitamin D236.  
 
Increasing calcification was initially associated with a reduction in the %diameter 
stenosis on angiography (p=0.003), likely mediated by a high rate of positive 
remodeling that slowed with severe calcification (R=0.363, p<0.001). Thus, moderate 
levels of calcification at the MLA site were associated with the highest RI. Previous 
studies have demonstrated that these moderate levels of calcium are deposited in a 
“spotty” fashion, increasing the number of interfaces between calcium and soft plaque 
and subsequently increasing shear stress across the lesion258. As well as facilitating 
positive remodeling to preserve lumen area, this turbulent flow may increase the rate 
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of damage to the vessel wall and, with impaired repair mechanisms unable to keep up 
with this, lead to a greater burden of atheroma and high risk plaque. 
 
Consistent with this theory, patients with moderate levels of overall coronary 
calcification had a higher MACE rate at 1 year (low: 9.5% vs. moderate: 31.6% vs. high 
12.0%, p=0.044), driven by an excess of repeat hospitalisation for ACS. This may also 
be partly due to the fact that these moderately calcified lesions had a higher 
residual %diameter stenosis post-PCI (23.1% vs. no calcification: 14.2%, mild 
calcification: 17.0%, severe calcification: 19.0%, p=0.014), a risk factor for restenosis.  
 
In a large registry of histological specimens, there was a clear relationship between 
plaque morphology and radiographic calcification (erosions: predominantly none, 
ruptures: predominantly speckled calcium, healed ruptures: predominantly blocks of 
diffuse calcification)274. However, there are no current consistent definitions of “spotty 
calcification” on in vivo coronary imaging. Utilisation of ratios of NC and DC on VH 
IVUS to derive a calcified interface area257 is limited by the impact of heavy calcification 
on over-measurement of NC. Observation of calcification without acoustic shadow on 
IVUS92 merits further investigation. OCT is probably best placed to identify small 
deposits of calcium within the vessel wall but could still be missed if located behind 
deep lipid pools. Frequency of spotty calcification on OCT (defined as length <4mm 
and arc <90o) was not significantly different in one study of patients with STEMI vs. 
stable angina275 but was higher in ruptured vs. non-ruptured culprit plaques in another 
study of patients with ACS276. To date, there have been no studies investigating spotty 
calcification on OCT with adverse patient outcomes after ACS, with previous research 
focussing on TCFA as the main vulnerable plaque phenotype, and we would argue 
that this is certainly warranted in light of the findings presented here. 
 
8.1.4 Clinical Relevance 
Due to the nature of the real-world population studied in this thesis, the results are 
applicable and very relevant to day-to-day practice in the coronary catheter laboratory. 
There is still a reluctance amongst interventionists to adopt an early invasive strategy 
in older patients with NSTEACS, possibly due to perceived risks or difficulty of the 
procedure in this groups. However, we have demonstrated a high angiographic 
success rate in the whole cohort (90.4%) and a low adverse event rate at 1 year 
(20.9%) confirming previous studies demonstrating that an early invasive strategy in 
141 
 
older patients with NSTEACS is not only safe but also potentially superior to 
conservative therapy22-24. This should serve to reassure operators that this group of 
high-risk patients really do have the most to gain from PCI following NSTEACS.  
 
Frailty is known to be a risk factor for adverse outcomes following NSTEACS and this 
may be related to procedural and anatomical factors identified in this work. Femoral 
access was far more common in frail patients (robust: 4%, vs. pre-frail: 2% vs. frail: 
26.7%, p=0.006) and is a well-recognised determinant of bleeding complications 
following PCI. Increasing frailty was also associated with increasing coronary 
calcification (robust: 13.7% vs. pre-frail: 13.0% vs. frail: 17.7%, p=0.018), another 
factor associated with adverse outcomes264. A simple frailty assessment of older 
patients prior to PCI would allow the operator to risk-stratify and plan in advance for 
the use of complex PCI techniques such as rotablation and laser atherectomy, as well 
as prioritising radial arterial access. Greater use of left radial access following failure 
of right radial puncture may reduce the procedural risk for these vulnerable patients.  
 
The identification of moderate calcification as a predictor of poorer angiographic results 
post-PCI and adverse outcomes at 1 year is of high clinical importance. Whilst vessels 
with severe calcification were more likely to be prepared with advanced PCI techniques 
(all 7 vessels that underwent complex PCI were in the high %DC tertile), moderately 
calcified lesions were not and stents deployed in these lesions may have been less 
well expanded and therefore at risk of stent thrombosis and restenosis. The results 
presented here have demonstrated that the use of IVUS or OCT in this cohort is safe 
and feasible and therefore these technologies could be used pre and/or post-PCI to 
optimise results.  
 
The majority of previous research into vulnerable plaque in ACS has focussed on 
therapies aimed at stabilising TCFA. However, there was discordance between OCT 
and VH IVUS in the identification of TCFA in this study, and they were not associated 
with adverse outcomes at 1 year, suggesting that it may not be clinically useful to 
attempt to identify these in the real world. Moderate spotty calcification may be the true 
vulnerable plaque phenotype in older patients with NSTEACS and future research 





8.2 Strengths and Limitations 
 
The main strength of this study lies in the population recruited. It is the first study of 
invasive coronary imaging to exclusively recruit older patients with ACS and complex 
coronary disease, a group that have been excluded from previous similar studies. 
However, the extent to which the results of this study can be generalised to all older 
people with ACS is limited. The study was an observational cohort study rather than 
an RCT and the strategies employed to yield the high recruitment rate may therefore 
not be applicable to the latter. In addition, the population screened was relatively small, 
from a single geographical area, and the majority of study participants were male 
(63.7%) despite efforts to recruit more women. The prospective patients in ICON1 had 
already been selected by cardiologists at district general hospitals to be fit for referral 
for PCI, and we may therefore have been recruiting from a more robust and motivated 
pool of patients. Furthermore, the median delay of 5 days from index presentation to 
intravascular imaging may have had an impact on plaque composition, lesion 
characteristics, and patient outcome. However, we believe that the cohort studied here 
is representative of older patients receiving contemporary invasive treatment for of 
ACS in the United Kingdom. 
 
Although a number of univariate analyses are presented here, the power calculation 
performed prior to the study commencement was to evaluate the association of TCFA 
with 1 year outcomes only. In addition, the actual adverse event rate of 20.9% is lower 
than the assumed rate of 28% and therefore is underpowered with respect to 
outcomes. The small number of adverse events also precluded multivariate regression 
analysis. Therefore, the results presented here should be viewed as exploratory 
findings only to provide a basis for further research. However, a strength of the 
statistical analysis is the use of a linear mixed-effects model to account for the 
covariance of the data, something that has not always been accounted for in previous 
studies utilising a mix of patient-level, vessel-level and lesion-level measurements. 
 
A further limitation of the invasive imaging protocol was that the VH IVUS and OCT 
pullbacks in each coronary artery were not co-registered therefore may not represent 
the same stretch of artery. This was often due to the practical difficulties in delivering 
both imaging catheters to the same location in the artery, given their different size and 
deliverability. Thus, direct comparison of the VH IVUS and OCT results (e.g. for 
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identification of an individual TCFA) is not feasible and the results presented for each 
technology should be viewed as complementary rather than interchangeable. Even if 
the EEP catheter was successfully delivered through vessels with heavy calcification 
or tortuosity, it was prone to “jumping” or “sticking” within lesions and therefore some 
pullbacks required repeating or removal from the study due to poor quality. 
 
In contrast to the PROSPECT and ATHEROREMO-IVUS studies, intravascular 
imaging in this study was performed in both culprit and non-culprit arteries prior to PCI. 
This has allowed a more complete study to be made of the intracoronary pathology of 
NSTEACS in older patients. Moreover, we have been able to correlate our 
intravascular findings with a comprehensive assessment of angiographic data for each 
patient. However, these analyses were done several days after the index event 
(median time to angiography from event was 5 days) and therefore we cannot say for 
certain that we have captured the true picture of plaque physiology at the time of acute 
coronary event. In addition, we only have data for all-cause mortality and therefore 
cannot comment specifically on cardiac death. 
 
The limitations of VH IVUS and OCT in identifying the plaque components measured 
here are well described. VH IVUS lacks the resolution to identify the thin cap of a 
vulnerable plaque, and OCT lacks the penetration to quantify deep lipid. Confounding 
factors such as thrombus (common in the setting of NSTEACS) can make identification 
of the border of the lumen difficult on both technologies, and the acoustic shadow of 
calcium on VH IVUS can obscure the EEM border. Although the reported intra-
observer variability in plaque component quantification was excellent (with <5% 
variability in fibrous tissue, NC and DC measurements), previous research has 
demonstrated that this may still represent large absolute measurement errors196. In 
addition, these limitations are compounded by the overall heavy burden of calcification 
in the arteries imaged, leading to overestimation of the NC component on VH IVUS 
and subsequent high false positive rate of diagnosis of VH-TCFA. However, the 
accuracy of calcium identification on VH IVUS is the highest of all four plaque 
components44, 49 and therefore, despite all the limitations of the technology, the main 





8.3 Future Directions 
 
Clinical application of intracoronary imaging techniques such as VH IVUS and OCT in 
identifying vulnerable plaque phenotypes at the time of PCI is currently limited by the 
time consuming manual frame-by-frame data interpretation. The current automated 
analysis systems only provide information on the area and percent of each plaque 
component, and only then once the lumen and vessel borders have been manually 
defined (the automated detection of the borders is inaccurate). Papaioannou et al 
devised a novel automated computational system in Java that calculated not only the 
area and percent of each plaque component, but also the number of solid segments 
of each component within the plaque and their relationship to the lumen border (Figure 
8.1)277. Although they did not validate this system against conventional manual 
analysis, and excluded plaques with heavy calcification, it provides hope that 













Figure 8.1 Varying features of a plaque component’s distribution on VH IVUS 
In plaques with the same area and % of a plaque component (e.g. DC or NC), there can be differing 
dispersities and relationships to the lumen border that may be quantifiable on automated analysis277. 
Panel A: Greater dispersity, with the plaque component scattered within the plaque at many discrete 
areas e.g. spotty calcification. 
Panel B: Lesser dispersity, with the component concentrated in a few areas e.g. advanced calcification. 
Panel C: Superficial plaque component, adjoined to the lumen border e.g. VH-TCFA. 
Panel D: Deep plaque component, with none in contact with the lumen border. 
 
This study confirms that moderate calcification is a high-risk plaque phenotype but 





definitions used. A universal definition of this term is urgently called for, whether it is 
an objective automated measurement of the surface area of the calcium or a subjective 
observation of calcification without acoustic shadow. This would then allow correlation 
of this vulnerable plaque phenotype with markers of cellular senescence, inflammation 
or novel genetic regulators such as micro-RNAs, ultimately enabling development of 
prognostic markers or therapeutic targets. For example, proprotein convertase 
substilisin/kexin type 9 (PCSK9), a regulator of low-density lipoprotein receptors, has 
been shown to be associated with increased NC and DC, but not TCFA, independently 
of serum cholesterol level278. The advent of PCSK9 inhibitors opens the door for a 
longitudinal study of coronary calcification, PCSK9 levels and the effect of inhibition. 
 
Non-invasive imaging technologies such as CT and MRI are becoming increasingly 
popular as research tools as they do not carry the same risk as invasive intracoronary 
imaging. When combined with positron-emission tomography, it is possible to 
simultaneously assess both plaque activity and morphology in coronary and carotid 
arteries92, 279, 280. This could prove to be valuable in assessing coronary vulnerability in 
patients currently perceived to be unsuitable for invasive angiography, a group who 
were not included in the current study. 
 
Although our study did not directly compare early invasive to conservative 
management in older high-risk patients with NSTEACS, the results demonstrated that 
this strategy was safe, successful and led to a low rate of MACE in this cohort. The 
British Heart Foundation SENIOR-RITA trial aims to investigate whether invasive or 
conservative management is superior in older patients with NSTEACS, with particular 
focus not only on MACE but on frailty, cognition, quality of life and service utilisation214. 
Future cardiovascular research in older patients should be mindful of including 




This thesis has established that the recruitment of older patients to complex and 
invasive cardiovascular research is feasible, and that this group is an under-valued 
resource in the investigation of the pathophysiology of advanced coronary disease. 
Even in these high-risk patients, PCI after NSTEACS is safe, successful and 
associated with a low rate of MACE at 1 year, and it is hoped that this will encourage 
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cardiologists not to discriminate on age alone when deciding when to refer for PCI. At 
no age does the accumulation of coronary plaque plateau but it was frailty, not age 
alone, which was associated with increased intracoronary calcification. This calcium is 
not an inert plaque component, but actively shapes vessel remodeling and its 
subsequent vulnerability to coronary events. Moderate coronary calcification had the 
highest risk for adverse outcomes at 1 year, driven by recurrent ACS, suggesting that 




















A Study to Improve Cardiovascular Outcomes 
in High Risk PatieNts with Acute Coronary 
Syndrome. 
 
 ICON 1 Study 




Gender  Male  Female  
Date of PCI         /       / 
Time from presentation to PCI  _________________________ 
NSTEMI  Yes  No  
UA  Yes  No  
STEMI  Yes  No  
Single Vessel-PCI  Yes  No  
Multivessel PCI  Yes  No  
LAD  Yes  No  
RCA  Yes  No  
CX  Yes  No  
SVG  Yes  No  
Culprit vessel LAD  Cx  RCA  
No. of stents  _________________________ 
Arterial Access  _________________________ 
Guide catheter size 5F  6F  7F  8F  
Contrast volume  _________________________ 
Radiation dose  _________________________ 
Duration of PCI  _________________________ 
Complications during PCI procedure  Yes  No  
 Please specify: _________________________ 
On admission to DGH: 
 Heart rate  _________________________ 
 Blood pressure  _________________________ 
 Creatinine  _________________________ 
 Killip class  _________________________ 
Any ST segment changes on ECG? Yes  No  
On a statin at admission to DGH? Yes  No  
List of medications on discharge: 
 Aspirin  Yes  No  
 Clopidogrel  Yes  No  
 Statin   Yes  No  
 ACEI/ARB   Yes  No  
 Betablocker   Yes  No  
 Others (please specify) _________________________ 
Height (cm)  _________________________ 
Weight (kg)  _________________________ 
BMI (kg/m2)  _________________________ 
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Hypertension  Yes  No  
Diabetes  Yes  No  
Smoking current  Yes  No  
Ex smoker   Yes  No  
Hypercholesterolemia  Yes  No  
Family history of IHD  Yes  No  
Renal disease  Yes  No  
Previous MI  Yes  No  
Previous angina  Yes  No  
Previous PCI  Yes  No  
Previous CABG  Yes  No  
Previous peripheral vascular disease  Yes  No  
Previous TIA/Stroke  Yes  No  
H/O arthritis  Yes  No  
H/O COPD  Yes  No  
H/O malignancy  Yes  No  
H/O congestive heart failure  Yes  No  
H/O dementia  Yes  No  
H/O liver disease  Yes  No  
H/O ulcer disease  Yes  No  
H/O bleeding problems  Yes  No  
H/O Anaemia   Yes  No  
H/O any other co-morbid condition  Yes  No  
Please specify  _________________________ 
 _________________________ 
Haemoglobin at time of PCI  _________________________ 
White cell count at time of PCI  _________________________ 
Platelet count at time of PCI  _________________________ 
Creatinine at time of PCI  _________________________ 
Glucose at time of PCI  _________________________ 
Cholesterol at time of PCI  _________________________  










Fried Frailty Index derived from Cardiovascular Health Study 
Criterion Frailty Status Yes or No 
Nutritional Status Frailty cut point: 
Baseline: Self-reported unintentional weight loss ≥10lb in 
previous year 
Follow-up: Unintentional weight loss ≥5% of previous year’s 






Geriatric Depression Scale: 
1. Do you feel full of energy?  
2. During the last 4 weeks how often you rested in bed 
during day? 
Response options:  Every day, every week, once, not at all. 
 
Frailty cut point: 
No to 1 and every day or every week to 2. 
 
Low physical activity Frequency of mildly energetic, moderately energetic and very 
energetic physical activity.  
Response options: ≥3 times per week, 1-2 times per week, 1-3 
times per month, hardly ever/never 
 
Frailty cut point: 
Hardly ever/never for very energetic physical activity AND for 
moderately energetic physical activity. 
 
Weakness Hand grip strength in Kg: GRIP-D hand held dynamometer, 
dominant hand, average of 3 measures. 
 
Frailty cut point: 
Grip strength: lowest 20% (by gender, body mass index) 
Men   
BMI ≤24    ≤29 
BMI 24.1–26    ≤30 
BMI 26.1–28    ≤30 
BMI >28    ≤32 
Women 
BMI ≤23    ≤17 
BMI 23.1–26    ≤17.3 
BMI 26.1–29    ≤18 
BMI >29    ≤21 
 
Slow walking speed Walking time in seconds (usual pace) over 15 feet 
 
Frailty cut point: 
Slowest 20%, stratified by gender and median standing height. 
Men      
Height ≤173 cm   ≥7 seconds 
Height >173 cm   ≥6 seconds 
Women 
Height ≤159 cm   ≥7 seconds 
Height >159 cm   ≥6 seconds 
OR  
Time to complete “timed up and go test” (TUG) 
 
Frailty cut point: 
TUG time ≥19 seconds 
 
Positive for frailty phenotype: ≥3 criteria present , Intermediate or prefrail: 1 or 2 criteria present, 







Rockwood Frailty Score 
 
1 Very fit – robust, active, energetic, well motivated and fit; these people commonly exercise 
regularly and are in the most fit group for their age 
  
 
2 Well – without active disease, but less fit than people in category 1. 
 
 
3 Well, with treated co-morbid disease – disease symptoms are well controlled compared 
with those in category 4 
 
 
4 Apparently vulnerable – although not frankly dependent, these people commonly 
complain of being “slowed up” or have disease symptoms. 
 
 
5 Mildly frail – with limited dependence on others for instrumental activities of daily living 
 
 









NYHA Symptom Class: 
 
I No symptoms and no limitation in ordinary physical activity, e.g. shortness of breath 
when walking, climbing stairs etc. 
 
 




III Marked limitation in activity due to symptoms, even during less-than-ordinary activity, 
e.g. walking short distances (20–100 m). Comfortable only at rest. 
 
 




The Canadian Cardiovascular Society Angina Grading Scale:  
I Angina only during strenuous or prolonged physical activity 
 
 
II Slight limitation, with angina only during vigorous physical activity 
 
 
III Symptoms with everyday living activities, i.e., moderate limitation 
 
 








QOL Index (SF 36) Questionnaire  
           
1- In general, would you say your health is: 
  1. Excellent   2. Very good   3. Good   4. Fair   5. Poor 
 
2- Compared to ONE YEAR AGO, how would you rate your health in general NOW? 
 1. MUCH BETTER than one year ago. 
 2. Somewhat BETTER now than one year ago. 
 3. About the SAME as one year ago. 
 4. Somewhat WORSE now than one year ago. 
 5. MUCH WORSE now than one year ago. 
 
3- The following items are about activities you might do during a typical day.  Does your 
health now limit you in these activities? If so, how much? 
Activities 1. Yes, 
Limited 
A Lot 
2.  Yes, 
Limited  
A Little 




a) Vigorous activities, such as running, lifting heavy 
objects, participating in strenuous sports? 
         
b) Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling, or playing golf? 
         
c) Lifting or carrying groceries?          
d) Climbing several flights of stairs?          
e) Climbing one flight of stairs?          
f) Bending, kneeing or stooping?          
g) Walking more than a mile?          
h) Walking several blocks?          
i) Walking one block?          
j) Bathing or dressing yourself?          
 
4- During the past 4 weeks, have you had any of the following problems with your work 
or other regular activities as a result of your physical health? 
 Yes No 
a) Cut down on the amount of time you spent on work 
or other activities? 
  1. yes   2. No 
b) Accomplished less than you would like?   1. yes   2. No 
c) Were limited in the kind of work or other activities?   1. yes   2. No 
d) Had difficulty performing the work or other activities 
(for example it took extra effort)? 
  1. yes   2. No 
 
5. During the past 4 weeks, have you had any of the following problems with your work or 
other regular daily activities as a result of any emotional problems (such as feeling 
depressed or anxious)? 
 Yes No 
a) Cut down on the amount of time you spent on work 
or other activities? 
  1. yes   2. No 
b) Accomplished less than you would like?   1. yes   2. No 
c) Didn’t do work or other activities as carefully as 
usual? 





6. During the past 4 weeks, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbors, or groups? 
 1. Not at all  2. Slightly  3. Moderately  4. Quite a bit   5. Extremely 
 
7. How much bodily pain have you had during the past 4 weeks? 
 1. None  2. Very mild  3. Mild  4. Moderate  5. Severe      
6. Very severe 
 
8. During the past 4 weeks, how much did pain interfere with your normal work (including 
both work outside the home and housework)? 
 1. Not at all  2. A little bit  3. Moderately  4. Quite a bit  5. Extremely 
 
9. These questions are about how you feel and how things have been with you during the 
past 4 weeks.  For each question, please give the one answer that comes closest to the 
way you have been feeling.  How much of the time during the past 4 weeks … 
























a) Did you feel full of pep?                   
b) Have you been a very nervous 
person? 
                  
c) Have you felt so down in the 
dumps that nothing could cheer you 
up?  
                  
d) Have you felt calm and peaceful?                   
e) Did you have a lot of energy?                   
f) Have you felt downhearted and 
blue? 
                  
g) Do you feel worn out?                   
h) Have you been a happy person?                   
i) Did you feel tired?                   
 
10. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with friends, 
relatives, etc.)? 
  1. All of the time 
  2. Most of the time. 
  3. Some of the time 
  4. A little of the time. 
  5. None of the time. 
 







11. How TRUE or FALSE is each of the following statements for you? 















a) I seem to get sick a little easier than 
other people? 
               
b) I am as healthy as anybody I know?                
c) I expect my health to get worse?                
d) My health is excellent?                
 
EuroQol EQ-5D™  
Please tick which statements best describe your own health state today. 
 
1A. Mobility 
I have no problems in walking about  
I have some problems in walking about  
I am confined to bed  
 
1B. Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
 
1C. Usual Activities (e.g. work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
 
1D. Pain/Discomfort 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
 
1E. Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  




Frail   Yes  No  
 
Fried Frailty Score  _________________________ 
 
Rockwood Frailty Score  _________________________ 
 
Charlson Co-morbidity Index  _________________________ 
 
Ankle Brachial Index  _________________________ 
 
EndoPAT Score  _________________________ 
 
Augmentation Index  _________________________ 
 
CIMT  _________________________ 
 
Echocardiogram and LV Function (Please tick) 
Mild LV   
Moderate LV   
Severe LV   
 
Ejection Fraction (%) if known   _________________________ 
Significant valve disease  Yes  No  













To help people say how good or bad a health state is,  
we have drawn a scale (rather like a thermometer) on 
which the best state you can imagine is marked 100 and 
the worst state you can imagine is marked 0. 
 
We would like you to indicate on this scale how good or 
bad your own health is today, in your opinion. Please do 
this by drawing a line from the box below to whichever 
point on the scale indicates how good or bad your health 
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Quantitative Coronary Angiography 







ANGIOGRAPHIC CORE LAB DEFINITIONS 
 
Cannot Assess (CNA): When film analysis cannot be performed due to a technical flaw 
in filming, procedure, or due to protocol violations, 'CNA' will be marked on the Case Report 
Form (CRF). When no data is available, a "-1" will be inserted on the data spreadsheet.  
 
Does Not Apply (DNA): When analysis does not apply to a given situation, 'DNA' will be 
marked on the Case Report Form (CRF). When no data is available, a "-1" will be inserted 
on the data spreadsheet.  
 





ASSESSMENT OF THE EPICARDIAL ARTERIES 
 
Lesion identification: All culprit lesions and all lesions that are subsequently intervened 
on should be recorded (irrespective of % stenosis). Lesion characteristics are to be 
recorded if the diameter stenosis is >40% in a vessel >1.5mm in diameter. Lesions are 
considered separately if they are >3 vessel reference diameters apart. 
 
Primary lesion location 
The coronary anatomy is divided into the following segments.  
 
1.  Proximal right coronary artery: Extends from the ostium of the right coronary 
artery (RCA) to the first of the three longest acute marginal branches.  
 
2.  Mid right coronary artery: Extends from the origin of the first acute marginal 
branch to the origin of the third acute marginal branch.  
 
3.  Distal right coronary artery: Extends from the origin of the third acute marginal to 
the origin of the posterior descending artery.  
 
4. Right posterior descending artery: In all but left dominant systems, this vessel 
runs in the posterior interventricular groove and supplies septal perforator branches.  
 
5. Left main stem: Extends from the origin of the left coronary artery to the bifurcation 
into the left anterior descending (LAD) and circumflex (Cx) arteries. 
 
6. Proximal left anterior descending artery: Extends from the bifurcation of the left 
main coronary artery to the origin of the first septal. 
 
7. Mid left anterior descending artery: Extends from the origin of the first septal artery 
to the origin of the third septal artery. 
 
8.  Apical left anterior descending artery: Extends from the origin of the third septal 
artery to the apex of the left ventricle. If there is no third septal branch, then the third 




9. First diagonal branch: The first of the three longest branches from the LAD, which 
supplies the anterolateral wall of the left ventricle. 
 
10. Second diagonal branch: The second of the three longest branches from the LAD 
which supplies the anterolateral wall of the left ventricle.  
 
11. Proximal circumflex artery: Extends from the origin of the Cx off of the left main to 
the origin of the first marginal or obtuse marginal branch. When a second obtuse marginal 
is present and the first marginal is absent, the Cl - C2 transition is defined as halfway from 
the origin of the circumflex to the origin of the second obtuse marginal. 
 
12. Intermediate artery: An artery whose origin bisects the origins of both the LAD and 
the Cx arteries. When an intermediate branch is present, the left main will be seen to 
trifurcate, and the intermediate artery is the middle artery at this point of trifurcation. When 
grouping with general culprit lesion location it is grouped with the Cx. 
 
12a. First obtuse marginal branch: A large branching artery which dominates the lateral 
left ventricular wall.  
 
12b. Second obtuse marginal branch: The second large branch from the Cx artery. 
 
13. Distal circumflex artery: Extends from the origin of the second marginal or obtuse 
marginal to the termination of the Cx artery in large right dominant anatomy or to the origin 
of the Cx posterior branch in all other dominance. 
 
14. Left posterolateral branch: In left or co-dominant systems this is the distal 
continuation of the Cx artery in the atrio-ventricular groove. It carries blood to the left 
posterior descending artery and circumflex inferior artery in left dominant systems and to 
just the circumflex inferior artery in balanced dominant systems. 
 
16. Right posterolateral branch: This is the distal continuation of the RCA after the 
origin of the posterior descending artery. It often has an inverted U shape and the AV nodal 






Disease Extent  
This variable refers to how many of the 3 major epicardial vessels have a narrowing of 
greater than 40%. Possible values are 1, 2, 3, and "-1" if none of the vessels meet the 
criteria or if analysis of one or more arteries is not possible.  
 
Dominance 
Describes how many of the three major branches supplying the inferior wall of the heart 
arise from the RCA and how many arise from the Cx.  
 
Right dominant:  This occurs when the descending and inferior both arise from the 
RCA (the posterior branch may also arise from the RCA).  
 
Co-dominant:  This occurs when only the descending branch arises from the RCA, 
while the inferior and posterior branches arise from the Cx.  
 
Left dominant:  This occurs when all three branches arise from the Cx.  
 
Definitions of Segmental Coronary Anatomy  
If a lesion occurs at a branch-point, then the lesion is said to be part of the proximal vessel 
adjacent to the branch-point.  
 
If the lesion involves both parent vessel and a side branch at a branch-point (such as 
occurs with a trifurcation lesion or "Mercedes Benz" emblem lesion involving the LAD and 
the origin of a diagonal) then the larger parent vessel is defined as the culprit.  
 
Only the branches> 1.5mm in diameter should be taken into account. To assess the 
diameter, the branch should be compared to the catheter size, given the fact that the 
French sizes correspond to millimeters as follows:  
 
4 Fr = 1.3mm 8 Fr = 2.7mm 
5 Fr = 1.7mm 9 Fr = 3.0mm 
6 Fr = 2.0mm 10 Fr = 3.3mm 





RAO (Right Anterior Oblique) Caudal: The best overall view to assess the Cx, as it 
minimizes intra- and inter-arterial overlap. In this view, the system in question appears 
angiographically to the right of the spine with a slight inferior angulation (from below).  
 
RAO Cranial: The best overall view to assess the LAD, as it minimizes intra- and inter-
arterial overlap. In this view, the system in question appears angiographically to the right 
of the spine with a slight anterior angulation (from above).  
 
RAO: In this view, the system in question appears angiographically to the right of the spine 
with little or no vertical angulation.  
 
AP (Anterior-Posterior): In this view, the system in question angiographically overlaps or 
is in line with the spine.  
 
LAO Caudal: Also called the spider view. In this view, the system in question appears 
angiographically to lie to the left of the spine with a slight inferior angulation (from below). 
  
LAO Cranial: In this view, the system in question appears angiographically to lie to the left 
of the spine with a slight anterior angulation (from above).  
 
LAO: The best overall view to assess the RCA. In this view, the system in question appears 




QUANTITATIVE CORONARY ANGIOGRAPHY (QCA) 
 
Analysis Software 
Medis QAngioXA version 7.3.54.0 
 
Performing QCA 
1. Insert the QAngio dongle into a USB port on the computer. 
2. Insert the CD with the patient’s angiogram. The study will open automatically when 
the QAngioXA program is started. 
3. Choose the image run with the appropriate projection for the lesion to be measured. 
4. Ensure the ECG trace is visible by selecting the ECG curve icon. 
5. Calibrate the software: Choose a frame where the catheter is fully opacified by contrast 
but where contrast has not yet entered the artery of interest. Select the catheter 
calibration icon and click two points within the catheter. Select the correct size of 
catheter (default is 6F). The coefficient of variation must be less than 8%. Click “Done”.  
6. Select a frame in end-diastole where the vessel is well opacified by contrast and the 
lesion of interest is at maximal stenosis. 
7. Choose either the straight segment analysis or bifurcation segment analysis 
depending on the type of lesion (use the straight segment analysis setting if possible 
as it gives more consistent results). Click two points proximal and distal to the lesion 
to create an automatic pathline. Adjust this with secondary points if necessary. On the 
next “contours” stage, either automatically adjust the vessel contours by clicking and 
dragging support points, or manually delete and redraw. 
8. On the next “markers” stage, adjust the reference vessel contours by using the 
“flagging” system to remove segments of vessel that have been contoured incorrectly. 













Definitions of Measurements 
 
Minimum Lumen Diameter (MLD): The minimum diameter of the stenosis relative to the 
reference diameter.  
 
Reference Diameter (RD): An interpolated reference diameter. The proximal and distal 
extremities of the lesion are identified by the software, a second degree polynomial 
function is applied to diameter measurements at 0.1mm intervals, and vessel tapering is 
taken into account. The reported vessel diameter is the RD on the diametric function curve 
at the point of the MLD. 
 
% Diameter Stenosis: [1-(MLD/RD)]x100 
 
% Area Stenosis: [1-(MLD/RD)2]x100 
 




INFARCT-RELATED ARTERY MORPHOLOGY 
 
Definitions of morphology 
Eccentric: The plaque is twice as large on one side of the arterial border compared with 
the other. "Stenosis noted to have one of its lumen edges in the outer one-quarter of the 
apparent normal lumen." 
 
Calcification: Densities noted within the apparent vascular wall at the site of the stenosis.  
 Mild: faint radio-opacities noted only during cardiac motion before contrast injection 
 Moderate: dense radio-opacities noted during cardiac motion before contrast 
injection 
 Severe: dense radio-opacities noted without cardiac motion before contrast 
injection, comprising both sides of the arterial lumen 
 
Diffuse: Lesion is ≥20mm in length.  
 
Bifurcation: Atherosclerotic plaque involves the origin of two separate arteries. It does not 
necessarily require two guidewires.  
 
Ostial Lesion: Lesion beginning within 3-5 mm of the origin of a major epicardial artery.  
 
Pulsatile Flow: Cessation of antegrade flow during systole or frank: flow reversal during 
systole. 
 
Deceleration: Dye flow down the artery is slowed at any point during the course of flow.  
 
Collateral Circulation 
Assessed visually using the following grading system:  
Grade 0: No collaterals present. Angiography fails to reveal evidence of collateral vessels.  
Grade 1 (or partial): Minimal collaterals present. Evidence of minimal to partial filling of the 
recipient branch epicardial arteries/infarct region. It is not necessary for one to see the 
branches connect directly to the major epicardial artery.  
Grade 2 (or complete): Well-developed collaterals. Evidence of collateral circulation with 






Assessed visually using the following grading system:  
Grade 0: No cineangiographic characteristics of thrombus present.  
Grade 1: Hazy, possible thrombus present. Angiography demonstrates characteristics 
such as reduced contrast density, haziness, irregular lesion contour, or a smooth convex 
"meniscus" at the site of total occlusion suggestive but not diagnostic of thrombus.  
Grade 2: Thrombus present - small size: Definite thrombus with greatest dimensions less 
than or equal to 1/2 vessel diameter.  
Grade 3: Thrombus present - moderate size: Definite thrombus but with greatest linear 
dimension greater than 1/2 but less than 2 vessel diameters.  
Grade 4: Thrombus present -large size: As in grade 3 but with the largest dimension 
greater than or equal to 2 vessel diameters.  
Grade 5: Recent total occlusion, can involve some collateralization but usually does not 
involve extensive collateralization, tends to have a "beak" shape and a hazy edge or 
appearance of distince thrombus.  
Grade 6: Chronic total occlusion, usually involving extensive collateralization, tends to 




A localized arterial widening (dilatation) that usually manifests itself as a bulge. Its 
presence may lead to weakening of the wall and eventual rupture.  
Grade 0: None - no ectasia present.  
Grade 1: Ectasia - visual assessment of ectasia> 1 and < 1.5 times the normal artery 
diameter located anywhere in the culprit artery.  
Grade 2: Aneurysm - visual assessment of an aneurysm> 1.5 times the normal artery 
diameter located anywhere in the culprit artery.  
 
NOTE: An aneurysm can be further classified as either saccular (wider than it is long) or 
fusiform (elongated).  
 
Ulceration 
A lesion with a small crater consisting of a discrete lumen widening in the area of the 
stenosis that does not extend beyond the normal arterial lumen. Assessed visually:  
Grade 0: No angiographic evidence of ulceration.  
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Grade 1: The lesion contains a neck with contrast material dissecting under the plaque 
either proximally or distally.  
Grade 2: Distinct extravascular extravasation of contrast material with the appearance of 
a mushroom.  
 
Lesion Complexity  
Graded as A, Bl, B2, or C according to the Abrupt Vessel Closure-AHA Task Force 
Definition as modified by Ellis et al:  
Type A: <10 mm, discrete, concentric, readily accessible, <45 degree angle smooth 
contour, little or no calcification, less than totally occluded, not ostial, no major side branch 
involvement, absence of thrombus.  
Type B1: One of the following characteristics:  
Type B2: Two or more of the following characteristics: 10-20 mm, eccentric, moderate 
tortuosity of proximal segment, irregular contour, presence of any thrombus grade 
moderate or heavy calcification, total occlusion <3 months old, ostial lesion or bifurcation 
lesion 
Type C: ≥20 mm diffuse, excessive tortuosity of proximal segment, total occlusion> 3 
months old and/or bridging collaterals, inability to protect major side branches, or 







Post -Intervention Complications 
 
Dissection: An intraluminal filling defect or flap associated with a hazy, ground-glass 
appearance.  
Type A:  Radiolucent areas within the coronary lumen during contrast injection, with 
minimal or no persistence of contrast after dye has cleared.  
Type B: Parallel tracts or double lumen separated by a radiolucent area during 
contrast injection, with minimal or no persistence after dye has cleared. 
Type C:  Contrast outside the coronary lumen, with persistence of contrast in the area 
after dye has cleared 
Type D:  Spiral luminal filling defects frequently with extensive contrast staining of the 
vessel 
Type E:  New persistent filling defects that may be caused by thrombus 
Type F:  These are non A - E dissection types that lead to impaired flow or total 
occlusion of the coronary artery 
 
Perforation: Presence of extraluminal contrast that develops during the procedure.  
 
Loss of side branch: Development of TIMI grade 0 or 1 flow in a side branch that 
was >1.5mm in diameter prior to the procedure and was initially patent with ≥TIMI grade 2 
flow.  
 
Distal embolisation: The appearance of an abrupt cutoff in the distal vessel following 
PCI.  
 
No reflow: Markedly delayed flow down the artery with minimal residual stenosis.  
 
Procedure Success: A procedure is considered a complete success if the post-procedure 
residual diameter stenosis is <30% with TIMI grade 3 flow. A procedure will be classified 
as a partial success if there is either a ≥30% residual stenosis by QCA or if TIMI Grade 2 
Flow is attained (this includes TFG 2.5). A procedure will be classified a failure if there is 














Virtual Histology IVUS Analysis  














Opening An IVUS Run 
 
1. Ensure the dongle is plugged into a USB port before opening 
QIvus. The light will glow green on the end of the dongle 
when operational. 
 
2. Open QIvus software.  
 
3. Insert DVD. 
 
4. Click                                                    or select File > Browse for Dicom... or use the keyboard 
shortcut Ctrl+O. 
 
5. Select the directory in which the image run is located (in this case, the DVD 
drive). The software will automatically search for all files that QIvus can open 














6. The panel below "Image file information" shows the patient study ID, date of 
study and vessel imaged. Before opening the image run, ensure that each 
patient has a separate analysis storage folder by clicking Change Analysis 
Storage Folder... and making a new folder (labelled with the patient study 
number) in an easy to find location. This is where all the previous analyses for 
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that patient will be stored. The software defaults to the last analysis storage 
folder used when opening a new file. 
 


















8. A dialogue box will pop up with further 
information about the image run. Enter 
the Segment and Intervention stage. 
Ensure that the pullback speed is set at 
0.500 mm/sec and click OK.  
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Preparing The Image For Analysis 
 
1. Remove any artefacts from the image by clicking 
 
2. Define the length of the segment to 
be analysed by clicking and dragging 
the blue segment markers to contain 
all frames of interest in the 
longitudinal view. Do not include 
frames at the beginning of the image 
run (distal) that are duplicated 
because the imaging catheter had 
not started moving, and do not 
include frames at the end of the run 




3. Make a note of any frames that are duplicated when the imaging catheter has 
become stuck (usually occurs at points of heavy calcification or tight stenoses). 




Vessel Contour Drawing 
 
1. By default, the vessel contour is selected.  
 
2. Click to analyse the longitudinal image.  
 
3. Review the attraction points (green circles) in the longitudinal view by dragging 
the red marker line. The red line in the transversal view corresponds to the red 





4. Refine the attraction points in the cross-sectional view so 
that they sit at the boundary of the media (dark) and the 





5. Moving an attraction point automatically updates the longitudinal contour and 
thus moves other attraction points that have not already been edited. Start with 
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refining the attraction points that are most inaccurate and continue until all 
points are on the vessel border. It is worth spending some time doing this 
accurately, as it reduces the time spent manually correcting the border. 
 
6. When happy with the position of the attraction points, click to analyse the 
contour in the transversal view.  
 
7. Select Options > Graphics line thin. 
 
8. Click and drag the window with the transversal view to maximise its size. 
 
9. Exclude the frames identified as duplicates above.  
 
10. Starting at the first (distal) frame, correct the vessel contour of each frame of 
the segment using correction points.  
 
 
11. These correction points edit the 
contour in one frame only. They 
can be picked up and moved, or 
removed by clicking the left and 









12. The vessel contour should be extrapolated as accurately as possible where it is 




















13. Where a side branch is entering a vessel, the vessel contour should be drawn 
to follow the original (distal) vessel boundary until the side branch is fully 





Lumen Contour Drawing 
 
1. Select the lumen contour. 
 
2. Click to analyse the longitudinal image.  
 
3. Move the red attraction points to the lumen border for the whole segment. These 
do not have to be as accurate as the vessel contour attraction points, as the 













4. When happy with the position of the attraction points, click to analyse the 
contour in the transversal view.  
 
5. Starting at the first frame, manually re-trace the lumen contours for each frame 
of the segment of interest. Omit any artefacts from the lumen contour. Use the 




The loop review button can help to visualise the lumen contour.  
 
At side branches, draw the lumen contour slightly outside the vessel contour to 
ensure that the software does not automatically add an area of media when 
















1. Click to load the VH overlay.  
 
2. Hide the contour lines by choosing either Vessel or Lumen and clicking 
Contour for each. 
 
 
3. Click on Results. 
 
4. In the results dialog box, the overall percentage plaque burden and percentages 













5. Use the decision tree below to decide which lesion subtype each frame 
represents, and enter the name of the lesion in the comments box. This will be 










































6. Measure the plaque thickness by selecting Options > Transversal caliper and 
clicking Indicate distance. 
 
7. Measure angles from the centre of the lumen by ticking the box marked Show 













8. Open the angle caliper by selecting Options > Transversal caliper > Indicate 
angle. Drag the corner of the angle into the centre of the lumen, where the 
diameter lines intersect. Measure the angle of every area of necrotic core that 
is in contact with the lumen and add them to obtain the total angle of necrotic 







1. Once finished classifying each frame, click the Excel button.  
 
2. An Excel spreadsheet will open automatically. Save the sheet in a separate 
folder entitled "completed analyses" and name the file based on the study ID 
and vessel analysed e.g. FRE148-Cx. 
 
3. Record the relevant data in the master database. 
 
4. A plaque becomes a lesion when the plaque burden is >40% for 3 consecutive 
images, and lesions separated longitudinally by >5mm of artery with a plaque 
burden <40% should be considered separate lesions. Where different plaque 
subtypes co-exist within a lesion, the lesion should be classified according to 
the highest risk subtype i.e. thin capped fibroatheroma (TCFA) > fibroatheroma 
(FA) > pathological intimal thickening (PIT) > fibrotic plaque (FP) > intimal 
medial thickening (IMT). TCFA, FA and FP are further subdivided into calcified 
and non-calcified lesions (if >3 consecutive frames are calcified, it is a calcified 
lesion). 
 
5. Close the image run, then 
re-open the Browse 
dialog box. Make a 
comment on the 
completed analysis that 
the analysis has been 













A Study to Improve Cardiovascular Outcomes 
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Patient study no.   _________________________ 
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DOB  _________________________ 
Date of enrolment _________________________         
Date of Follow up  _________________________  
Clinic   Telephone  GP letter  
 
List of current medications 
Aspirin  Yes  No  
Thienopyridine  Clop  Pras  Ticag  
Warfarin  Yes  No  
Statin   Yes  No  
ACEI/ARB   Yes  No  
Betablocker   Yes  No  
Furosemide  Yes  No  
Calcium channel blocker  Yes  No  
Long acting nitrate  Yes  No  
Nicorandil  Yes  No  
Vitamin D supplement  Yes  No  
Others (please specify)   _________________________ 
  _________________________ 
  _________________________ 
  _________________________ 
 
Height (cm)  _________________________ 
Weight (kg)  _________________________ 
 
Social history 
Current smoker  Yes  No  
Lives alone  Yes  No  
Carers  Yes  No  
If yes, how often per day  _________________________ 
Residential home  Yes  No  
Nursing home  Yes  No  
 
 
Major Adverse Cardiovascular Events in the last year 
Death  Yes  No  
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Date of death _________________________ 
Cause of death _________________________ 
 
Acute coronary syndrome Yes  No  
Date of ACS _________________________ 
STEMI   NSTEMI  UA  
 
Stroke  Yes  No  
Date of stroke _________________________ 
 
Urgent repeat revascularisation Yes  No  
Date of revascularisation _________________________ 
PPCI   Urgent PCI  Urgent CABG  
 
 Bleeding problems  Yes  No  
Date of bleeding  _________________________ 
Bleeding type  _________________________ 
 
 
Bleeding Academic Research Consortium (BARC) definition for bleeding 
Type 1 Bleeding that does not cause the patient to seek unscheduled investigation or treatment 
by a healthcare professional. May include episodes leading to self-discontinuation of 
medical therapy by the patient without consulting a healthcare professional. 
Type 2 Any overt, actionable sign of haemorrhage that does not fit the criteria for Type 3, 4 or 5 
but does prompting evaluation by a healthcare professional. 
Type 3a Overt bleeding plus haemoglobin drop of 3 to < 5 g/dl 
Any transfusion with overt bleeding 
Type3b Overt bleeding plus haemoglobin drop ≥ 5 g/dl 
Cardiac tamponade 
Bleeding requiring surgical intervention for control (excluding dental/ nasal/ skin/ 
haemorrhoid) 
Bleeding requiring intravenous vasoactive agents 
Type 3c Intracranial or intraspinal haemorrhage (does not include haemorrhagic transformation) 
Intraocular bleed compromising vision  
Type 4: CABG-related bleeding: 
 Perioperative intracranial bleeding within 48 hours 
Reoperation following closure of sternotomy for the purpose of controlling bleeding 
Transfusion of ≥ 5 units of whole blood or packed red blood cells within a 48-hour period 
Chest tube output ≥ 2 litres within a 24-hour period 
Type 5a Probable fatal bleeding; no autopsy or imaging confirmation, but clinically suspicious 







Stable angina   Yes  No  
Elective PCI   Yes  No  
Congestive cardiac failure  Yes  No  
Transient ischaemic attack  Yes  No  
Dialysis  Yes  No  
 
Hospitalisation for any other reason  Yes  No  
If yes, diagnosis/date  _________________________ 
  _________________________ 
  _________________________ 
  _________________________ 
 
Blood results at follow up   
PT  _________________________ 
APTT  _________________________ 
Fibrinogen  _________________________ 
Vitamin D  _________________________ 
HS-CRP  _________________________ 




























Fried Frailty Index derived from Cardiovascular Health Study 
 
Criterion Frailty Status Yes or No 
Shrinking Frailty cut point: 
Baseline: Self reported unintentional weight loss ≥10lb in 
previous year 
Follow-up: Unintentional weight loss ≥5% of previous 






Geriatric Depression Scale: 
1. Do you feel full of energy?  
2. During the last 4 weeks how often you rested in 
bed during day? 
Response options:  Every day, every week, once, not at 
all. 
Frailty cut point: No to 1 and every day or every week 
to 2. 
 
Low physical activity Frequency of mildly energetic, moderately energetic and 
very energetic physical activity.  
Response options: ≥3 times per week, 1-2 times per 
week, 1-3 times per month, hardly ever/never 
Frailty cut point: 
Hardly ever/never for very energetic physical activity AND 
for moderately energetic physical activity. 
 
Weakness Hand grip strength in Kg: GRIP-D hand held 
dynamometer, dominant hand, average of 3 measures. 
Frailty cut point: 
Grip strength: lowest 20% (by gender, body mass index) 
Men   
BMI ≤24    ≤29 
BMI 24.1–26    ≤30 
BMI 26.1–28    ≤30 
BMI >28    ≤32 
Women 
BMI ≤23    ≤17 
BMI 23.1–26    ≤17.3 
BMI 26.1–29    ≤18 
BMI >29    ≤21 
 
Slow walking speed Walking time in seconds (usual pace) over 15 feet 
Frailty cut point: 
Slowest 20%, stratified by gender and median standing 
height. 
Men      
Height ≤173 cm   ≥7 seconds 
Height >173 cm   ≥6 seconds 
Women 
Height ≤159 cm   ≥7 seconds 
Height >159 cm   ≥6 seconds 
OR  
Time to complete “timed up and go test” (TUG) 
 
Frailty cut point: 










Rockwood Frailty Scores 
 
1 Very fit – robust, active, energetic, well motivated and fit; these people 
commonly exercise regularly and are in the most fit group for their age 
  
 
2 Well – without active disease, but less fit than people in category 1. 
 
 
3 Well, with treated co-morbid disease – disease symptoms are well controlled 
compared with those in category 4 
 
 
4 Apparently vulnerable – although not frankly dependent, these people 
commonly complain of being “slowed up” or have disease symptoms. 
 
 




6 Moderately frail – help is needed with both instrumental and non-instrumental 
activities of daily living 
 
 
7 Severely frail – completely dependent on others for the activities of daily 








Symptoms Please tick 
I No symptoms and no limitation in ordinary physical activity, e.g. 
shortness of breath when walking, climbing stairs etc. 
 
II Mild symptoms (mild shortness of breath and/or angina) and 
slight limitation during ordinary activity. 
 
III Marked limitation in activity due to symptoms, even during less-
than-ordinary activity, e.g. walking short distances (20–100 m). 
Comfortable only at rest. 
 
IV Severe limitations. Experiences symptoms even while at rest. 
Mostly bedbound patients. 
 
 
The Canadian Cardiovascular Society Angina Grading Scale:  
0 No angina  
I Angina only during strenuous or prolonged physical activity 
 
 
II Slight limitation, with angina only during vigorous physical 
activity 
 
III Symptoms with everyday living activities, i.e., moderate 
limitation 
 
IV Inability to perform any activity without angina or angina at rest, 






QOL Index (SF 36) Questionnaire  
1. In general, would you say your health is: 
  1. Excellent   2. Very good   3. Good   4. Fair   5. Poor 
 
2. Compared to ONE YEAR AGO, how would you rate your health in general NOW? 
 1. MUCH BETTER than one year ago. 
 2. Somewhat BETTER now than one year 
ago. 
 3. About the SAME as one year ago. 
 4. Somewhat WORSE now than one year 
ago. 




3. The following items are about activities you might do during a typical day.  Does 
your health now limit you in these activities? If so, how much? 
Activities 1. Yes, 
Limited 
A Lot 
2.  Yes, 
Limited  
A Little 




a) Vigorous activities, such as running, lifting 
heavy objects, participating in strenuous sports? 
         
b) Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling, or playing 
golf? 
         
c) Lifting or carrying groceries?          
d) Climbing several flights of stairs?          
e) Climbing one flight of stairs?          
f) Bending, kneeing or stooping?          
g) Walking more than a mile?          
h) Walking several blocks?          
i) Walking one block?          
j) Bathing or dressing yourself?          
 
4. During the past 4 weeks, have you had any of the following problems with your 
work or other regular activities as a result of your physical health? 
a) Cut down on the amount of time you spent on work 
or other activities? 
  1. yes   2. No 
b) Accomplished less than you would like?   1. yes   2. No 
c) Were limited in the kind of work or other activities?   1. yes   2. No 
d) Had difficulty performing the work or other 
activities (for example it took extra effort)? 
  1. yes   2. No 
 
5. During the past 4 weeks, have you had any of the following problems with your 
work or other regular daily activities as a result of any emotional problems (such as 
feeling depressed or anxious)? 
 
a) Cut down on the amount of time you spent on work 
or other activities? 
  1. yes   2. No 
b) Accomplished less than you would like?   1. yes   2. No 
c) Didn’t do work or other activities as carefully as 
usual? 




6. During the past 4 weeks, to what extent has your physical health or emotional 
problems interfered with your normal social activities with family, friends, neighbors, or 
groups? 
  1. Not at all   2. Slightly   3. Moderately     4. Quite a bit   5. Extremely 
 
7. How much bodily pain have you had during the past 4 weeks? 
  1. None   2. Very mild   3. Mild    4. Moderate    5. Severe   6. Very severe 
 
8. During the past 4 weeks, how much did pain interfere with your normal work 
(including both work outside the home and housework)? 
  1. Not at all   2. A little bit   3. Moderately      4. Quite a bit   5. Extremely 
 
9. These questions are about how you feel and how things have been with you during 
the past 4 weeks.  For each question, please give the one answer that comes closest 
to the way you have been feeling.  How much of the time during the past 4 week … 






3. A good 











a) Did you feel full of pep?                   
b) Have you been a very 
nervous person? 
                  
c) Have you felt so down in 
the dumps that nothing could 
cheer you up?  
                  
d) Have you felt calm and 
peaceful? 
                  
e) Did you have a lot of 
energy? 
                  
f) Have you felt downhearted 
and blue? 
                  
g) Do you feel worn out?                   
h) Have you been a happy 
person? 
                  
i) Did you feel tired?                   
 
10. During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting with friends, 
relatives, etc.)? 
  1. All of the time 
  2. Most of the time. 
  3. Some of the time 
  4. A little of the time. 
  5. None of the time. 
 






11. How TRUE or FALSE is each of the following statements for you? 










a) I seem to get sick a little easier 
than other people? 
               
b) I am as healthy as anybody I 
know? 
               
c) I expect my health to get worse?                
d) My health is excellent?                
 
EuroQol EQ-5D™  - Please tick which statements best describe your own health 
state today. 
1A. Mobility 
I have no problems in walking about  
I have some problems in walking about  
I am confined to bed  
 
1B. Self-Care 
I have no problems with self-care  
I have some problems washing or dressing myself  
I am unable to wash or dress myself  
 
1C. Usual Activities (e.g. work, study, housework, family or leisure activities) 
I have no problems with performing my usual activities  
I have some problems with performing my usual activities  
I am unable to perform my usual activities  
 
1D. Pain/Discomfort 
I have no pain or discomfort  
I have moderate pain or discomfort  
I have extreme pain or discomfort  
 
1E. Anxiety/Depression 
I am not anxious or depressed  
I am moderately anxious or depressed  




To help people say how good or bad a health state is,  we have drawn a 
scale (rather like a thermometer) on which the best state you can imagine 
is marked 100 and the worst state you can imagine is marked 0. 
 
We would like you to indicate on this scale how good or 
bad your own health is today, in your opinion. Please do 
this by drawing a line from the box below to whichever 
point on the scale indicates how good or bad your health 
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